Intensity modulated radiation therapy and arc therapy: validation and evolution as applied to tumours of the head and neck, abdominal and pelvic regions by Duthoy, W
Intensitymodulated radiation therapy and arc therapy:
validation and evolution as applied to tumours of
the head and neck, abdominal and pelvic regions
Wim Duthoy
Promotor:
Prof. Dr. W. De Neve
Thesis submitted to fulfil the requirements for achievement
of the degree of Doctor in Medical Sciences
Ghent, January 2006
Department of radiotherapy
FACULTY OF MEDICINE AND
HEALTH SCIENCES
 
  
 
 
Universiteit Gent 
Faculty of Medicine and Health Sciences 
Department of radiotherapy 
 
Intensity modulated radiation therapy and arc therapy: validation and evolution as 
applied to tumours of the head and neck, abdominal and pelvic regions 
 
Wim Duthoy 
 
Thesis submitted to fulfil the requirements for the degree of Doctor in Medical Sciences 
February 2006 
 
 
Promotor  
Prof. Dr. W. De Neve Department of radiotherapy 
Ghent University Hospital 
President of the examination commission 
Prof. Dr. C. De Wagter Department of radiotherapy 
Ghent University Hospital 
Examination commission  
Prof. Dr. Y. De Deene Department of radiotherapy 
Ghent University Hospital 
Ir. W. De Gersem Department of radiotherapy 
Ghent University Hospital 
Prof. Dr. M. Peeters Department of gastro-enterology 
Ghent University Hospital 
Prof. Dr. G. Storme Department of radiotherapy 
Free University of Brussels 
Prof. Dr. D. Verellen Department of radiotherapy 
Free University of Brussels 
Prof. Dr. H. Vermeersch Department of head and neck surgery 
Ghent University Hospital 
Prof. Dr. E. Wong Department of Oncology 
Department of Applied Mathematics 
University of Western Ontario, 
London Regional Cancer Centre,  
London, Ontario, Canada 
 
From 1-10-2000 until 30-9-2004, Wim Duthoy was an Aspirant of the FWO-Vlaanderen 
 
  
Contents 
I Summary – Samenvatting – Résumé 6 
II Objectives and outline of the thesis 12 
III Intensity-modulated radiation therapy 14 
III. 1. Physical principles of IMRT..................................................................................... 15 
III. 2. IMRT treatment planning ......................................................................................... 17 
III. 2.1. “Optimized fluence map”-based segmentation............................................ 18 
III. 2.2. Anatomy-based segmentation...................................................................... 20 
III. 3. IMRT at Ghent University Hospital ......................................................................... 21 
III. 4. Clinical implementation of IMRT for HNC ............................................................. 28 
III. 4.1. Challenges in head and neck radiotherapy................................................... 28 
III. 4.2. IMRT implementation for pharyngo-laryngeal carcinoma.......................... 33 
III. 4.3. IMRT implementation for sinonasal cancer................................................. 36 
III. 4.4. Introducing biological imaging in IMRT planning...................................... 37 
IV Intensity modulated arc therapy 44 
IV. 1. Introduction............................................................................................................... 44 
IV. 2. Indications for IMAT................................................................................................ 45 
IV. 2.1. Concave PTV around an OAR with large radius......................................... 45 
IV. 2.2. IMAT for the delivery of biological imaging guided radiotherapy ............. 48 
IV. 3. IMAT delivery issues on Elekta linacs at GUH........................................................ 48 
IV. 4. IMAT planning issues............................................................................................... 51 
IV. 4.1. Anatomy-based planning for IMAT (the GUH approach)........................... 52 
IV. 4.2. Inverse IMAT planning................................................................................ 57 
IV. 5. Dosimetry for IMAT................................................................................................. 58 
V Publications 60 
V. 1. Intensity-modulated radiation therapy for head and neck cancer. ............................ 62 
V. 2. Intensity modulated radiation therapy for oropharyngeal and oral cavity 
tumors: clinical use and experience. ......................................................................... 78 
  
V. 3. Postoperative intensity modulated radiotherapy in sinonasal carcinoma: 
clinical results in 39 patients. ....................................................................................90 
V. 4. Positron emission tomography (PET) guided dose escalation with intensity 
modulated radiotherapy in head and neck cancer....................................................108 
V. 5. Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc 
therapy (IMAT): First clinical experience...............................................................122 
V. 6. Definition and delineation of the clinical target volume for rectal cancer. .............142 
V. 7. Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal 
cancer.......................................................................................................................158 
VI Discussion. 176 
VI. 1. IMRT: is it worth all the trouble?............................................................................176 
VI. 2. Comparison between IMAT and Tomotherapy.......................................................179 
VI. 3. Future perspectives ..................................................................................................185 
VII Bibliography 188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An electronic version of the thesis can be downloaded at http://hdl.handle.net/1854/3000 
 
 Abbreviations 
3D   three-dimensional 
3D-CRT  three-dimensional conformal radiotherapy 
 
aSOWAT  arc-therapy adapted segment outline and weight adaptation tool 
ABST   anatomy-based segmentation tool 
ADR   angular delivery rate 
BEV   beam’s eye view 
CP(s)   control point(s) 
CT   computed tomography 
CTV(s)   clinical target volume(s) 
DMLC   dynamic multileaf collimator 
DVH(s)  dose-volume histogram(s) 
FDG   2-[18F]fluoro-2-deoxy-D-glucose 
GTV   gross tumour volume 
GUH   Ghent University Hospital 
Gy   gray 
HNC   head and neck cancer 
IGRT   image-guided radiation therapy 
IMRT    intensity-modulated radiation therapy 
IMAT    intensity-modulated arc therapy 
linac(s)   linear accelerator(s) 
LNR(s)   lymph node region(s) 
LPO   leaf position optimization 
LVC   leaf velocity constrainer 
MLC   multileaf collimator 
MLS   maximal leaf speed 
PGD   polymer gel dosimetry 
MRI   magnetic resonance imaging 
MS(s)   machine state(s) 
MU(s)   monitor unit(s) 
NTCP   normal tissue complication probability 
OAR(s)   organ(s) at risk 
PET   positron emission tomography 
PTV(s)   planning target volume(s) 
SMLC   static multileaf collimator 
TCP   tumour control probability 
TPS   treatment planning system 
WAPRT  whole abdominopelvic radiation therapy 
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I Summary – Samenvatting – Résumé 
Summary 
Intensity-modulated radiotherapy (IMRT) is a relatively new approach for the old quest of 
three-dimensional conformal radiation technique (3D-CRT). IMRT allows for a greater 
control over the distribution of the delivered dose and by this, enables to create concave dose 
distributions and to conformally spare organs at risk (OARs), like the spinal cord, the optic 
pathways or the parotid salivary gland. Technically, there are several approaches to both the 
planning (segment creation, optimization and dose computation) and the delivery (static 
gantry, rotational, dynamic or static multileaf collimator (MLC)). At the Ghent University 
Hospital (GUH), a unique treatment planning system (TPS) was developed, built on anatomy-
based segmentation and leaf position optimization (LPO), driven by a bio-physical 
optimization function.  
At GUH, IMRT has been clinically implemented for a variety of sites, of which the 
implementation for head and neck cancer (HNC) is the focus of the first part of this thesis. 
The planning strategy is described for re-irradiation of recurrent or second primary HNC and 
for HNC originating from the pharynx or oral cavity. Furthermore, the implementation of 
IMRT for the irradiation of sino-nasal cancer has shown that IMRT results in at least equal 
local control (LC) and overall survival (OS) as conventional radiation techniques, and 
clinically confirms the sparing of the optic pathways. None of the patients who were 
irradiated by means of IMRT lost vision due to radiation-induced toxicity. A review of the 
clinical results of IMRT in HNC, summarizing the experience of the leading IMRT centers 
shows a parallel conclusion: IMRT results in a favourable toxicity profile, but until now, no 
effect on LC or OS has been shown in a well-controlled trial. The observation that most of the 
HNC relapse within the “high-dose” region, indicates that these conventional “high dose” 
levels (+/- 70 Gy) are not sufficient to eradicate all clonogenic cancer cells. Therefore, we 
studied the possibility of dose escalation, guided by biological imaging (positron emission 
tomography; PET) within a clinical phase I trial, with a stepwise dose escalation protocol.  
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Besides the implementation and clinical validation of static-gantry IMRT, the second focus of 
this dissertation is on the development of intensity-modulated arc therapy (IMAT). IMAT is a 
rotational, MLC-based delivery technique, in which the modulation of the intensity is 
obtained by overlapping arcs. The anatomy-based approach, in conjunction with the LPO, 
makes our TPS suitable for the transition from IMRT to IMAT. IMAT has some distinct 
advantages over IMRT in selected cases. In situations where a large concavity in the dose 
distribution is needed, IMAT offers an infinite number of beam directions. Another situation 
where IMAT could be beneficial over IMRT occurs when multiple dose peaks have to be 
created within a lower “dose bath”, a situation often encountered in biological imaging guided 
radiotherapy. A planning strategy for IMAT was developed, and a class solution for whole 
abdominopelvic radiotherapy and radiotherapy for rectal cancer were implemented, after the 
formulation of target delineation guidelines. IMAT was compared with non-intensity-
modulated 3D-CRT, and showed a better OAR sparing for equal or better target coverage. 
IMAT was dosimetrically verified by polymer gel dosimetry (PGD), which allows 3D 
absolute dosimetry. PGD showed a good correlation between calculated and measured dose. 
Finally, IMAT is discussed in comparison with helical tomotherapy: both delivery systems 
are rotational, and have the same indications. Future research will concentrate on the 
improvement of LC in HNC by careful dose escalation, compiling and analyzing the observed 
toxicity in IMRT and on the further automation, development and implementation of IMAT. 
 
Samenvatting 
Intensiteitsgemoduleerde radiotherapie (IMRT) is een relatief recente benadering van een oud 
radiotherapeutisch streefdoel, namelijk de driedimensionale conformele radiotherapie (3D-
CRT). IMRT laat een betere controle over de dosisdistributie (DD) toe dan conventionele 3D 
bestralingstechnieken. Zo is het met IMRT mogelijk om concave DDs te bereiken en om de 
risico-organen, zoals het ruggenmerg, de speekselklier, het oog en de oogzenuwen, 
conformeel uit te sparen. Vanuit een technisch oogpunt zijn er verschillende benaderingen 
voor IMRT mogelijk, zowel op het vlak van planning (creëren van segmenten, optimalisatie 
en dosisberekening) als van de uitvoering (statische versus roterende gantry, statische versus 
dynamische multileaf collimator). In het Universitair Ziekenhuis Gent (UZG) werd er een 
uniek planningssysteem ontwikkeld, dat voornamelijk steunt op anatomie gebaseerde 
segmentatie (ABS) en de optimalisatie van de segmentvorm (SVO) en het relatieve belang 
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van elk van deze segmenten. De optimalisatie wordt gestuurd door een bio-fysische objectieve 
functie.  
IMRT werd in het UZG klinisch toegepast voor een hele waaier van tumorlocalisaties. De 
toepassing van IMRT voor de bestraling van hoofd- en halstumoren (HHT) vormt het 
onderwerp van het eerste deel van deze thesis. De planningsstrategie voor herbestralingen en 
bestraling van HHT, uitgaande van de keel en de mondholte wordt beschreven, evenals de 
eerste klinische resultaten hiervan. De studie van de implementatie van IMRT voor tumoren 
van de neus(bij)holten heeft aangetoond dat IMRT in deze indicatie leidt tot minstens even 
goede lokale controle (LC) en overleving als conventionele bestralingstechnieken. Bovendien 
werd het op planning uitsparen van de optische structuren bevestigd door de klinische 
resultaten: geen van de patiënten die met IMRT behandeld werden, ontwikkelde blindheid 
tengevolge van stralingsgeïnduceerde schade. Een overzicht van de bereikte klinische 
resultaten van IMRT in HHT in andere centra levert een gelijkaardige conclusie op: IMRT 
leidt tot een gunstiger toxiciteitprofiel maar heeft tot op heden nog geen bewijs kunnen 
leveren van een gunstig effect op LC of overleving. De meeste hervallen van HHT worden 
gezien in het gebied dat tot een hoge dosis bestraald werd, wat erop wijst dat deze “hoge 
dosis” (+/- 70 Gy) niet volstaat om alle clonogene tumorcellen uit te schakelen. We startten 
een studie op, om de mogelijkheid van dosisescalatie uit te testen. Hierbij wordt de dosis 
verhoogd op geleide van informatie van biologische beeldvorming (positron emissie 
tomografie; PET).  
Naast de toepassing en klinische validatie van IMRT bestond het werk in het kader van deze 
thesis ook uit de ontwikkeling en het klinisch opstarten van intensiteitgemoduleerde arc 
therapie (IMAT). IMAT is een rotationele vorm van IMRT (d.w.z. de gantry draait rond 
tijdens de bestraling), waarbij de modulatie van de intensiteit bereikt wordt door overlappende 
arcs. Dankzij de ABS, samen met de SVO, is het planningssysteem dat aan het UZG 
ontwikkeld werd uitermate geschikt om naast IMRT ook IMAT aan te kunnen. IMAT heeft 
enkele duidelijke voordelen ten opzichte van IMRT in bepaalde situaties. Als het doelvolume 
concaaf rond een risico-orgaan ligt met een grote diameter, biedt IMAT eigenlijk een 
oneindig aantal bundelrichtingen aan. Ook als er verschillende dosispieken bereikt dienen te 
worden, die elk omringd zijn door relatief lagere dosis, kan IMAT voordelen hebben. Deze 
laatste situatie doet zich vaak voor bij radiotherapie op geleide van de biologische 
beeldvorming. Een planningsstrategie voor IMAT werd ontwikkeld, en type-oplossingen voor 
totaal abdominale bestraling en rectumbestraling werden onderzocht en klinisch toegepast. Dit 
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laatste kon uiteraard enkel gebeuren nadat duidelijke richtlijnen voor de bepaling en 
intekening van het doelvolume waren opgesteld. In vergelijking met conventionele 3D 
technieken, werden betere planningsresultaten bekomen met IMAT. De dosimetrische 
controle van IMAT gebeurde aan de hand van polymeer gel dosimetrie, een techniek die een 
3D absolute dosimetrie toelaat. Er werd een goede overeenkomst gevonden tussen de 
berekende DD, en de met PGD opgemeten DD. Tenslotte wordt een theoretische vergelijking 
gemaakt tussen IMAT en tomotherapy, die beide rotationele therapieën zijn en beide dezelfde 
indicaties hebben. Toekomstig onderzoek zal zich voornamelijk richten op het verbeteren van 
de LC bij HHT, het bijhouden en analyseren van de bijwerkingen van IMRT, en het verder 
automatiseren, ontwikkelen en toepassen van IMAT. 
 
Résumé 
La radiothérapie conformationnelle avec modulation d’intensité (RCMI) est une technique 
relativement nouvelle, qui sert le vieux rêve de la radiothérapie conformationnelle 
tridimensionnelle (RC-3D). RCMI permet une plus grande influence sur la distribution de la 
dose (DD) dans le patient. En utilisant RCMI, il est devenu possible de créer une distribution 
concave de la dose déposée, ce qui permet donc d’épargner d’une façon conformationnelle les 
organes à risque (OAR), comme les structures oculaires, les parotides et la moelle. Au niveau 
du plan technique, plusieurs possibilités de RCMI existent, aussi bien en ce qui concerne la 
planification (génération des faisceaux, l’optimisation, et le calcul dosimétrique), que le 
traitement lui-même (collimateur multilame (MLC) statique ou dynamique, technique 
rotationele ou faisceaux statiques). A l’Hôpital Universitaire de Gand (HUG), un système de 
planification a été développé, basé sur la génération de segments en partant de l’anatomie du 
patient (anatomy-based segmentation; ABS). L’ABS est complétée par l’optimisation de la 
position des lames (OPL) et de l’importance relative de chaque faisceau. Cette optimisation 
est basée sur une fonction objective à part biologique et physique.  
A l’HUG, la RCMI a été introduite dans la pratique clinique depuis plusieurs années et pour 
un éventail de localisations tumorales. L’application de la RCMI pour les tumeurs de la tête et 
du cou (TTC) est le sujet de la première partie du travail présenté. La stratégie de planification 
RCMI et les résultats dosimétriques aussi bien que cliniques pour les ré-irradiations et 
l’irradiation primaire de tumeurs originelles de l’oropharynx et la cavité orale sont discutés. 
L’application de la RCMI dans le traitement des tumeurs des fosses nasales et paranasales 
(TFPN) a résulté dans un contrôle local (CL) et une survie qui est au moins comparable aux 
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résultats obtenus avec les techniques conventionnelles. Sur le plan de toxicité oculaire, aucun 
patient traité par la RCMI n’a développé une perte de vue à cause d’une pathologie radio-
induite. Une mise au point de l’expérience et des résultats publiés des centres de 
radiothérapie, renommés pour la CRMI, nous donne le même message : la CRMI a un profil 
de toxicité avantageux, mais une amélioration du CL reste jusqu'à aujourd’hui a prouver. 
Dans la plupart des patients avec une TTC, qui souffrent d’une récidive, la récidive se 
développe dans la région qui a reçu une dose « maximale ». Cette observation nous montre 
que cette dose, dite « maximale » (d’environ 70 Gy), est insuffisante pour éliminer tous les 
cellules cancéreuses. Nous avons initié une étude d’escalade de dose. La dose escalée est 
dirigée par l’imagerie biologique (la tomographie à émission de positrons, TEP). 
Au delà de l’application et la validation de la RCMI, une nouvelle technique de traitement à 
modulation d’intensité a été développée, à savoir l’arc-thérapie à modulation d’intensité 
(ATMI). La modulation d’intensité est obtenue par la superposition de plusieurs arcs. Grâce à 
l’ABS et l’OPL, notre système de planification est bien équipé pour l’ATMI. L’ATMI a 
plusieurs avantages par rapport à la RCMI. Dans les cas où le volume-cible est drapé autour 
d’un OAR avec un grand diamètre, l’ATMI offre un nombre infini de faisceaux. Aussi dans la 
radiothérapie dirigée par l’information de l’imagerie biologique, l’ATMI pourrait avoir un 
rôle. L’ATMI a été développée pour la radiothérapie abdominopelvienne et pour le traitement 
radiothérapeutique du cancer du rectum. Pour ce dernier, une définition du volume-cible a été 
proposée, basée sur des données de la littérature. Comparé à des techniques 3D, l’ATMI 
résulte dans une protection dosimétrique des tissues normales. Le contrôle de qualité 
dosimétrique pour l’ATMI a été fait à l’aide de gels radiosensibles. Ces gels sont un important 
atout, vue que ces gels sont des dosimètres absolus en 3D. Une bonne corrélation a été 
trouvée entre les DD calculées et mesurées. Dans le proche futur, l’amélioration du CL dans 
les TTC sera un sujet de recherche important. L’incidence de toxicité, et la relation entre 
l’incidence et la dose délivrée, serra analysée, et pour l’ATMI, l’automatisation de 
planification et le développement du traitement viendront au premier plan. 
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II Objectives and outline of the thesis  
Intensity-modulated radiation therapy (IMRT) is a relatively new technique for delivering 
radiation dose to the patient. IMRT permits more control over the distribution of the delivered 
dose than conventional radiotherapy and three-dimensional conformal radiotherapy (3D-
CRT). This results in some new possibilities: 
(1) Creation of concave dose distributions, allowing to homogeneously irradiate a target 
volume that is wrapped around an organ at risk (OAR) [1]. 
(2) Conformal sparing of normal tissue. 
(3) Delivery of multiple dose levels per fraction, creating the possibility of optimization of 
radiobiological characteristics [2]. 
 
The clinical implementation of IMRT aims at an improved complication-free loco-regional 
control. Although IMRT has been increasingly used around the world, clinical validation of 
its results is still scarce (although hardly needed).  
By creating new possibilities, IMRT also raises new questions. The most important question 
introduced by IMRT is concerning the definition of target volumes. Unlike in conventional 
radiotherapy, the outline of the beams is defined by the delineated structures. Therefore, tissue 
wrongly not assigned as target volume will be underdosed. On the other hand, the possibility 
of sparing the OAR is largely influenced by the delineation of the target volume(s) [3]. 
Another related question is how we can use IMRT in order to further improve local control by 
focused dose escalation and how these volumes for dose escalation can be best identified.  
One of the disadvantages of IMRT is the prolonged treatment time which increases with the 
number of beams. It can be shown that for target volumes with a large inner radius, or with 
multiple prescribed dose peaks, more beam directions are needed in order to obtain similar 
results regarding target volume homogeneity and sparing of OARs. Current IMRT delivery 
techniques might be sub-optimal for treating large tumours, and show room for further 
improvement. 
Objectives and outline of the thesis 
The objectives for this thesis were to: 
 
1. validate the implementation hypothesis for IMRT:  
IMRT was implemented for several head and neck cancer (HNC) sites. A clinical protocol 
was developed, specifying the indications, target delineation and planning goals. IMRT has 
been implemented for oral cavity, pharyngeal, laryngeal and sinonasal tumours. For sinonasal 
carcinoma, radiation therapy plays an important role in the multidisciplinary approach. 
Conventional radiotherapy, however, might lead to ocular toxicity, resulting in (bilateral) 
blindness. With IMRT, it is possible to spare the optic pathways without compromising the 
dose to the target volume. IMRT for this site was therefore implemented with the hypothesis 
of higher complication-free local control rates. This has previously been shown for the acute 
toxicity [4]. It was investigated whether the implementation hypothesis was valid by 
examining the treatment results and the long-term toxicity. 
 
2. incorporate biological imaging technologies into IMRT planning: 
For advanced stage HNC, radiotherapy, in combination with chemotherapy, is a possible 
treatment option, and even standard treatment for inoperable cases. Despite optimal 
radiotherapy techniques, a large proportion of these patients will suffer disease relapse. The 
majority of these recurrences are mostly located in the original gross tumour volume (GTV). 
This urges for higher doses to those regions in which clonogenic cells survive. Dose 
escalation should be directed to a small volume, in order to keep toxicity acceptable. The 
incorporation of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET, 
further referred to as PET) in IMRT treatment planning for guiding the dose escalation was 
explored. 
 
3. develop and implement intensity-modulated arc therapy  
Some clinical situations, in which static-gantry IMRT would possibly result in sub-optimal 
results, were identified. An anatomy-based planning approach for intensity-modulated arc 
therapy (IMAT) was developed, and class solutions were set up for whole abdominopelvic 
and pelvic (rectal) irradiation and compared with 3D-CRT techniques on the treatment 
planning level. Before bringing conformal techniques for rectal cancer into clinical practice, a 
clear definition of the target volume, and delineation guidelines were developed.  Polymer gel 
dosimetry was used for dosimetrical control of the planning and delivery.  
Intensity-modulated radiation therapy 
III Intensity-modulated radiation therapy 
IMRT was previously described as “an advanced form of 3D-CRT that uses non-uniform 
radiation beam intensities that have been determined using various computer-based 
optimization techniques” [5]. Crucial in this description is the modulation of the intensity (or 
fluence, which would be a more appropriate term [6]) throughout the beam. The most 
common form of intensity modulation is the use of wedges. However, this is not considered 
as IMRT, as it is not an advanced form of 3D-CRT. There has been an exponentially growing 
interest in the development and the clinical use of IMRT, as reflected by the number of 
publications on this subject (Figure 1).  
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Figure 1: Evolution of the number of publications on IMRT. A Medline (http://www.pubmed.com) search 
was done on June 1st, 2005 using the following terms: [(intensity AND (modulation OR modulated) AND 
(radiotherapy OR radiation OR irradiation)) OR IMRT] in Title. 
 
It is beyond the scope of this work to exhaustively review all the previously described aspects 
of IMRT. IMRT has been excellently reviewed both concerning its physical aspects [5;7] as 
well as the clinical implementation of IMRT [8]. This section on IMRT will give a brief 
summary on IMRT, putting the emphasis on the approach used at Ghent University Hospital 
(GUH).  
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III. 1. Physical principles of IMRT 
Brahme et al [9] tackled the problem of a concave target volume, wrapped around an OAR. A 
clinical example of this often, but not exclusively, encountered situation is HNC, in which the 
tumour and the regional lymph nodes lie concavely around the spinal cord. He showed that, 
for rotational therapy, it is possible to calculate an intensity profile that would result in a  
 
(a) (b) 
 
(c) (d) 
Figure 2: Visual and simplified representation of the work of Brahme et al [9]. The circle represents a 
simple phantom, in which the inner circle represents the organ at risk (OAR), while the outer ring (red) 
represents the planning target volume (PTV), as indicated. The bar represents a simplified beam, with 
omission of attenuation and penumbra. Instead of rotating the beam (as it is the case in rotational 
therapy), the phantom is rotating and the beam is kept stationary, which represents, in fact, the same 
relative situation. Two points in the PTV are followed: one point (A) lies close to the OAR, while the other 
(B) lies far away from the OAR. When the points are “irradiated” by the idealized beam (i.e. they lie in the 
bar), they accumulate dose. Thus, as the rotation progresses (panels (a) and (b)), point B will accumulate 
more dose (D(B)>D(A)), when the beam has a flat intensity profile (c). Brahme has shown that an intensity 
profile can be calculated for which the accumulated dose in all points (represented by A and B; 
D(B)=D(A)) in the PTV is equal, or, in other words, the PTV is homogeneously irradiated (d). 
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homogeneous absorbed dose in such a target volume. This intensity profile is as follows: the 
closer a point in the beam profile is to the OAR, the higher the intensity should be in this 
point. This is graphically explained in Figure 2. This paper is considered as the kick-off for 
IMRT by authorities in the field of IMRT [10-12]. In his paper (time is then 1982), Brahme 
suggested the use of a non-linear wedge-shaped filter to obtain this intensity profile. There 
have been several methods for delivering intensity-modulated beams. The one most 
resembling to the linear wedge is the use of cast metal compensators. However, this is a 
 
 
Figure 3: Representation of the MLC delivery technique for intensity modulation. In the left upper 
corner (a), panel (d) from Figure 2 is portrayed, and the desired intensity profile (curve) is enlarged in 
(b). The ideal intensity profile can be approximated by the superposition (in time) of three beams (or 
segments) with a flat intensity. The two parameters for optimization, to be known the aperture of the 
segment (defined by the leaf positions), and the relative weight “W”, are indicated by the arrows. 
Whereas the phantom is looked at in a transverse view in (a), the same setup is represented in a beam’s 
eye view in (c). A simplified MLC, with two banks of 4 leaves, defines the three segments. In the SMLC 
delivery technique (“step-and-shoot”), the radiation will be switched off between the leaf transition from 
one segment to the following. In the DMLC delivery technique (“sliding window” or “close-in”), the 
leaves will travel during radiation, thus giving a more precise approximation of the desired intensity 
profile. 
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cumbersome technique, as the compensators have to be changed between each beam, and 
have to be made on a patient- and beam-specific basis.  
The first established IMRT delivery technique used the MIMiC multileaf collimator (MLC) 
from the NOMOS® company [7]. This (serial) tomography approach is discussed in section 
IV. 1 on p. 44. 
Today, however, most IMRT treatments are delivered using a MLC, as shown in Figure 3. 
Two modes of delivery exist, known as dynamic MLC delivery (DMLC), in which the leaves 
travel during irradiation, and static MLC (SMLC) delivery. The former form of delivery is 
sometimes referred to as “sliding window” or “close-in” technique, while the latter is more 
commonly known as “step-and-shoot” (Figure 3). In SMLC delivery, the modulation of the 
intensity is obtained by superposed segments. Two parameters can be optimized: the aperture 
of the segment (leaf position) and the relative weight (W) of the segments. 
III. 2. IMRT treatment planning 
The treatment planning strategies for IMRT were historically divided into “forward” and 
“inverse” planning. These terms refer to the points where the planning starts, and where it 
ends. In this view, “inverse planning” starts with defining the goals of the treatment plan, and 
works to an optimized solution, which will ultimately result in a set of beams and segments. 
One could indeed call this “inverse”, as opposed to, e.g. 3D-CRT, in which the beams are 
defined first while their relative weights are then optimized iteratively (by human interaction 
or computer-based). In the same thinking frame, forward IMRT planning denotes the planning 
strategy in which the segments are generated as a first step and then optimized in order to 
reach the predefined goals. However, these descriptions are troublesome, as one could say 
that even for a conventional planning of two tangential fields (as for a breast cancer radiation 
treatment), the goals of the treatment plan are also preset, and a solution (wedge factor and  
relative weights) is also searched for by iteration. Therefore, we suggest adopting the 
nomenclature as proposed by the Intensity Modulated Radiation Therapy Collaborative 
Working Group [5]. Forward planning is then defined as “treatment planning in which the 
planner defines the beam directions and shapes, beam weights, wedges, and so on, followed 
by the dose calculation and then the display and evaluation of the dose distribution. Iteration 
through the process is performed manually to reach an acceptable plan”. Inverse planning is 
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then defined as “treatment planning in which the clinical objectives are specified 
mathematically and a computer optimization algorithm is used to automatically determine 
beam parameters that will lead to the desired dose distribution”. Although unambiguous, these 
definitions fail to propose a useful classification of IMRT planning approaches. Indeed, it is 
theoretically possible to make a forward IMRT planning [1], but it is evident that a computer-
based optimization algorithm will result in a better solution (as was also proven, e.g. [13;14]). 
Therefore, using the proposed definition, all IMRT plans are considered to be “inverse”. Still, 
two largely differing groups of planning strategies can be identified, based on the method of 
segment generation: (1) “optimized fluence map”-based segmentation; and (2) anatomy-based 
segmentation. 
III. 2.1. “Optimized fluence map”-based segmentation 
Most commercially available IMRT treatment planning systems use the “optimized fluence 
map”-based planning approach. An introduction to the different aspects involved is given in a 
recent review [10]. Briefly, it goes as follows: the planner defines a number of beam 
parameters (gantry and collimator angle, energy, modality) and a number of goals (planning 
constraints). Then, for each chosen beam direction, a two dimensional grid is made out of 
“elementary beams” (called beamlets or bixels), after which a fast calculation algorithm 
(referred to as pencil beam algorithm) calculates the dose delivered per beamlet. These data 
form the basis for the subsequent optimization process. The optimization can be separated 
into two components: (1) the objective function; and (2) the search algorithm. 
An objective function (also called cost function) is a mathematical description of the clinical 
objectives for the treatment plan optimization [5]. In fact, an objective function should closely 
mimic the clinical decision-making of an experienced radiation oncologist and physicist. 
However, a computer is unable to visually inspect and compare dose distributions, and take a 
clinical decision on which would be the preferred plan. Therefore, all these data have to be 
summarized into one value (the “cost” or “score”). Several types of objective functions exist: 
- Dose- and/or dose-volume-based objective functions: some simple dose or dose-
volume points are used to describe the treatment goals. Some examples are: maximal 
dose, minimal dose, maximal volume receiving more than 20 Gy. 
- Biological model-based objective functions: more integrative criteria like normal 
tissue complication probability (NTCP) and tumour control probability (TCP) are used 
in the objective function. 
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Thus, any situation of the relative weights of the beamlets can be reduced to one value. 
However, in optimization, we want to compare several situations. Therefore, the weights of 
the beamlets (or other parameters that could be optimized) will have to be adapted, and the 
new situation re-evaluated. If we consider an IMRT plan with 6 beam directions, where all 
beams are divided into 100 beamlets and each 10 possible intensity levels, there would be 
100x106 possible “plans” to evaluate. Obviously, this cannot be done by human interaction. 
Thus, the weight of the beamlets is adapted by a search algorithm. Search algorithms define  
how the next beamlet weight will be adapted. Here too, several methods exist, of which 
gradient search [15] and simulated annealing [16] are the most widespread. An overview of 
these methods is given elsewhere [17]. For each new situation, a score is calculated by the 
objective function. By minimizing (or maximizing, depending on the characteristics of the 
objective function) this score, optimized fluence maps can be made for each beam direction. 
However, these optimized fluence maps cannot be delivered as such, and have to be converted 
to deliverable segments. 
In this conversion, an algorithm tries to define the outlines (for SMLC-IMRT) or the leaf 
trajectories (for DMLC-IMRT) of the MLC leaves that are required to produce a deliverable 
intensity distribution that closely matches the distribution obtained by the optimized fluence 
maps. This “conversion” from optimized fluence maps to a deliverable series of segments, or 
leaf sequence generation, is one of the main disadvantages of the “optimized fluence map”-
based planning approach.  
Indeed, this procedure will lead to a deterioration of the optimized plan quality [18], as the 
number of segments will usually be limited, and the MLC leaves have some physical 
constraints that have to be obeyed. The conversion of optimized fluence maps is further 
explained in Figure 4. Another source for the deterioration of the quality of the optimized plan 
lays in the use of fast (but approximative) dose calculation algorithms for this optimization. A 
fast dose calculation, like the pencil beam method, is indispensable in optimization, as the 
optimization algorithm will go through it for thousands of times. For the sake of speed, these 
algorithms harbour serious flaws, such as inaccurate computation of scatter dose and a limited 
number of dose points in the structures that are included in the objective function. These flaws 
will be abused by the optimization algorithm.  After leaf sequencing and final dose calculation 
using a more precise dose calculation algorithm, the final plan might therefore differ 
substantially from the optimized one, even urging for a new cycle of optimization. 
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Figure 4: The process of leaf sequencing in “optimized fluence map” IMRT planning. (a) typical 
optimized fluence map for one beam direction. The darker the bixels (= elementary beamlet, see text), the 
higher the intensity. At the right, a one-dimensional (1-D) intensity profile along the dashed line is shown. 
(b) shows the 4 segments (1-4) that will be used to approximate the optimized fluence map. The 
deliverable fluence map is shown in (c), with the 1-D intensity profile at the right side. As the eventual 
fluence map deviates from the optimized fluence map, the resulting dose distribution of the optimized plan 
and the deliverable plan (presented here as dose-volume histograms in (d) and (e), respectively) will also 
differ. This difference can also be caused by the different calculation algorithm used during optimization 
(mostly a simple pencil-beam algorithm) and for final dose calculation (see text). 
 
III. 2.2. Anatomy-based segmentation 
Although the work of Brahme [9] was carried out for an ideal cylindrical phantom, using an 
ideal beam (no attenuation, no penumbra), it is obvious that the principle also stands for the 
more complex human anatomy, and for “real life” beams. In contrast to the previous 
approach, here, the creation of segments is the first planning step. Therefore, the number of 
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segments is known before optimization, and cannot increase by the optimization. The 
optimization can be based on very accurate dose calculations, as effects like head scatter or 
leaf leakage can easily be accounted for. Anatomy-based segmentation is also more intuitive 
than “optimized fluence map”-based IMRT plans, thus minimizing reluctance at its 
implementation, and simplifying quality control procedures. The creation of these segments 
can be done in a number of ways, be it manual, or using a computer algorithm. The GUH 
implementation of anatomy-based segmentation is discussed in more detail below. 
III. 3. IMRT at Ghent University Hospital 
De Neve et al [1] repeated the mathematical exercise from Brahme for static beams, and 
implemented the methodology for the concave sparing of the spinal cord. The idea behind this 
development was that, at that time, IMRT (then called beam intensity modulation or BIM) 
could only be planned using a dedicated treatment planning system (TPS). De Neve et al [1] 
showed that it was possible to plan and deliver an IMRT plan with a standard 3D TPS. Since  
this proof of principle, several software tools have been developed in-house, resulting in a 
unique anatomy-based TPS, which we will discuss into more detail.  
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Figure 5: Number of patients treated with IMRT at GUH. Data from the year 1996 have been grouped 
with 1997.  
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IMRT was first applied for patients with a recurrent or second primary tumour of the head and 
neck region, who had been irradiated previously. In this group of patients, the main goal was 
to enable full-dose re-irradiation by selective sparing of the spinal cord [19]. Since then, the 
number of indications for IMRT has been growing to include prostate cancer, lung cancer and 
the majority of HNC. One of the three linear accelerators (linacs) at GUH is dedicated to 
IMRT treatments. The number of patients, treated with IMRT, reached 250 in 2004, and will 
approximate 300 patients in 2005, thus representing one fourth of all treated patients at GUH 
(Figure 5). The number of indications is likely to include gynaecological tumours (cervical 
and/or endometrial cancer) and gastro-intestinal cancer (rectal cancer) in the near future. 
The GUH TPS is a planning system that is largely based on in-house developed software, and 
uses the GRATIS® virtual simulator [20]. As shown previously by Brahme et al [9] and De 
Neve et al [1], the optimal beam intensity profile can be calculated for any given situation. 
Although both calculations are based on a simplified phantom model, the same principle is 
valid for clinical anatomical situations. Thus, segment widths and weights can be roughly 
calculated in advance. This lead to the development of a segmentation tool, creating segments 
based on the anatomy of the patient (anatomy-based segmentation tool, ABST) [21]. The 
input that is provided to ABST consists of one (ore more) planning target volume(s) (PTVs) 
and one or more OARs, the skin contour, and a template beam, defining the isocenter, the 
beam incidence, the linac, the radiation modality and beam quality. The segments are then 
created in a nine-step algorithm: 
1. All PTVs and OARs are projected on the isocentric plane along raylines from the 
source. 
2. A rectangular grid, encompassing the PTV projection, is formed, with a pixel size of 
1x1 mm2. All pixels are assigned a value of zero. This grid is further called 
segmentation grid 
3. Per PTV, all pixels within the PTV projection (=PTV-pixels) are assigned a value of 1. 
4. In the same way, the values of all OAR-pixel are decremented by five. 
5. All pixels with a positive value are divided by (1+D), with D the distance of the pixel 
to the nearest contour point of the OAR projection. This procedure is repeated for each 
OAR. 
6. Rays are traced from the source point to each pixel, and the distance d from the skin to 
the isocentric plane is determined. The value of each positive pixel is multiplied by its 
respective (1+d) value.  
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7. The contours of the segments are now based on the iso-value lines of the segmentation 
grid. A first set of iso-value lines encompasses all grid points with positive values. 
This will form “exclusion contours”, covering parts of the PTV(s), but excluding all 
OAR(s). Further iso-value lines (inside the exclusion contours) are then selected in 
such that they result in segment contours with increasing area. The area of the smallest 
contour is user-defined, as is the multiplication factor, which will define the area of 
the next contour (minimal area x multiplication factor). Contours are further created 
by repeating this procedure, until the area of the segment would be larger than the area 
of the exclusion segment. 
8. Leaves and jaws are placed by closing-in on the previously determined segment 
contours. During this step, the minimal distance constraint of the Elekta MLC – 
opposed and diagonally opposed leaves should be separated with at least 1 cm - is 
disregarded. 
9. During the last step, the leaf settings are adapted in order to meet the minimal distance 
constraint. This is done in such a way that adaptations away from the OARs will be 
favoured, and that the total repositioning distance is minimized  
ABST will result in a number of segments, with an increasing number of (superposed) 
segments the closer a point gets to the OAR. Unlike for “optimized fluence map”-based 
IMRT, no dose computation is needed for the generation of segments. This makes ABST a 
fast method for the generation of segments which serve as a starting point for further 
optimization. A disadvantage of ABST is that it needs an OAR that runs through the 
projection of the PTV in a direction perpendicular to the direction of the leaf motion. 
Therefore, it is sometimes necessary to create a “dummy” structure that complies with this 
prerequisite (like in publication V. 7).  
At GUH, typically, class solutions are developed per site (and disease stage, if appropriate). 
The IMRT Collaborative Working Group describes a class solution as “… a set of criteria for 
optimization (the form of the objective function and the values of its parameters) and the 
specifications of the beam techniques used, typically including beam directions and number 
(of beams). …” [5]. A class solution for a given disease site (and stage) should be designed in 
such a way that its application will lead to an acceptable plan in e.g. 90% or 95% of the cases. 
The major advantage of the use of class solutions is a reduction in planning time (by 
eliminating a priori a lot of parameters that could otherwise be optimized, e.g. beam direction, 
energy,…). Other advantages include homogeneity of the treatments, which is important for 
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the delivery (no “unexpected” collision problems; radiographers are more confident) and 
reporting. By definition, however, the use of a class solution – for a given patient - will result 
in a plan that is sub-optimal (clearly, the optimum plan does never exist [10]!). Therefore, it is 
important to specify the criteria that will be used for plan acceptance or rejection. It is obvious 
that each “candidate class solution” should be tested against these acceptance criteria before it 
can be adopted as “class solution”. Ideally, a class solution in clinical use should be re-
analysed regularly over a group of treated patients, to see if it complies with the needs.   
By using class solutions, only two treatment parameters remain for optimization: (a) the 
relative weight of the segments and (b) the leaf positions of the segments. The optimization of 
both parameters is driven by a bio-physical cost function [14]. As can be inferred from its 
name, both a biological and a physical term are used in this case. For the biological part of the 
objective function, the NTCP is calculated according to the earlier work of Burman et al [22] 
and Kutcher et al [23].  
In this model, three parameters were determined by fitting clinically-derived dose-toxicity 
data points [24], namely (a) “TD50” : dose to the whole organ (or to a reference volume, Vref) 
that would lead to a complication probability of 50%; (b) volume parameter “n” and (c) the 
slope of complication probability “m” (more details are provided in Figure 6). All these data 
were entered in a database used by our TPS. Some new - virtual - organs were added to the 
database, in order to deal with specific clinical situations. As an example, for re-irradiation of 
the head and neck region, it is clear that other biological parameters are needed for the earlier 
irradiated spinal cord. One could set the TD50 to 30 gray (Gy) instead of 65 Gy, and increase 
the slope of the dose-NTCP function by decreasing the slope parameter “m”. These 
parameters for the spinal cord have lost their relationship with the clinical observations by 
Emami et al [24] from which the original parameters were extracted [22]. Still, these “virtual 
organs” have proven to be very useful, and, theoretically, one could extract these parameters 
from clinical data (in this case, from a series of re-irradiated head and neck patients). In the 
same philosophy, virtual organs were constructed which are (ab)used as a replacement for 
physical parameters. By setting both the slope parameter “m” and the volume parameter “n” 
to a very low value, a physical constraint for maximum dose is mimicked, as any point in the 
volume of interest, to which these parameters are assigned, receiving a dose higher than the 
TD50, will give rise to a very high NTCP, and will be severely penalized by the optimization 
algorithm. 
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Figure 6: Relation between dose (Gy) and normal tissue complication probability (NTCP), showing the 
effect of the three parameters on the dose-NTCP relation. TD50 (in Gy) = dose to the whole organ (or to a 
reference volume, Vref) that would lead to a complication probability of 50%; n = volume dependence of 
the NTCP; m = the slope of the NTCP curve; V = relative volume of the organ that receives a specified 
dose. For each panel, the parameters that were kept constant are shown in the left upper legends box, 
while the variable parameter is displayed in the legend box in the right lower legend box. (a) shows the 
effect of the TD50 on the dose-NTCP curve. (b) shows the impact of the slope parameter “m”, while the 
influence of the volume dependence parameter is presented in (c). Subpanel (d) shows the influence of the 
relative volume “V” that was irradiated, for two different volume dependence parameters “n”, namely 
n=0.8 (black lines) and n=0.2 (black dashed line and grey line). As the relative volume V equals unity for 
the black dashed line, there is no impact of “n” on this curve.  
 
The TCP is also incorporated in the biological term, but mostly, the TCP factor is set to unity, 
because to date, for most tumour sites, there are not enough clinical and biological data to 
provide accurate TCP calculations. When using this TCP/NTCP model as the sole base for 
optimization, the dose in (parts of) the target volume (and thus the TCP) will increase, as long 
as the influence of this higher dose on the NTCP of the neighbouring OARs does not 
outweigh the gain in TCP. This might result in dose distributions with very high doses in parts 
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of the PTV. To date, no clinical experience exists for such a type of dose distributions. It is 
clear that such dose to the target volumes might lead not only to higher tumour control rates, 
but also to higher complication probabilities, due to chronic injury to the connective tissue, in 
which the tumour is embedded. The use of a purely biological optimization function, or the 
addition of a physical function, has been discussed in more detail elsewhere [25;26]. It can be 
concluded that, from a theoretical point of view, a purely biological optimization will always 
lead to a higher rate of uncomplicated tumour control, on condition that the biological models 
used fully reflect the in vivo (radio)biologic processes. This assumption cannot be made to 
date, and present TCP models have evident flaws, urging the use of additional physical factors 
in order to control the dose to and inside the target volume(s). The TPS allows the use of 
several physical factors, like maximally allowed inhomogeneity and root-mean-square-
deviation minimization. 
Besides the optimization of the segment weights, the position of the leaves is also optimized 
[27]. This leaf position optimization (LPO) starts from an existing dose distribution, 
calculated by any dose calculation algorithm, and is used as a tool for customization of an 
existing plan. Deliverable segments and the corresponding calculated dose distribution (per 
segment) serve as input for LPO. A leaf adaptation value (e.g. +1 cm) is selected, and the leaf 
position of the first leaf is adapted according to that value (+ stands for an outward placement 
of the leaf). The effect of the change on the dose matrix of the given segment is calculated 
using a fast calculation algorithm, and this effect is accounted for in the summed (over all 
segments) dose distribution. Then, the objective function (as described earlier) is recalculated, 
and if the change in leaf position results in an improvement, the new position is retained 
(“accept”), and the dose matrix for that segment is updated. In case of no improvement, the 
leaf is reset to its original position (“reject”). This procedure is executed for all collimating 
leaves of all segments, and represents one cycle in the LPO process. Each LPO cycle is 
followed by a (short) segment weight optimization. Subsequently, the next leaf adaptation 
value (e.g. -1 cm) is picked, and the whole procedure is repeated. The values that are used 
become progressively smaller (in absolute value), with bounces, and are partly user-defined. 
After all cycles are completed, the new segments are saved, and a final dose calculation (using 
an external dose calculation algorithm) is performed. This final dose calculation is necessary, 
as the dose distributions obtained after LPO are (partly) resulting from the fast (but 
approximate) calculation engine inside the LPO tool. The objective function in LPO was 
initially identical to the one used for segment weight optimization, but this sometimes resulted 
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in segments with a highly irregular aperture. This kind of segments is undesirable due to the 
tongue and groove effect [28], and the difficulty and/or uncertainty for the dose calculation of 
such segments. For this reason, an additional factor was added to the objective function in 
order to minimize these irregular forms (W. De Gersem, data unpublished). It has been shown 
that LPO results in significantly better IMRT plans for HNC [29] without any increase in the 
number of segments (and thus delivery time). Other groups have adapted a similar strategy, 
under the name of “direct aperture optimization” [30]. In a small, unpublished planning 
exercise, Claus showed that, for a head and neck case, it is perfectly possible to generate a 
clinically acceptable plan starting from 5 rectangular “segments” per beam direction (typically 
6), and allowing the LPO algorithm to shape the segments in order to meet the planning 
requirements (Filip Claus, personal communication). Claus’ experiment illustrates how thin 
the line between anatomy-based IMRT planning and “optimized fluence map”-based planning 
can be. A summary of the comparison between both strategies is given in Table 1. 
 
 Favourable characteristics Unfavourable characteristics 
“Optimized 
fluence map”- 
based 
planning 
• Implemented in most 
commercially available planning 
platforms. 
• Independent of any anatomical 
“relationship” between OAR and 
PTV. 
 
• Number and shape of segments 
largely dependent on the 
quality of the conversion 
algorithm. 
• Generally less MU efficient* 
than anatomy-based approach. 
 
Anatomy-
based 
planning 
• Segments are deliverable at any 
time in the optimization 
• The number of segments is 
known and constant at the start 
of optimization. 
• Results in more intuitive and 
smooth segment shapes. 
• Specifically developed for 
situations in which the OAR 
runs through the PTV in BEV 
projection  
• Requires additional, dedicated 
optimization software (LPO) 
 
Table 1: Summary of favourable and unfavourable characteristics of “optimized fluence map”- based 
planning and anatomy-based planning. Abbreviations: PTV = planning target volume; OAR = organ at 
risk; MU = monitor unit; BEV = beam’s eye view; LPO = leaf position optimization.
* MU efficiency: a measure for the number of MUs needed to obtain a certain specified dose. The clinical 
relevance of the MU efficiency is discussed on p. 178. 
 
The problem of deterioration of the planning quality in “optimized fluence map”-based 
planning has also been described by the protagonists of these planning systems [10]. Several 
research groups are working on the incorporation of the MLC restrictions into the 
optimization part, in order to avoid the need for re-optimization [31;32]. It can be expected 
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that both planning strategies will learn from each others weaknesses and advantages, and will 
tend to converge. This “fusion” is already apparent in some commercially available TPSs like 
PrecisePLAN (Elekta) and Pinnacle (Philips Medical Systems) [33]. 
III. 4. Clinical implementation of IMRT for HNC 
III. 4.1. Challenges in head and neck radiotherapy 
HNC is a collective term harbouring a range of tumours, all arising from the head and neck 
region and usually from epithelial origin, differing not only in anatomical subsite, but also in 
risk factors, histological type and natural history. Mainly, six sites are considered under HNC 
[34]: (1) lip and oral cavity ;(2) pharynx, subdivided into nasopharynx, oropharynx and 
hypopharynx; (3) larynx; (4) nasal cavity and paranasal sinuses; (5) salivary glands and (6) 
thyroid gland. The most prevalent HNC sites are the oral cavity, the pharynx and larynx. 
Cancer of the thyroid gland largely differs from the other sites in terms of pathology, 
treatment and prognosis, and will not be considered here. The treatment of HNC is based on a 
multidisciplinary approach towards the patient, in which surgery, radiotherapy and, more 
recently, chemotherapy are sequentially or concomitantly combined. Radiotherapy for HNC 
deals with some problems, which can be grouped into two classes: (1) loco-regional failure 
and (2) toxicity (acute and chronic). Both problems are related to one another, and depend on 
the combination of irradiated volume and delivered dose. Conventional radiotherapy is 
associated with some technical limitations, possibly inducing suboptimal treatments leading 
to an unfavourable outcome. IMRT allows for more flexibility in the dose distributions, with 
creation of concave dose distributions, and conformal avoidance of OARs. The general 
hypothesis for the implementation of IMRT for head and neck radiotherapy is that IMRT 
would widen the therapeutic window, thus resulting in a higher complication-free loco-
regional control.  
Î A general overview on IMRT for HNC is given in publication V. 1 (p. 62). 
III. 4.1.1. Loco-regional failure 
The origin of loco-regional failure lies in the survival of at least one clonogenic tumour cell. 
This can be caused by (1) a geographical miss or (2) an insufficient delivered dose, or a 
combination of both. In standard treatment protocols, there are mainly three levels of dose 
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prescriptions, depending on the load of clonogenic tumour cells. For macroscopic tumour, 
doses of (at least) ± 70 Gy are needed in order to eradicate all clonogenic tumour cells. In 
regions at high risk of microscopic tumour, like the post-surgical tumour bed, doses of ± 60 
Gy are applied. For regions deemed at moderate to low risk for microscopic disease, doses 
around 50 Gy are delivered [35]. Knowledge about the pattern of spread, both locally and 
regionally, is indispensable in the definition of the target volumes, be it at simulation, or on 
the planning computed tomography (CT) and in the formulation of the dose prescription. 
Independent of the definition problem of the target volumes of HNC, good dose coverage to 
the PTV is necessary in order to obtain loco-regional control. The most commonly adopted 
technique in conventional radiotherapy consists of two lateral fields and one anterior lower 
neck field to cover the whole PTV. However, due to the limited tolerance of the spinal cord, 
the end dose with this beam configuration is around 40-44 Gy. At this dose, the posterior 
border of the lateral photon beam is set anteriorly to the spinal cord, and the posterior part of 
the neck is from then on irradiated using electrons, thus sparing the spinal cord (Figure 7).  
  
Figure 7: Illustration of the underdosage, 
induced by the use of a photon-electron 
match line technique. A transverse slice 
through a patient is shown, with the 
mandible and the vertebra (grey shaded 
structures). The planning target volume is 
indicated by the red/darker shaded 
structure. The two lateral photon beams are 
depicted by the dashed-dotted line (black 
arrows), while the dotted lines represent the 
posterior electron beams (grey arrows). The 
dashed lines represent the isodose lines 
(expressed as percent of the prescribed dose). 
The asterisk indicates the region in the PTV 
that receives less than 90% of the prescribed 
dose.  
*
100%
100% 100%
90%90%
70%
Adapted from Fogliata et al [36]. 
  
However, this field matching between the photon and the electron beam can be responsible 
for gaps between the fields, resulting in an underdosage at the junction [36]. In the anterior 
lower neck field, a central block is placed in order to shield the spinal cord. For low-lying 
tumours, like laryngeal and hypopharyngeal carcinoma, this can result in shielding of 
microscopic disease or even of the macroscopic tumour. This is routinely solved by using 
isocentric table top rotations, thus treating the lower neck by lateral photon fields only. Due to 
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the larger radiological path length, however, this nearly always results in underdosage in the 
lower neck region. Both problems can be avoided using IMRT, as the concave dose 
distributions spare the spinal cord during the whole treatment, omitting the need for electron 
beams. 
III. 4.1.2. Treatment related toxicity 
Radiation-induced toxicity is rather arbitrarily divided in acute toxicity and chronic toxicity. 
Acute toxicity starts during radiotherapy, and usually resolves within three months after the 
commencement of the radiotherapy course. Acute toxicity originates from the radiation-
induced loss of the proliferative capacity of the so-called “target cells” , e.g. the clonogenic 
keratinocytes in the skin and oral mucosa, in addition to the ongoing physiological cell loss at 
epithelial surfaces [37]. This imbalance results in tissue hypoplasia and function loss. Other 
processes, like acute vascular response and other inflammatory reactions also play an 
important role in the clinical presentation and course of the acute toxicity [38].  
 
 
Figure 8: Dose-volume histograms (DVHs) for PTV69, PTV56, the spinal cord and the spared parotid. The 
DVHs represent the result of a typical IMRT plan for head and neck cancer, consisting of 32 fractions 
(more details are provided in III. 4.2.2 on page 33). The definition of PTV69 and PTV56 is given in Table 2 
(p. 34). The full lines represent the total physical dose in Gy, while the dashed lines represent the 2Gy-
normalized iso-effective dose – volume histograms (NID2GyVH) for the same structures. The NID2GyVH 
are computed from the DVH data, by applying the formula given by Lee et al [39] with the same 
parameters as given in the caption of Table 2. 
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Chronic toxicity, by convention, appears from 90 days onwards after the start of radiotherapy, 
is considered irreversible and is characterized by vascular injury and tissue fibrosis [40]. 
Apart from other factors, like co-morbidity, genetic susceptibility, and concomitant 
chemotherapy, toxicity is influenced by the total dose, the irradiated volume, and the dose per 
fraction (for the sake of completeness, it should be mentioned that the dose per fraction will 
have a larger impact on chronic toxicity than on acute toxicity). Therefore, IMRT can result 
not only in physical selectivity (= the physical dose to the OARs is lower than the dose to the 
PTV), but also in biological selectivity [41]. Indeed, the sparing of the OARs in IMRT is not 
the result of coning down the treatment fields, like in conventional radiotherapy, but mainly 
by selective sparing through the whole treatment. IMRT results in a lower dose per fraction to 
the OARs than to the PTV, and so, the biological advantage of IMRT will even be more 
pronounced when the ratio of the α/β-values for tumour and OARs is larger than unity. An 
example is given in Figure 8. Here, both the physical dose for the whole treatment is given, as 
well as the normalized iso-effective dose (NID). The NID2Gy represents the biologically 
effective dose, as if the dose was given in 2 Gy fractions [39].  
In head and neck radiotherapy, the target volumes are in the vicinity of multiple OARs:  
(1) Spinal cord: Radiation-induced spinal cord injury leads to the loss in function, not only 
of the stricken segment of the spinal cord, but to the part of the spinal cord that is located 
distally to this segment. On the macroscopic level, the grey matter and the white matter can be 
easily distinguished. The grey matter (centrally located in the spinal cord) is radioresistant in 
comparison with the white matter. As the white matter is mainly composed by longitudinally 
running myelinated axons, white matter necrosis is responsible for downstream paralysis. It is 
believed that the target cells for radiation damage are both the endothelial cells (thus 
compromising the blood supply), and the glial cells (resulting in demyelinisation of the axons, 
and so in loss of signal transduction).  Besides the role of endothelial and glial cells, there is 
emerging knowledge on the influence of cytokines and growth factors in white matter 
necrosis. Clinical presentation largely depends on the position of the injured segment of the 
spinal cord. However, spinal cord injury is a never tolerated side effect of radiotherapy. 
Therefore, the spinal cord will always have the highest importance in planning. The TD5/5 (the 
total dose, given in 2 Gy fractions, that is associated with a chance of a certain endpoint of 5% 
at 5 years after administration) for spinal cord necrosis is 50 Gy [22]. Detailed information 
about the biological response of the spinal cord to radiation can be found elsewhere [42]. We 
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adopted a hard constraint of 50 Gy to the planning risk volume around the spinal cord (dose 
per fraction is then around 1.5 Gy) 
(2) Optic nerve and optic chiasm: Just like the spinal cord, the optic nerves are serial 
structures. Radiation optic neuropathy can lead to vision field defects and, if severe, (bilateral) 
loss of vision [43]. The threshold dose for radiation-induced optic neuropathy lies between 50 
and 60 Gy [22;43]. For doses above 60 Gy, the dose per fraction seems to be a very important 
factor. A dose limit of 60 Gy was adopted as a hard constraint for optic chiasm and optic 
nerves, keeping in mind that the dose per fraction for a 70 Gy prescription in 35 fractions of 2 
Gy to the target volume would thus result in 1.7 Gy per fraction to these optic structures. 
(3) Retina: radiation retinopathy is caused by injury to the vascular supply of the retina, 
causing ischemia, hypoxia and neovascularization. In its turn, this can cause retinal 
haemorrhages, neovascular glaucoma and retinal detachments [44;45]. Retinal damage caused 
by radiation is observed at doses from 45 Gy on [22;46], although Takeda et al [47] found no 
retinal toxicity at doses below 50 Gy.  
(4) Salivary glands: There are three major salivary glands, to be known the parotid, the 
submandibular and the sublingual gland. Furthermore, minor salivary glands are dispersed 
over the mucosa of the oral cavity (mostly buccal, labial, palatal and lingual). Saliva moistens 
the oral mucosa (and dry food), acts as a solvent for molecules that stimulate taste buds, 
contains amylase and lipase for food digestion, and has anti-bacterial actions. A deficient 
salivation leads to the subjective feeling of a dry mouth (=xerostomia), difficulties with eating 
(dry) food, decreased taste and dental caries, and affects the patient’s quality of life. The 
salivary glands are relatively sensitive to radiation, with a TD50 (whole organ irradiation) of 28 
Gy [48] for the parotid salivary gland. The reasons for this radiosensitivity are not completely 
understood, although a possible mechanism suggests a role for redox-active metal ions, that 
are associated with the secretion granules [49]. Serious efforts have been done for sparing the 
parotid salivary gland by using 3D-CRT [50] or IMRT techniques [3;51;52]. A mean dose 
below 26 to 30 Gy is advised when sparing of the parotid is achievable [53].  
(5) Mandible: Mandibular osteoradionecrosis is a serious adverse effect that is relatively 
frequently encountered in head and neck cancer. It is nearly never seen at doses below 60 Gy, 
[54;55], but can reach an incidence of around 10% at doses of 70 Gy. Known risk factors for 
osteoradionecrosis are dose per fraction, invasion of the mandible by the tumour, dental 
extraction after radiotherapy (but also too close before radiotherapy), and concomitant 
chemotherapy [54-56]. 
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(6) Swallowing apparatus: Swallowing is a complex physiological process [57]. The 
deglutition reflex is initiated by the voluntary action of collecting the oral content on the 
tongue, and propelling it backward to the pharynx. From then on, a wave of involuntary 
contraction in the pharyngeal musculature pushes the bolus towards the oesophagus. Just 
caudal to the pharyngo-oesophageal junction, the tension in the oesophagus is high at rest. 
This works as a physiological sphincter. The tension decreases as a part of the swallowing 
reflex. Inhibition of respiration and glottic closure are also essential parts of the reflex. It is 
clear that many different structures play an important role, and that the coordination between 
all the events is of utmost importance. In many patients suffering from a HNC, swallowing is 
already affected by the tumour itself. However, serious swallowing dysfunction can be seen in 
more than half of HNC patients, treated with concurrent chemotherapy, with aspiration in 
60% of the patients [58].  
III. 4.2. IMRT implementation for pharyngo-laryngeal carcinoma 
In HNC, squamous cell carcinoma originating from the larynx and pharynx (oro-, hypo- and 
nasopharynx) represents the largest group. The main reasons to implement IMRT in this 
group of patients is to avoid the photon-electron matchline problem, and to spare the parotid 
gland in well-selected cases [53]. 
Î The implementation of IMRT for oropharyngeal and oral cavity tumours, together 
with the first clinical results, are discussed in publication V. 2 (p. 78). 
III. 4.2.1. Target volume definition and delineation 
The delineation process results in various CTVs, depending on the estimated tumour load they 
contain. A PTV is constructed by applying a 3D expansion to each CTV, using a margin of 
3mm. A description of all PTVs is given in Table 2.  
Î The target definition and delineation process as used for pharyngo-laryngeal 
carcinoma is given in publication V. 4 (p. 108) and in [59]. 
III. 4.2.2. Dose prescription and IMRT planning 
In conventional radiotherapy, the different dose levels result from a “cone-down technique”: 
the neck region, including both macroscopic and subclinical disease, is irradiated up to a dose 
of e.g. 56 Gy, in 2 Gy fractions. After that dose level is reached, the fields are reduced so to 
encompass the macroscopic tumour with an adequate margin, and the treatment is continued 
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until the end dose of 70 Gy is reached, again in 2 Gy fractions. Theoretically, this could be 
done in IMRT treatments too, resulting in one plan per dose level. In this approach, the first 
IMRT plan would deliver a dose of 2 Gy per fraction to PTVAll, a PTV structure containing all 
different target volumes. After the first dose level (e.g. 56 Gy) is reached, a new plan is made 
in order to deliver 2 Gy per fraction to the remaining PTVs (= PTVAll minus PTV56), and so 
on. The advantage of this approach is that conventional fractionation can be used for all target 
volumes. Still, this approach has some clear disadvantages: (1) multiple plans are needed, and 
thus more planner time is needed; (2) during subsequent plans, the previous dose level (e.g. 
PTV56 in the second plan) would accumulate dose that was not accounted for during the first 
plan, and thus, in the end-result, would receive more dose than initially prescribed. No evident 
planning tools exist to take previous IMRT planning results into account. This could result in 
a treatment that violates some planning constraints, like maximal dose to the spinal cord, even 
if this constraint had been met in all separate plans.  
Another approach is to deliver the different dose levels in one plan. This approach is called 
the simultaneous integrated boost (SIB) technique. It has previously been shown that this SIB 
technique results in the more conformal dose distributions than when several IMRT plans are 
used for one treatment [60]. The fractionation scheme used at GUH is shown in Table 2.  
 
Target volume Description Dose/fx 
(Gy) 
TPD  
(Gy) 
NID2Gy 
(Gy) 
PTV69 PTV around the regions containing macroscopic 
tumour. 
 
2.16 69.1 72.5 
PTV66 PTV around the (post-operative) tumour bed and 
resected LNR containing positive lymph nodes 
with capsular rupture 
 
2.06 65.9 67.2 
PTV62 PTV around (resected) LNR containing positive 
lymph nodes without capsular rupture. 
 
1.94 62.1 60.9 
PTV56 PTV around LNR that are to be irradiated 
electively 
 
1.75 56.0 51.1 
Table 2: Fractionation strategy for head and neck IMRT at GUH. Abbreviations: fx: fraction; TPD: total 
physical dose; NID2Gy: normalized iso-effective dose, as for 2 Gy fractions, and calculated according to Lee 
et al [39], with: (1) a total treatment time that is calculated as 7(n-1)/5 with n the number of fractions; (2) 
an α/β-value of 10 Gy; (3) a β-value of 0.035/Gy² [61] and (4) a potential doubling time of 4 days; PTV: 
planning target volume; LNR: lymph node region. 
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The use of multiple PTVs introduces a new problem of priority ranking. Indeed, as the CTVs 
are lying against each other, an overlap region will be created by the expansion of CTVs to 
PTVs. The points in this overlap region will be submitted to a double request concerning the 
delivered dose. It is clear that the PTV with the highest dose prescription (=PTVhigh) has 
priority over the PTV with the lower dose prescription (=PTVlow). To obtain this, the PTVlow 
is split up into an optimization volume (=PTVlow-optim) from which the PTVhigh is subtracted 
with a specific margin. By this method, the overlap region is prevented, and the priority to 
PTVhigh is assured. The dose gradient will be laid between the PTVhigh and the PTVlow-optim. 
The beam-defining part of the class solution that is used for IMRT treatments of patients with 
a pharyngo-laryngeal carcinoma consists of 6 non-opposed, non-equidistant coplanar beams 
(Figure 9). This beam arrangement is rather different than the generally proposed 9 
equidistant coplanar beams [62]. Although the beam directions (45°, 75°, 165°, 195°, 285° 
and 315°) are on themselves non-equidistant , their trajectories could be viewed as 12 
 
 
 
Figure 9: Beam arrangement for head and neck IMRT treatment, as applied at Ghent University 
Hospital. The six beam directions (45°, 75°, 165°, 195°, 285° and 315°) are depicted by the arrows and 
dashed lines. A transverse slice of the planning CT through the oropharynx is shown, as well as a 
projection of the shoulders (dotted lines). The couch is shown, together with the metal components of the 
Elekta table top, in their most outward position (as placed for these treatments). 
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equidistant directions (every 30°). The directions are chosen in such a way that the entrance 
dose through the oral cavity is minimized and beams entering via the (rather mobile) 
shoulders are avoided, as are the metal components of the table couch (see Figure 9). 
Although the use of more beam directions might lead to a better planning result [63], it will 
also lead to longer treatment times. Therefore, the number of beams will always be a 
compromise between delivery time and planning quality. It should also be kept in mind that 
the gain in planning quality is not always clinically relevant. It is only in a minority of the 
patients that the planning goals and constraints, as specified in [59], cannot be reached with 
this setup. In these few patients, an individualized beam arrangement has to be looked for. 
III. 4.2.3. Planning evaluation 
The evaluation of an IMRT plan is done on basis of the dose-volume data and a visual 
inspection of the dose distributions on multiple slices in the three planes. The dose-volume 
data are visually inspected on cumulative dose-volume histograms (DVHs), and automatically 
checked using a UNIX-based shell script. The script checks all imposed constraints for all 
OARs and for the PTV homogeneity (the specific constraints can be found elsewhere [59]). If 
a constraint is violated, the reason for this can often be found by close inspection of the dose 
distribution. As an example, an underdosage in the PTV can be caused by a neighbouring 
OAR. In such a case, a clinical decision has to be made as whether respecting the constraint 
for the OAR is less or more important than reaching the goals for the PTV minimal dose. If 
such a conflicting situation is encountered, an extra optimization cycle is initiated, with a new 
evaluation at the end.  
The use of objective planning evaluation constraints should be a dynamic process, with 
regular review of the applied constraints: if all consecutive plans pass all constraints, 
constraints might be too loose (or the class solution might be too complex for the given 
clinical situation). On the other hand, if no plan can reach all imposed constraints, these might 
be too tight (or the class solution might be inadequate). Of course, clinical treatment results 
(published and own experience) will also play an important role in the evaluation of the 
constraints. 
III. 4.3. IMRT implementation for sinonasal cancer 
Sinonasal sinus carcinoma groups all cancers arising from the nasal cavity and the paranasal 
sinuses. The incidence of this type of cancer is very low, representing only +/- 5% of all HNC 
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[64]. Most prevalent histological types are adenocarcinoma and squamous cell carcinoma, 
while other histological types like esthesioneuroblastoma, melanoma, lymphoma etc. are less 
frequent [65]. The treatment of sinonasal carcinoma is mainly based on a surgical approach in 
combination with radiotherapy [66]. Indeed, these tumours are in close proximity to important 
OARs like the optic apparatus. Also, these tumours often only cause symptoms in a relatively 
advanced stage, when surrounding organs are already affected. This makes radical surgery 
difficult to achieve. Therefore, at GUH, radiotherapy is a standard treatment modality for 
these tumours. One of the major concerns in the irradiation of sinonasal cancer is the risk of 
radiation-induced blindness. In older reported patient series, up to 30% of surviving patients 
developed radiation-induced blindness [67;68]. At GUH, IMRT was implemented for 
sinonasal cancer with the hypothesis that it would result in a higher uncomplicated local 
control. The planning strategy has been reported previously [69]. Briefly, seven beam 
directions (of which 5 in the sagittal plane) are used (see also Figure 2 in publication V. 1). 
Since July 1998, all patients suffering from a sinonasal cancer are treated by IMRT. Acute 
toxicity of this treatment is typically mild, and there is a reduction of dry eye syndrome [4]. 
Long-term results confirm these findings [45], and show equal treatment results in terms of 
local control and overall survival for IMRT as for conventional techniques. However, such a 
comparison is difficult to interpret, due to the patient selection bias that is typically associated 
with this rare cancer.  
Î The long-term results of IMRT for post-operative irradiation of sinonasal carcinoma 
are presented and discussed in publication V. 3 (p. 90). 
III. 4.4. Introducing biological imaging in IMRT planning 
III. 4.4.1. Introduction 
Biological or functional imaging – as opposed to anatomical imaging - denotes all imaging 
modalities that visualize some biological properties of tissues. The use of biological imaging 
can serve three different goals in radiation therapy: 
1. Improving diagnostic and staging accuracy: 
The choice of therapy ultimately relies on an accurate staging. In HNC, the presence 
and location of involved lymph nodes has important therapeutic implications, not only 
for surgery, but also concerning the radiation field size and dose prescription. 
Anatomical imaging, like CT, largely relies on measurements of diameter of lymph 
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nodes [70]. In a prospective study with histopathological control, Adams et al found a 
sensitivity and specificity of +/- 80% for CT and magnetic resonance imaging (MRI) 
(anatomical imaging), while this was 90% (sensitivity) and 95% (specificity) for FDG-
PET [71].  
Also in other sites, and most clearly in non-small cell lung cancer, biological imaging 
(and mainly FDG-PET) has provided promising results in staging. A review of all 
these sites is beyond the scope of this thesis, and is given elsewhere [72].  
2. Guidance for target delineation and dose distributions 
Target delineation is the cornerstone of conformal radiotherapy. Until present, 
anatomical imaging has been the basis for this delineation. CT and MRI both provide 
excellent resolution in the axial plane (+/- 1 mm), but the discrimination between 
malignant and surrounding non-malignant tissue is not always easy. Biological 
imaging might add important information on the extent of the tumour. Daisne et al 
showed that FDG-PET-based automated delineation of the GTV corresponded better 
to tumour macroscopy than CT- or MRI-based GTV delineation for laryngeal cancer 
[73]. 
Biological imaging is also capable of indicating tumour characteristics that are 
important with regard to the tumour response to radiation. Therefore, they could be 
used to create subvolumes within the GTV, each of which could be prescribed a 
different dose, as proposed by Ling et al [74]. The most important radiobiological 
properties that can be imaged currently, are presented in (the non-exhaustive) Table 3.  
3. Therapeutic response evaluation: 
Currently, response to treatment is evaluated by physical examination, anatomical 
imaging, and follow-up. Although important, physical examination is difficult after 
treatment, and is not always sensitive. The major problem with anatomical imaging is 
that it is difficult to differentiate between necrotic tumour, post-therapy oedema and/or 
fibrosis, and tumour recurrence. Waiting for an evident recurrence might preclude an 
adequate second-line treatment. Moreover, early identification of non-responders 
might allow interrupting the therapy and to start alternative treatments, or define the 
need for additional therapy. Biological imaging with FDG-PET, executed early during 
treatment, has shown to be predictive for local control and survival in HNC [75].  
The work presented in this thesis focuses on the use of biological imaging (more specifically 
FDG-PET) in the guidance of target delineation and dose distributions.  
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Tumour characteristic Tracer Imaging modality 
Hypoxia 18F-misonidazole PET 
 60Cu-ATSM PET 
 [lactate]/[NAA] ratio MRS 
 19F-MRI MRI 
Proliferation 18F-fluorothymidine PET 
 11C-methyl-methionine PET 
 [choline+creatine]/[citrate] ratio MRS 
Apoptosis 99mTc-Annexin V SPECT 
Microvasculature leakage DCE-MRI MRI 
Table 3: Biological imaging for radiobiologically important tumour characteristics. Data from the table 
were extracted from [72;76-79]. Abbreviations: ATSM: diacetyl-bis(N-4-methylthiosemicarbazone); 
DCE: dynamic contrast enhanced; MRS: magnetic resonance spectroscopy; NAA: N-acetyl aspartate; 
SPECT: single photon emission computed tomography; Tc: technetium. 
 
III. 4.4.2. FDG-PET 
FDG is the most widely used PET tracer in oncological imaging. The basic principle resides 
in the increased uptake of (deoxy)glucose by malignant cells by the upregulation of glycolytic 
enzymes and glucose transporters. The FDG is phosphorylated by hexokinase and is trapped, 
as it is not further metabolised. Therefore, there is an accumulation of FDG in neoplastic 
cells. However, the (radio)biological significance of the amount of FDG uptake is not yet 
fully understood. The uptake of FGD by neoplastic cells has been positively correlated  to the 
proliferative activity [80], the blood flow and microvessel density in the tumour, and to 
hypoxia (due to hypoxia-induced increase in glucose metabolism). However, other authors 
found a negative correlation between tumour perfusion or cellular proliferation and FDG 
uptake [81]. Differences in tumour models might be partially responsible for these 
discrepancies. 
Another limitation of FDG is that it is far from a specific tracer, as there is also uptake of 
(deoxy)glucose in normal cells (brain, inflammatory cells, active muscle,…). In some cases, 
therefore, it is impossible to differentiate between malignant tissue and inflammation. 
Interpretation of FDG-PET images should therefore best be done in conjunction with 
anatomical imaging, like CT. Furthermore, a careful assessment of patient history and clinical 
examination are of utmost importance. 
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An important drawback of FDG-PET is the poor spatial resolution, being around 5 to 8 mm. If 
the source of positron emission (i.e. the tumour) is smaller than twice this value, the FDG 
activity will be underestimated, due to a partial volume effect, eventually leading to a false-
negative interpretation. Clearly, if FDG-PET is used for the delineation of the tumour, this 
limitation should be kept in mind, as superficial extension of the tumour will not be indicated 
as such by FDG-PET [73]. 
III. 4.4.3. Rationale for the use of FDG-PET in IMRT 
Despite the use of conformal techniques like IMRT, the majority of relapses in HNC patients 
who receive primary radio-(chemo-)therapy occurs within the GTV [82-84]. This relapse 
pattern suggests that doses of 65 to 70 Gy are insufficient to kill all clonogenic tumour cells. 
A logical approach to this would be to escalate the dose to the GTV, or another (better) 
volume that contains those tumour cells that are most likely to survive the standard dose. 
However, Fowler et al found that altered fractionation and dose escalation is limited due to 
acute (mucosal) toxicity [61]. Their data were all based on studies using conventional 
radiotherapy techniques, in which relatively large volumes are treated to these higher doses. 
With IMRT, it is possible to limit the volume treated to a higher dose, and thus, the maximal 
values found by Fowler et al might be irrelevant to IMRT-based dose escalation, which is also 
reported by the authors [61]. In a planning study, Zhou et al [85] showed that, using 9 co-
planar intensity modulated beams, it was possible to escalate dose to the GTV up to 76-82 Gy 
without major influence on the dose to the surrounding CTV and OARs. It seems obvious that 
the volume to which the dose escalation will be directed, should fulfil the following two 
criteria: (1) the volume should contain the most radio-resistant cells, i.e. the origin of a 
possible subsequent relapse, and (2) the volume should be as small as possible, in order to 
avoid an excess of toxicity.  
Biological imaging, like FDG-PET, MRI and magnetic resonance spectroscopy; could 
provide 3D maps of radiobiologically important parameters within the tumour [74]. To date, it 
is unknown which biological imaging modality provides the most valuable information to the 
radiation oncologist (probably, it will be a combination of several imaging techniques). At 
GUH, a dose escalation trial was initiated, in which the escalation is guided by FDG-PET. 
The design of the study is shown in publication V.1, Figure 6. Despite of its known 
limitations, we choose FDG-PET mainly because of two reasons: (1) high FDG uptake in the 
tumour correlates with worse local control and disease-free survival [75;86] , and (2) FDG-
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PET based delineation of the target volume correlates better with the macroscopic extent of 
the tumour than current CT- and MRI-based delineation [73]. Moreover, FDG-PET based 
target delineation results in smaller volumes than CT-based target volumes [73;87]. 
Î The use of biological imaging in target delineation and in dose escalation using IMRT 
is presented in publications V. 1 (p. 62) and V. 4 (p. 108) 
III. 4.4.4. Image segmentation of FDG-PET images 
By segmentation of images, we understand the process of identification and localization of 
each region of interest (CTVs and OARs). This can be done by manual delineation, but for 
biological imaging, other techniques are being developed, mainly for two reasons. First, and 
most important, the interpretation of the biological image – and therefore the delineation - 
strongly depends on the level and window settings. By using an automated image 
segmentation tool, this problem is largely obviated (i.e. the inter-observer variation is 
minimized). Second, the manual delineation is a time-consuming activity, certainly when 
multiple imaging modalities are used (e.g. planning CT, MRI and PET).  
The majority of (semi)automated image segmentation tools use an edge detection. An 
example is given in Figure 10. In the case of FDG-PET, of course, the difficulty is to find a 
threshold so that the obtained volume matches the tumour as closely as possible. Daisne et al. 
[88] developed a methodology for image segmentation, based on the source-to-background 
ratios. A phantom, filled with 6 spheres (with a known volume, ranging from 0.55 to 17.15 
ml) was used. Each of the spheres was filled with 2-3 µCi of 18F. The phantom itself then was 
filled with increasing concentration of 18F, in order to obtain source-to-background ratios 
ranging from 1.5 to 8.7. PET scans were acquired, and an threshold-based image 
segmentation was performed, with increasing thresholds (expressed as a percentage of the 
maximal activity in the spheres). The threshold resulting in a segmented volume closest to the 
true volume of the sphere was retained. These data points were fitted to an inverse function.  
Limitations of the described method are overestimation of small tumour volumes, and the fact 
that the phantom measurements are PET-camera specific, and therefore not easily exportable. 
Also, it is not certain if the methodology that was elaborated on spheres, will hold for 
irregularly shaped tumours. However, the same group applied this image segmentation 
technique to a group of patients with a laryngeal cancer, and found a better correlation 
between the macroscopic tumour (after laryngectomy) and the PET-volume, than with CT or 
MRI [73]. 
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Figure 10: Segmentation of a biological 
image. In (A), a transverse section 
through a tumour is shown in light 
grey, with a zone of necrosis in dark 
grey. A one-dimensional projection 
along the dashed line is also shown 
below.  
(B) shows the concentration of the 
tracer (e.g. FDG) throughout the 
tumour, along the one-dimensional 
projection in (A). In the necrotic part of 
the tumour, there is nearly no tracer 
uptake, resulting in very low 
concentrations. 
(C) shows the voxel intensities, as 
obtained from (B). The dashed line 
represents a threshold value, used for 
automatic segmentation. Several 
methods exits for the determination of 
this threshold value. Voxels will be 
assigned as “in” or “out” of the volume. 
(D) are 1-D representations of 
segmented volumes, obtained by two 
different methods (D1 and D2), 
compared to the true tumour volume 
(D3). In D1, “holes” (like for necrosis) 
are not taken in account, while this is 
the case in D2. Note that in D2, the 
small part of tumour with tracer uptake 
(* in D3), is not delineated due to the 
partial volume effect. 
 
 
Another approach is to directly use the information of the biological imaging modality into 
the planning, thus bypassing the step of image segmentation [89]. Here, a hypothetical 
relationship between the voxel intensity and the intended dose is made. The most simple 
example is a linear relationship between an arbitrarily defined minimum and maximum voxel 
intensity. Once the voxel intensities are translated to intended doses, this new planning 
objective is added to the optimization algorithm. This direct incorporation of biological 
information seems promising, but more work is needed to establish the relationship between 
signal intensity – biological significance – intended dose. 
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IV Intensity modulated arc therapy 
IV. 1. Introduction 
Arc therapy is not a novel delivery technique in radiation oncology. It has been used on cobalt 
machines for deep seated tumours (and was then rather called rotation therapy), compensating 
the lack of high energy photons. A major advantage of all forms of rotational radiotherapy is 
the infinite number of beam directions, resulting in more degrees of freedom, and possibly 
better planning results than those obtained with a limited number of beam directions. The first 
intensity-modulated rotational (or arc) therapy should be attributed to Proimos [90], who 
obtained modulation of the beam intensity by hanging gravity-oriented attenuating blocks on 
the radiation machine. As the gantry rotated, the OARs were shielded by the blocks. Due to 
the rather confined nature if the intensity modulation, however, dose to the target volume was 
not very uniform. The production of the blocks was also labour-intensive, and the technique 
has never been widely applied. With the introduction of MLC-based IMRT, it has been 
abandoned [91]. 
Tomotherapy using the NOMOS® MIMiC MLC was the first widespread delivery method for 
IMRT [92], and was introduced in 1993. In this sequential tomotherapy approach, the linac 
gantry, to which the MIMiC MLC is attached, rotates around the patient and the binary 
position of the leaves (open or closed) are adjusted at every 0.5 degrees of gantry rotation. 
After one pair of slices (there are two banks of leaves) is treated, the table moved 
longitudinally with 2 or 4 cm (the length of one leaf position was adjustable to 1 or 2 cm), and 
the next pair of slices is irradiated. This process is repeated until the whole target volume is 
covered. Patient immobilization and a perfect couch control are of the utmost importance in 
this approach. Moreover, even assuming a perfect control of the couch position and no intra-
fraction patient motion, both under- and overdosages can be created by the use of small arcs 
[93]. Another approach consists of helical tomotherapy, in which the patient is moved 
longitudinally through a slit-collimated fan beam [94]. A clear disadvantage of tomotherapy 
(serial and helical) is the need for a dedicated delivery system. Intensity modulated arc 
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therapy (IMAT) using MLC-equipped linacs was first proposed in 1995 by Yu as an 
alternative to tomotherapy [95]. IMAT is a form of rotational therapy, but has the advantage 
that it can be implemented on widely installed linacs equipped with an MLC. Instead of using 
a slit beam, a conventional MLC is used to form the field apertures. Both the gantry and the 
MLC leaves move during radiation. The modulation of the intensity originates from 
overlapping arcs, each arc consisting of “beams” with a flat intensity on their own. IMAT 
differs from conformal arc therapy in the fact that, in the latter, the field aperture covers the 
whole PTV, while in the former, field apertures of (some) arcs will only cover parts of the 
PTV. Some characteristic features of different radiation techniques are given in Table 4.  
 
Gantry Static Dynamic 
 3D-CRT IMRT CAT OSAMAT IMAT 
Leaves static static or dynamic dynamic dynamic dynamic 
Intensity 
modulation none 
temporal 
superposition 
of segments 
none none 
temporal 
superposition 
of arcs 
Segment 
outline whole PTV part of PTV whole PTV part of PTV part of PTV 
Indications convex PTV  
concave PTV 
(small inner 
radius) 
convex 
PTV convex PTV 
concave PTV 
(large inner 
radius) 
Table 4: Some characteristic features of the most prevalent MLC-based conformal radiotherapy 
techniques. Abbreviations: 3D-CRT = three-dimensional conformal radiotherapy; IMRT = intensity 
modulated radiation therapy; CAT = conformal arc therapy; OSAMAT = optimized segment aperture 
mono-arc therapy; IMAT = intensity modulated arc therapy; PTV = planning target volume. 
IV. 2. Indications for IMAT 
IV. 2.1. Concave PTV around an OAR with large radius. 
We hypothesized that IMAT might have both planning and delivery advantages over static-
gantry IMRT in some clinical cases. More specifically, it was presumed that IMAT would 
obtain better planning results than IMRT in those cases where the PTV is wrapped concavely 
around an OAR with a “large” radius. The modulation of the intensity is needed in order to 
create a concave dose distribution, while the large radius of the concavity demands a high 
number of beam directions. Still, the higher the number of beam directions used, the longer 
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the treatment will take for delivery. Arc therapy represents an infinite number of beam 
incidences, and certainly is the most efficient way for delivery when a large number of beam 
incidences is desirable. IMAT combines these two features.  
 
 
         (A)                                               (B) 
Figure 11: Examples of two distinct planning situations, showing the planning CT scan, with the 
delineated PTV and OAR (upper row), and their abstract representation (lower row). In the left column 
(A), a head and neck case is represented, while in the right column (B), a case of rectal cancer is shown. In 
both cases, the OAR lies within the concavity formed by the PTV, and they only differ in the radius of the 
OAR (and, logically, also the inner radius of the concave PTV).  
 
A planning experiment was done to support this hypothesis. We considered two cases (A and 
B) with a concave PTV, having an OAR within this concavity (Figure 11). In one case (A), 
the OAR has a small radius, and so is the inner radius of the PTV. This situation is typically 
found in the irradiation for a HNC. In the other case (B), the OAR’s radius (and the PTV’s 
inner radius) is relatively large. Again, for this latter situation, there are several clinical 
examples, of which rectal cancer irradiation is the one depicted here. Both distinct clinical 
cases were than simplified in a cylindrical phantom, depicted in Figure 11. For each of these 
phantoms, three plans were made. The first plan consisted of 3 intensity-modulated beams, 
while the second plan used 7 intensity-modulated beams. The last plan consisted of an IMAT 
plan using 4 arcs. All plans were optimized in order to deliver a median dose of 50 Gy to the 
PTV (the dose is chosen arbitrarily). The same PTV homogeneity requirements were used for 
all plans. A hard constraint was set on the maximal dose to the OAR of 30 Gy, while a soft 
constraint was used in order to minimize the mean dose to the OAR and the dose to the 
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surrounding tissue, in order to avoid hot spots outside the PTV. The dose distributions and the 
DVHs for all three plans for both case A and B are shown in Figure 12.  
  
Figure 12: planning results for case A (left) and B (right), represented by dose distributions (upper row) 
and DVHs (lower row). An arbitrary end dose of 50 Gy was chosen. The DVHs are shown for the PTV 
(red, full lines), the OAR (green, dashed lines) and the total phantom volume (black, dashed-dotted lines). 
 
For case A, the 3 beam IMRT plan is unable to produce a homogeneous dose in the PTV for 
the given OAR dose constraint. Also, the use of only three beam directions results in hot spots 
outside the PTV. These problems can be solved by increasing the number of beam directions. 
The 7 beam IMRT indeed results in a homogeneous PTV irradiation, with no overdosage in 
the surrounding tissue, and only at the cost of a larger volume of surrounding tissue receiving 
low doses (and a longer treatment time). The IMAT plan results in a comparable PTV dose 
homogeneity, with a slightly better sparing of the OAR. The DVHs for the three plans for 
case A are summarized in Figure 13
 
Figure 13: summary of the planning results for both cases 
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For case B, the use of three beams results in a larger inhomogeneity in the PTV than for case 
A. The use of more beam directions largely settles this inhomogeneity problem. The IMAT 
plan, however, results in an even better PTV dose homogeneity and a major decrease in dose 
to the OAR. These results are summarized in Figure 13b. This experiment thus confirms the 
hypothesis that a higher number of beam directions is needed to obtain the same planning 
results (= PTV dose homogeneity and OAR sparing) as the inner radius of the concave PTV is 
larger. This hypothesis is also discussed in [96] (see publication V. 5, p. 122). It is of note that 
the number of intensity levels is less for the IMAT plan than for the static-gantry IMRT plans. 
Still, planning results are more favourable for the IMAT plans, indicating that the limited 
number of intensity levels is compensated for by the infinite number of beam directions. This 
was also suggested by other investigators [95]. 
IV. 2.2. IMAT for the delivery of biological imaging guided radiotherapy 
The integration of biological imaging in radiotherapy (section III. 4.4) will lead to the 
fragmentation of PTVs in multiple regions, possibly all with different dose prescriptions. 
Although it has been suggested by Zhou et al [85] that there was no additional benefit – for 
dose escalation - by increasing the number of beam directions (from 9 to 15), this was only 
done on one patient. Moreover, in his study, there was only one dose peak. This does – 
however – not reflect the situation in which several regions, to which a higher dose is 
prescribed, exist. In these cases, a large concave target volume exists, within which reside 
multiple (mostly convex) islands of target subvolumes. For convex dose distributions, it is 
obvious that conformal arc therapy will create the steepest dose gradient when considered 
over the whole target contour. IMAT has the possibility to combine both features of intensity 
modulation and arc therapy, and therefore has advantages over static-gantry IMRT for these 
cases. 
IV. 3. IMAT delivery issues on Elekta linacs at GUH 
The radiation therapy desktop (RTD) from Elekta is the computer system that controls the 
linac. In this RTD, both the linac and the MLC are controlled. However, IMAT is – at the 
moment – not yet possible on the RTD. Therefore, IMAT has to be delivered using prototype 
linac control software, using the “Javelin” control cabinet. In Javelin, the linac (gantry and 
collimator angle, beam quality, dose rate) and the MLC are controlled separately, both driven 
Intensity modulated arc therapy 
by the monitor unit (MU) counter. The dynamic (both gantry angle and MLC) delivery is 
executed as described hereafter [19]. A prescription of an IMAT plan consists of both a 
prescription file for the linac controller (manual input), and a prescription file for the MLC 
controller (transferred over the network).  
The main elements in the linac prescription file consist of a start and stop gantry angle, a 
collimator angle, the beam quality and the number of MUs to be delivered. Other non-field 
related parameters, like table top rotation, are also specified here. Although some 
investigators were able to specify the nominal dose rate (MU/min) [95], we were unable to do 
so without eliminating important safety locks. The nominal dose rate is automatically selected 
from a set of discrete values (32, 65, 130, 260 and 520 MU/min) and is chosen in such a way, 
that the gantry speed is as close as possible to 157.5°/min, with a possible range in gantry 
speed between 105°/min and 210°/min (see Figure 14). The gantry rotational speed within one 
arc is kept proportional to the (slightly fluctuating) nominal dose rate. Therefore, the angular 
delivery rate (ADR), expressed in MUs/°, is constant within one arc. 
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Figure 14: Graph showing the relation between the angular delivery rate (ADR), which is the number of 
MUs that have to be delivered per degree (abscissa), the gantry speed (in °/min; ordinate), and the 
nominal dose rate, selected by the linac controller software. An example is indicated by the dashed lines 
and the arrows: for an arc with a length of 100° and 200 MUs to deliver (= 2 MUs/°), the linac controller 
software will pick a nominal dose rate of 260 MUs/min, and the gantry speed will be 130 °/min. 
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 The MLC prescription file contains a sequence of control points (CPs), in which a CP defines 
a machine state (MS, defined by the gantry and collimator angle, leaf and diaphragm positions 
…) and the cumulative MU count that has to be delivered at reaching the actual CP. The 
transition from one CP to the next one is steered by the MU counter. The value of each 
parameter (like leaf position, diaphragm position, gantry angle, collimator angle) that changes 
between two successive CPs is linearly interpolated as a function of the MU count. All 
machine parameters are constantly monitored during radiation. For the Elekta MLC, the 
actual leaf positions are monitored using a camera in the linac head. When the difference 
between an actual machine parameter, like the position of a leaf, and the prescribed value (or 
the value obtained by interpolation) exceeds a preset tolerance range, the radiation is 
interrupted. The parameter is adjusted until it is within tolerance, and the radiation is resumed. 
When the interruption lasts longer than 5 seconds, the beam is terminated, and an operator 
intervention is needed to finish the remaining arc.  
 
(a)                                                   (b) 
 
Figure 15: Illustration of the maximal leaf speed constraint. The coordinate system from the beam’s eye 
view (BEV) is shown, with the origin through the central axis. A pair of leaves is shown at the first 
control point (CP) (a), and at the next CP (b). The gantry positions at each CP (0° and 8°) are also 
depicted in the left lower corner. The difference in position for the left leaf is only 1 cm, while it is 4 cm 
for the right leaf. If we would assume the maximal gantry speed of 210°/min, the time needed for the 
transition between the two CPs is 2.3 seconds. The requested leaf speed would thus be 1.75 cm/sec, 
exceeding the maximal leaf speed of 0.92 cm/sec. Thus, this prescription has a high probability of 
causing a termination of the arc delivery.  
 
 Any premature termination during IMAT delivery is highly unwanted, as the operator 
interventions needed to complete the prescribed arc considerably extend the treatment time 
and – even more important - are prone to human error. Therefore, they should be avoided, in 
the first place, by making “executable” prescriptions. It is obvious that the dynamic delivery 
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is restricted by the physical constraints imposed by the linac hardware characteristics. The 
gantry speed and the dose rate are automatically set by the linac controller software, and are 
always within the limits. The requested leaf speed, however, depends on the difference in the 
position of that leaf between two CPs (Figure 15). De Gersem found a relationship between 
the requested leaf speed, and the number of beam terminations (Werner De Gersem, personal 
communication), and the maximal leaf speed (MLS) in arc mode was set to 0.92 cm/s for 
planning purposes. This is a value that is obtained empirically, which, if respected in the 
planning, will not lead to treatment interruptions due to leaf lag. The same reasoning is valid 
for the jaws that move orthogonally to the leaves, for which a maximal speed of 1.5 cm/s is 
proposed. 
IV. 4. IMAT planning issues 
In the planning process, an arc is approximated by a large number of static “beams” (as 
mentioned earlier, these are called machine states), interspaced with an equal gantry angle. 
Typically, these MSs are created using a gantry angle interval of 5-10°. It was shown by 
others [97] and also by our group [98], that the size of the angular spacing between 
consecutive MSs does only minimally influence the obtained dose distributions. When the 
angular spacing was varied between 5° and 20°, dose to the central axis nor target dose 
coverage changed [97]. We examined the influence of the angular spacing in a rectal cancer 
IMAT plan. An IMAT plan was optimized and calculated using 8° interspaced MSs. The 
resulting prescription parameters were duplicated at the end of the planning process, and 
additional MSs were created every 2° by interpolating the parameters (gantry angles, leaf and 
jaw positions) of the existing MSs. Then, a dose calculation was done for both (the original 
and the “interpolated”) plans, and both dose grids were compared using dose distributions and 
DVHs. No clinically relevant differences were found for the dose to the target volume. In the 
low dose regions, dose folds appear as a consequence of the coarse 8°-discretization of the 
arc. These ripples in the low-dose regions can be explained by the gaps in overlap near the 
surface. However, in most cases, these dose ripples are of no clinical significance [98].  
At GUH, we chose a gantry angle interval of 8°, which represents a compromise between a 
better approximation of arcs, and available time for planning. As for static-gantry IMRT, two 
planning approaches exist for IMAT: inverse and forward (or better: anatomy-based) 
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planning. Here, we will discuss the anatomy-based planning. Inverse planning for IMAT will 
be discussed later in Section IV. 4.2 (p. 57). 
IV. 4.1. Anatomy-based planning for IMAT (the GUH approach) 
After the delineation of all relevant target structures and OARs, and after the generation of 
optimization structures [96;98;99], the first step in an IMAT plan is the positioning of an 
isocenter. This is done in such a way, that it lies at the center of mass of the PTV. For large 
volumes, like in WAPRT, the position of the isocenter can be critical with regard to the 
maximal aperture of the MLC, and has to be chosen with care. The IMAT planning 
procedure, as it is developed and used at GUH, is shown in Figure 16.  
 
  aSOWAT (3)(1) generate 
machine 
states (MS) 
(2) order MS 
into arcs 
(4) extract arcs with 
constant ADR 
(5) aSOWAT with MU 
optimization per arc
(7)
evaluation of 
plan 
prescription transfer 
to linac and delivery 
constrain 
leaf 
velocities 
MU optimization 
per step (with 
ADR constraint) 
leaf position 
optimization 
n cycles 
no
(6) final dose 
computation with 
CCC/S (Pinnacle) 
accepted 
rejected 
executed? yes
Figure 16: Planning process for IMAT. Abbreviations: ADR = angular delivery rate; aSOWAT = arc-
therapy adapted segment outline and weight adaptation tool; MU = monitor unit; CCC/S = collapsed cone 
convolution/superposition dose calculation algorithm; MS = machine state. A MS is defined as a set of 
machine parameters (gantry angle, position of the leaves, photon beam quality). A step is defined as the 
transition from one MS to the next. More details about all steps are provided in the text, according to the 
numbers in the figure. 
 
(1) Generation of MSs: MSs are generated every 8° using ABST in a pre-defined range of 
gantry angles. This range of possible gantry angles depends on the specifications of the 
treatment couch. The range of usable gantry angles is restricted by the need to avoid that 
beams would traverse metal components of the couch before entering the patient. The Elekta 
table top for the SLi18 has two metal C-arms, which can be swung down in steps of 30°. The 
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largest range of gantry angles was obtained by setting the C-arms on 120° or 150° (with their 
most lateral position being 0°). Aside from the table top structure, the range of possible gantry 
angles also depends on the PTV geometry and the relative position of the isocenter (and the 
PTV as a whole) to the table. For WAPRT, the range of gantry angles was from -128° to 128° 
[96], while this was from -136° to 136° for rectal cancer cases [98]. For the WAPRT cases, 
this limited range of useable gantry angles, in conjunction with the geometry of the PTV, 
urged the need for an additional posterior sliding window beam. Recently, the Elekta table top 
has been replaced by a carbon-fibre table top, called Mastercouch® (Sinmed BV, Reeuwijk, 
The Netherlands), as was suggested earlier [96]. It was shown that the use of the 
Mastercouch® table top allowed more beam incidences, due to the absence of metallic 
elements in its design [100]. Since the implementation of the carbon-fibre, MSs are generated 
in a broader range, being from -176° to 176°.  
  
  
Figure 17: Smooth transition between two adjacent machine states, interspaced with 8 degrees of gantry 
angel rotation. In the upper row, an axial projection is shown, while the BEV can be seen in the lower row. 
The leaf motion from the first machine state to the next is limited, and complies with the constraint of the 
maximal leaf speed.  
 
One of the most important prerequisites for a fluent IMAT delivery is the compliance with the 
MLS constraint. This is largely secured by ABST, as the change in the beam’s eye view 
(BEV) projection of the PTV between two adjacent MSs of the same type will be small 
(Figure 17). Theoretically, the largest leaf motion between two 8°-interspaced MSs is 3.5 cm 
for volumes within 20 cm of the longitudinal axis (20 cm is the maximal aperture of the 
Elekta MLC), thus violating the MLS constraint. However, this only happens in the worst 
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case, and an additional planning tool (a leaf velocity constrainer (LVC), see point 3a for more 
details) was developed to deal with this situation. For a typical case with one PTV and one 
OAR (that is used as segmentation structure), the parameters for ABST are set in such a way 
that they result in 4 MSs per gantry angle: one MS covering the part of the PTV at the left of 
the OAR, one covering the PTV portion at the right of the OAR, and then, again at each side 
of the OAR, a MS covering a small part of the PTV close to the OAR.  
(2) Ordering of MSs into arcs: In this step, MSs are linked to each other to form arcs. The 
MSs are stratified per type (e.g. all MSs covering the part of the BEV projection at the left 
side of the OAR), and ordered on base of the gantry angle. As the gantry cannot rotate over 
the 180° position, the arcs start at -176° and end at 176° (or inversely). If, at a certain gantry 
angle, no MS of a certain type is created (due to the specific anatomical situation), this will 
result in the ending of this arc (Publication V. 7, Figure 2). Thus, if there are 4 MSs per gantry 
angle, this ordering will result in 4 arcs. These provisional arcs will then be used as starting 
point for the optimization. 
(3) aSOWAT optimization: The optimization procedure for IMAT consists of a user-
defined number (=n) of cycles, in which one cycle executes three distinct processes: (a) the 
LVC; (b) MU optimization, with ADR constrainer, and (c) LPO. 
a) The optimization starts with the LVC tool (L. Olteanu and W. De Gersem, method 
unpublished). The LVC checks if the constraints for the minimal separation between 
opposed leaves, diagonally opposed leaves, and opposed jaws is met. This is done for all 
collimating leaves per CP. If the criteria for minimal separation are not met, a force F1 is 
calculated by multiplying the surplus distance (minimal separation minus actual separation; 
in cm) with a constant (1 N/cm). In addition to this, the LVC also examines the maximal 
leaf travel between two CPs. The maximal leaf travel (between two CPs) can be obtained 
from the MLS, the gantry speed and the angular separation between two CPs. If the 
maximal leaf travel constraint is violated, a force F2 is calculated using the same approach, 
in which the surplus distance (actual leaf travel minus maximal leaf travel) is multiplied by 
a constant (1 N/cm). For each leaf, the applied correction (= distance in cm) is calculated 
by multiplying (F1+F2) with a constant 0.5 cm/N.  The whole procedure is repeated until all 
leaves are within the constraints. Then, a fast dose calculation algorithm (the same as used 
in the LPO tool) will calculate the difference in dose between the original and the adapted 
CPs. The dose grids that are used for the further optimization are adapted accordingly. 
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b) The second step consists of MU optimization. Here, it is the number of MU per step that 
is optimized, in which a step is defined as the transition from one CP to the next. As the 
number of MUs per step varies due to this optimization, this will result in an arc with a 
variable ADR. As explained earlier, this is – at present – not deliverable on the Elekta 
linac. Finally, the IMAT plan must consist of (deliverable) arcs with a constant ADR. 
These arcs will be extracted from the preliminary arcs (see point 4: “arc extraction”). This 
arc extraction procedure is a manual operation, and in order to facilitate this, a constraint is 
imposed in order to minimize too large differences between the number of MUs assigned 
to one adjacent step. In fact, this constraint acts like a smoothing tool on the ADR graph 
(Figure 18b). 
c) The LPO is the same algorithm as used in static-gantry IMRT (see p. 26). Thus, during 
this step, the MLS constraint is not considered. If the LPO would result in a violation of 
the constraint, this will be solved by the next LVC execution. 
  
  
(b) (a) 
Figure 18: Illustration of the angular delivery rate (ADR) and the process of the extraction of deliverable 
arcs from preliminary arcs with variable ADR. On the x-axis, the gantry angle (in degrees) is shown, 
while the y-axis gives the number of monitor units that have to be delivered per degree of rotation. (a) 
Theoretical case, with the ADR of one preliminary arc (dashed line). As the Elekta linac is not capable of 
delivering an arc with a variable ADR, this preliminary arc has to be split into several arcs, each with a 
constant ADR. These deliverable arcs are depicted by the full line rectangles, and approximate the 
original ADR curve. The range (R) of the deliverable arcs is thus selected manually, and can be 
“optimized” by trial-and-error. The final (constant) ADR, that can also be viewed as the relative “weight” 
(W), of the deliverable arcs is further optimized by the optimization algorithm. (b) A clinically 
encountered example of an ADR graph, obtained after optimization without (dashed line) or with the 
ADR constrainer (dotted line). The rectangles show the deliverable arcs, derived from the dotted ADR 
graph. 
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(4) Arc extraction (Figure 18): After aSOWAT, the IMAT plan consists of the 
preliminary arcs, of which the apertures and the MU/step are optimized. As in conventional 
radiotherapy, some beam directions (or, for arc therapy: some arc segments) are more 
favourable than others. This is directly reflected by the variable ADR. Arc segments with a 
low ADR might reflect these parts of the arc, where primary dose to the OAR cannot be 
avoided. Still, these arcs are still not deliverable, and have to be split into arcs with a constant 
ADR per arc. This decomposition problem could be compared with the leaf sequencing 
procedure (see p. 19 and also Figure 4) converting optimized fluence maps to deliverable 
segments. In the clinical example in Figure 18b, it is easy to appreciate the difficulty of 
decomposing the ADR graph as obtained after optimization without ADR constrainer. The 
optimization of the MU per step operates in a very large search space. For an example with 4 
preliminary arcs spanning from over the full range, there are 4x44=176 steps to optimize. This 
large “freedom” results in the spiked ADR graph, as shown. The ADR constrainer results in a 
smoother graph, that is easier to decompose [98]. The extraction of deliverable arcs from the 
preliminary arc is not a one-step procedure, as this would result in a very rough discretization. 
Rather, each arc is split off separately. After the isolation of each deliverable arc, the MUs of 
all deliverable arcs are (shortly) optimized (over the whole arc, and not per step), as well as 
the remnant MUs of the preliminary arc (here, MUs are optimized per step). By an additional 
factor in the optimization algorithm, the number of MUs in the original arc is downforced, in 
favour of the MUs of the deliverable arcs. In order to keep the IMAT delivery time-efficient, 
care is taken to keep the number of deliverable arcs low. The extraction procedure for one 
preliminary arc is finished when the remaining number of MUs in the original arc is 
negligible. The range of the deliverable arcs can be optimized by the planner by trial-and-
error, which is a very time-consuming activity. 
(5) aSOWAT with MU optimization per arc: As the optimized original arc is discretized 
by several arcs with a constant ADR, the quality of the IMAT plan deteriorates by this 
procedure. Again, this closely resembles the deterioration in inverse IMRT planning due to 
the conversion from optimized fluence maps to deliverable segments. Therefore, an additional 
aSOWAT cycle is necessary, in order to counteract this decline. The only difference between 
the previous aSOWAT optimization resides in the MU optimization, which is now done per 
arc instead of per step. This guarantees a constant ADR and thus deliverable arcs. 
(6) Final dose calculation: A final dose calculation is done with an external (= not a part 
of the in-house developed planning software) dose calculation engine. Until now, the 
Intensity modulated arc therapy 
collapsed cone convolution/superposition algorithm from Pinnacle® was used. The software 
to convert beam data to the Pinnacle® station was developed in our department. However, 
other dose calculation engines, like Monte Carlo based dose calculations algorithms, might be 
used as well. As for the planning and delivery stage, dose distributions of arcs are 
approximated by calculating the dose delivered by the 8°-interspaced MSs. In order to 
calculate the dose distribution, a number of MUs has to be assigned to each MS. The first and 
last MS receive a number of MUs equal to the total number of MUs for that arc, divided by 
twice the number of steps. The MUs assigned to the other MSs is equal to the total MU count 
for that arc, divided by the number of steps. A final optimization of the weights per arc is 
done, using the results of the final dose calculation. 
(7) Plan evaluation: The evaluation of the plan is done as described earlier (p. 35). If the 
plan does not fulfil the goals, the planning process is re-entered at point 3, 4 or 5, depending 
on the extent of the deviation of the preset goal. If all goals are reached, or no further 
improvements can be made, the plan is finalized, and the prescription is entered into the linac 
controller. The IMAT prescription is then evaluated by executing a dummy run, in order to 
prevent any possible problem at the delivery. 
IV. 4.2. Inverse IMAT planning 
This anatomy-based approach, as described above, differs substantially from the inverse 
planning method that was initially proposed by Yu et al [95]. Yu used a commercial TPS 
(PEACOCK, NOMOS), and adapted it to suit the IMAT needs. An intensity-modulated beam 
is generated every 5°, and after optimization of the fluence map per gantry angle, the 2D 
intensity distribution is segmented into multiple one-dimensional intensity profiles. Each one-
dimensional intensity profile is than translated into a number of “subfields”. Arcs are then 
formed by picking one subfield from the stack of subfields at each beam angle in a top-down 
order. The decomposition pattern of a given beam angle is compared to the finalized 
decomposition pattern of the previous beam angle. Once a decomposition pattern is found that 
meets the constraint of the maximal leaf travel, it is accepted. If none of the decomposition 
patterns meet this criterion, a less stringent criterion is set, resulting in longer leaf travels 
between two gantry angles, and thus a lower dose rate (and subsequently gantry speed) is set 
(which we were unable to do on our linac!). In this method, the outlines of the arcs are thus 
established in a unidirectional way. The inverse planning method was illustrated for a simple 
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phantom geometry [95], but was – to our knowledge - never clinically implemented. Other 
centers who developed IMAT also applied the anatomy-based approach [101-103]. 
IV. 5. Dosimetry for IMAT 
In terms of the requirements asked from the linac and MLC control system, as well as from 
the TPS, IMAT is a demanding technique. Due to the dynamic character of the delivery, both 
concerning the MLC leaves and the gantry, quality assurance for IMAT is not a trivial task. 
The comparison of measured and calculated dose distributions occupies a central position in 
the quality assurance of conformal irradiation techniques [5]. The approach that was used to 
validate IMAT for clinical use consisted of mimicking the whole treatment chain on an 
anthropomorphic phantom. The major advantage of this policy is that it validates the planning 
and delivery procedure as a whole. The apparent drawback of this method is the difficulty to 
dissect any deviation that is found between the measured and calculated dose.  
Different dosimeters have been used for IMAT, such as ionization chambers (1D dosimetry) 
and radiographic films (2D dosimetry) [97;104]. However, as IMAT treatments typically 
result in highly 3D-sculpted dose distributions, a dosimeter capable of measuring in 3D is 
desirable. For the moment, only polymer gel dosimetry (PGD) is capable to combine 3D 
measurements with high spatial accuracy [105]. At GUH, a longstanding and extensive 
experience in PGD is available [106-108]. For these reasons, we selected PGD for the IMAT 
dose measurements. The basis of PGD is the radiation-induced polymerization of (vinyl) 
monomers dispersed in a hydrogel structure [109]. The polymerization reaction is initiated by 
reactive radicals, which are formed by radiolysis during irradiation of the gel. The amount of 
polymer formed is related to the absorbed dose. The polymer alters the nuclear magnetic 
resonance spin-spin relaxation rate R2 of the water protons. This enables the quantification of 
the polymerisation reaction (and thus of the absorbed dose) by MRI. IMAT typically is 
indicated for the irradiation of large volumes, and the dosimeter itself should have a large 
volume to enable the measurement of all relevant dose regions. This prerequisite represents a 
specific challenge to PGD due to technical reasons concerning MRI measurements. [110]. A 
review of the history, principles and implementation of PGD is given elsewhere [108].  
For the two classes of IMAT treatment (WAPRT and rectal cancer), a PGD verification was 
performed [96;98]. A PGD experiment is executed as follows: 
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(1) The relevant region of the Rando phantom (Alderson Research Laboratories, Stamford, 
CT, USA) is selected, and a 4mm thick Barex cast is vacuum moulded over it. Care is taken 
to hermetically close the Barex cast from air, as oxygen would inhibit the response of the gel 
dosimeter. Full scatter condition is obtained by placing three supplemental Rando slices at the 
cranial and caudal side of the Barex phantom during CT acquisition and irradiation. 
(2) The gel-filled Barex phantom is positioned within the treatment room, and laser lines 
are delineated on the phantom in a transverse, coronal and sagittal plane, defining a reference 
point. Fiducial markers, that are readily visible on both CT and MRI, are placed on these laser 
lines for future registration. The phantom is then transferred to a CT scanner that is also 
equipped with calibrated positioning lasers, and positioned according to the delineated lines. 
(3) The CT scan is imported in the planning system, and the delineated structures (PTV, 
OARs and optimization structures) of a selected patient are transferred to the phantom CT 
scan. If necessary, small modifications are done to the delineated structures. An IMAT plan is 
made as described earlier. The prescription is rescaled in order to obtain a fraction of 7.5 Gy 
as a median dose to the PTV. This ensured the maximal response range of the gel, while 
avoiding saturation effects.  
(4) The gel-filled phantom is positioned on the treatment couch, using the laser lines and 
fiduciary markers and is subsequently irradiated. Afterwards, a series of gel-filled test tubes 
were irradiated to known doses for gel calibration purposes. 
(5) The phantom and the test tubes are scanned together in the MRI scanner [110], and a 
dose-R2 relationship is established using the calibration tubes. The R2 maps of the phantom 
are translated to a 3D dose distribution, using the calibration curve. The gel-measured dose 
distribution was registered with the calculated dose distribution as follows: on both the 
planning CT and the MRI, the gel was automatically contoured. Then, the centre of volume of 
both gel-contours was identified, and positioned onto each other. Rotations between the two 
data sets were minimized by the laser line positioning system on both the CT scan and the 
MRI scan, and were assumed to be negligible, which was checked by visual inspection).  
(6) The comparison between the measured and the calculated dose distributions was done 
by visual inspection of both dose distributions and their subtraction image. Also, DVHs were 
computed for all relevant structures, truncated to the gel-volume, both for the measured and 
the calculated dose maps. Additionally, a γ-index [111] was calculated in 3D. 
Î The use of PGD for the dosimetrical validation of IMAT is described in publications  V. 5 
and V. 7 , and in [112]. 
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Key issues discussed in this paper:  
• IMRT is a new technique to fine tune the radiation dose distribution, with the aim to 
reduce the dose to sensitive organs, while delivering a higher prescription dose to the 
tumour. 
• IMRT was performed for oral cavity, pharyngeal and laryngeal cancer with functional 
sparing of salivary glands and reduction of xerostomia, and without increased 
incidence of recurrences near the spared region. 
• In sinonasal cancer, IMRT allows avoiding dry-eye syndrome and optic neuropathy 
but cannot reverse the high failure rates in T4b disease. 
• IMRT allows dose escalation to reduced volumes by concomitant boost techniques. 
• Progress in biological imaging, based mainly on positron emission tomography, may 
allow us to identify recurrence-prone regions inside the tumour as targets for dose 
escalation. 
Intensity Modulated Radiation Therapy
for Head and Neck Cancer
Wilfried De Neve, M.D., Ph.D. and Wim Duthoy, M.D.
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Abstract
In head and neck cancer, intensity-modulated radiation therapy (IMRT) makes the use of electron beams
for irradiation of the posterior neck obsolete, inherently performs missing tissue compensation and allows
concave and intentionally non-homogeneous dose distributions. By clinical use of these physical charac-
teristics, salivary or lacrimal glands, optic pathway or auditory structures can be selectively under-dosed
and good evidence of decreased radiation toxicity is available. Evidence for increased local control is still
lacking. Recurrences are mainly located in the high dose-prescription regions (macroscopic disease, tumour
bed), suggesting the need for higher doses in these regions. Image-aided design of IMRT dose distributions
is an area of intense research. New positron emission tomography and magnetic resonance imaging devel-
opments might allow definition of volumes inside the tumor where treatment failure is most likely to occur.
If these volumes are small, focused dose escalation of large magnitude can be attempted and the hypothesis
of improved local control by IMRT can be tested.
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Introduction
Within a year of discovery, more than a century ago,
x-rays were used therapeutically. Over time, many
technological developments took place that aimed to
improve the delivery of radiation to the tissues where
it is wanted and that reduced the radiation to nor-
mal tissues. This aim, for which the modern im-
plementations are called conformal radiotherapy, is
obviously as old as radiotherapy itself. For many
decades, improvements in radiotherapy were ham-
pered by inability to determine accurately the geo-
metrical location of tumors. In so-called conven-
tional radiotherapy, bony landmarks, air-soft tissue
edges, skin-topography or contrast (liquid, surgical
clips) related to the location of the tumor were used
to define roughly shaped fields. With the develop-
ment of medical CT-scanners, progress in radiother-
apy was boosted. The 3-dimensional (3D) informa-
tion given by CT was further fine-tuned by magnetic
resonance and functional imaging. In conformal ra-
diotherapy, fields from which the aperture was con-
formed to the edges of the tumor replaced roughly
shaped fields. Gantry-based linear accelerators and
isocentric pedestal treatment couches offered a large
window of possible beam orientations in space. Con-
formal radiotherapy became the issue of tightening
the dose distribution to the target shape in 3D.
Treatment machines were designed to deliver flat
(unmodulated: the radiation fluence is practically the
same over the whole cross-sectional area of the beam)
and later also wedged beams. Spatial combinations
of flat and wedged beams collimated to the projec-
tion of the target create a convex high-dose volume
(i.e. it cannot create high-dose volumes with con-
cave surfaces). Using flat beams, the treatment of
tumor volumes with concave surfaces would over-
dose sensitive tissues in the concavities. In the 80s,
Brahme demonstrated the unique potential intensity
modulated (IM) beams to create homogeneous con-
cave dose distributions [1]. Inside IM-beams, the ra-
diation fluence (intensity) was not equal but had a
value that was function of its geometrical location in-
side the cross section of the beam [2]. The concept of
inverse planning was proposed by Brahme as a pos-
sible strategy to make the design of IM-beams feasi-
ble [3]. In inverse planning, computer optimization
technology is used to convert a (medically) desired
dose distribution into instruction files of the (robo-
tized) treatment machine. Execution of the instruc-
tion files by the machine leads to a dose deposition in
the patient that is as close as possible to the desired
dose distribution.
IMRT remained a research topic in physics labo-
ratories until, in 1993, Carol proposed an integrated
planning and delivery system (NOMOS MiMiC) ca-
pable of clinical IMRT tomotherapy [4]. Since 1993,
much happened. The major vendors of linear acceler-
ators developed multileaf collimator (MLC) technol-
ogy capable of delivering IMRT. Smaller companies
developed micro-MLCs for IMRT. IMRT research is
intense and clinical results have been published for
various tumor sites including prostate, head and neck
and base of skull. A variety of methods to plan and
deliver IMRT are available. Now, the field of IMRT
application is not only the generation of concave dose
distributions but includes almost any clinical situa-
tion in which precise control of the dose distribu-
tion, inside as well as outside the tumor volume, is
required.
IMRT for head and neck cancer was pioneered
by investigators from the University of Michigan in
Ann Arbor [5, 6]. Several other groups have recently
reported on the use IMRT for head and neck can-
cer [7, 8, 9, 10, 11]. A PubMed search on February
25, 2004 using IMRT and head and neck neoplasms
as keywords yielded 88 publications, mostly dealing
with treatment planning and physics-related issues.
Reports of clinical outcome of IMRT are scarce. Re-
sults from randomized trials testing the hypothetical
benefit of IMRT over un-modulated beam techniques
are inexistent. Conclusions about efficacy and toxic-
ity have to be derived from small case series in sin-
gle institutions (level of evidence III). In most series,
the IMRT techniques have changed during the stud-
ies. Nevertheless, some pertinent conclusions can be
drawn. This review will discuss i) the rationale for
using IMRT in the head and neck region, ii) the ben-
efit obtained by IMRT according to clinical data, iii)
the need for improvement of the clinical results and
iv) the present and future directions of research.
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Figure 1: Locoregional control and survival in 44 sinonasal tumors.
Rationale for IMRT in head and neck
cancer
Six major head and neck cancer sites can be distin-
guished: paranasal sinus, oral cavity, pharynx (naso-
, oro- and hypopharynx), larynx, salivary gland and
thyroid gland. The anatomical challenges for safe de-
livery of radiotherapy are site dependent and increase
with T-stage.
In head and neck cancer, IMRT has been ad-
vocated for its ability to create concave dose dis-
tributions [12, 13] in order to spare organs at risk
(OAR) including spinal cord, salivary glands, optical
pathway structures; to avoid photon-electron beam
matching planes [13] and to facilitate prescription of
intentionally inhomogeneous dose distributions as in
case of simultaneous application of multiple dose lev-
els [13, 14].
Beautiful examples of concave PTVs are found
in each of the 3 subsites of pharyngeal cancer [15].
The pharynx is located anteriorly and antero-laterally
from the brain stem and spinal cord. The phar-
ynx is spaced (distance 1-2.5 cm) from these ner-
vous structures by the sphenoidal body (corpus os-
sis sphenoidalis) and the cervical vertebral bodies and
their pre-vertebral muscles. Brainstem and/or spinal
cord are the posteriorly located organs at risk (OARs)
in the irradiation of pharyngeal cancers. Superi-
orly (cranially), various other central nervous sys-
tem (CNS) structures form a corona of OARs (brain,
pituitary, chiasma opticum, optical nerves) that give
rise to planning problems especially for nasopharyn-
geal tumors. Antero-superiorly, the eyes and acces-
sory structures restrict access to incoming or outgo-
ing beam trajectories. Left and right lateral OARs are
mandibular bone and parotid glands for nasopharynx
and oropharynx sub-sites. Pharyngeal cancers show a
high incidence of sub-clinical or macroscopic lymph
node metastases to many areas of the cervical lym-
phatic drainage system. Lymph node area II is of spe-
cial concern to the radiotherapy planner when parotid
sparing is a treatment objective [16].
Tumors that invade the lateral pharyngeal re-
cesses or the para-pharyngeal space pose a dosimet-
rical challenge. The matching plane between elec-
tron and photon beams, used in conventional irradi-
ation techniques to spare the spinal cord, typically
transects through gross tumor. Because of a rapidly
widening of the electron beam penumbra with depth,
the conventional technique carries substantial risk for
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under-dosage of the anatomical structures located at
the deep portion of the matching plane at the electron
beam side. Photon IMRT-techniques allow avoidance
of under-dosage at the lateral pharyngeal recesses and
the parapharyngeal space.
For paranasal sinus tumours, concave dose dis-
tributions are needed to spare optic pathway struc-
tures [17]. For oral cavity and pharyngeal tumours,
the advantages of IMRT are most prominent if ir-
radiation of the primary tumour and cervical lymph
node chains is prescribed, especially if sparing of the
parotid is attempted [5]. For most head and neck
sites, planning studies show an improved target cov-
erage compared to conventional techniques [19, 20,
21, 22, 23]. For paranasal sinus, improved dose re-
duction to OARs at equal target coverage was re-
ported [24].
Clinical results
Typical for the achievements of IMRT in head and
neck tumors are the results from Eisbruch [25] and
Dawson [26] of University of Michigan for oral cav-
ity, oropharyngeal, hypopharyngeal and laryngeal tu-
mours; from Lee [27] of University of California
at San Francisco for nasopharyngeal tumours; from
Claus [17] of Ghent University Hospital for sinonasal
sites and from Chao [28] of Washington University
for all sites except salivary and thyroid gland. The
study of Chao also included cancers of unknown pri-
mary (CUP).
Oral cavity, oropharyngeal, hypopharyngeal
and laryngeal tumours
Eisbruch reported on the outcome of 88 patients irra-
diated with parotid sparing 3D-CRT or IMRT. Saliva
flow rates before and after radiotherapy were mea-
sured for 152 parotid glands. From these data a
dose/volume/function relationships was obtained that
showed that a parotid mean dose < 26 Gy was consis-
tent with preservation of salivary gland function [29].
None of the recurrences in 12 of 58 patients were ob-
served nearby the spared parotid glands [26]. The
main conclusions were that parotid function sparing
may be achieved without increased risk for relapses
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Figure 2: Directions of the 7 beams used at Ghent
University Hospital to treat N0 sinonasal tumours. In
most patients, the major lacrimal glands and the lat-
eral parts of the tarsal and accessory glands are not
exposed to primary radiation from beams 1, 2 and 3.
adjacent to the spared area and that failures occur
mainly in the high-dose area. Amosson et al. showed
that IMRT allowed dosimetric sparing of the parotid,
which resulted in less subjective feeling of xerosto-
mia [30].
Sinonasal cancer
The report on IMRT for sinonasal cancer [9] was up-
dated in 2003 (De Neve: teaching course at ECCO
12, Copenhagen, 21-25 Sept 2003). A summary of
the update is presented here. Between 1999 and 2002,
44 patients received R0 surgery for ethmoid sinus
(n=33), maxillary sinus (n=6) or nasal cavity (n=5)
cancer. PTV prescription dose was 60 Gy with a max-
imum dose constraint of 50 Gy to the optic nerves and
chiasm for the first 4 patients, 66 Gy for next 4 pa-
tients and 70 Gy for the remaining 36 patients. In one
patient no dose constraint was implemented for the
IMRT for head and neck cancer
Table 1: Complications of post-operative radiation therapy for ethmoid sinus tumors.
Period Radiation therapy Number of patients Grade 4 optic neuropathy Dry-eye syndrome 
1985-1994 2D 19 0 5
1995-1998 3D 11 2 2
1999-2002 IMRT 33 1  0
  Chronic conjunctivitis and keratitis,visus drop to < 20 of visus before RT. Enucleation in 1
patient.  No dose constraint was applied to the left optic nerve damaged by tumor. A dose of 70
Gy to the optic nerve resulted in blindness of the left eye.
left optic nerve because of a pre-existing severe drop
in visual acuity caused by tumour extension. This pa-
tient developed full blindness of the left eye. For the
optic nerves and chiasm of the remaining 39 patients,
the structures were expanded by 2 mm and a max-
imum dose constraint of 60 Gy was implemented.
None of these patients developed blindness. Loco-
regional control and survival are shown in figure 1.
Median duration of follow-up in surviving patients is
14 months. Loco-regional control was excellent for
patients with T1-T3 stage but poor in T4 stage. All
patients with T4b developed local or lepto-meningeal
relapses within 8 months after treatment.
Table 1 gives a summary of optic pathway in-
jury for the subgroup of patients with ethmoid sinus
primary tumours. A comparison with historic con-
trols was performed. During the period 1985-1994,
most patients were treated using anterior and ipsi-
lateral wedged fields, sometimes complemented with
an opposed lateral field. Of 19 patients, receiving
prescription doses of 54-66 Gy (1.8 Gy/fraction), 5
patients developed severe dry-eye syndrome. During
the period 1995-1998, 3D-conformal non-coplanar
techniques were used. Of 11 patients, receiving pre-
scription doses of 60-70 Gy (2 Gy/fraction), grade 4
optic neuropathy was observed in 2 patients and se-
vere dry-eye syndrome in another 2 patients. For the
33 patients treated by IMRT during the period 1999-
2002, grade 4 optic neuropathy was seen in the one
patient where optic nerve sparing was not attempted.
For this group of patients, the duration of follow-up
is too short to draw conclusions regarding optic path-
way injury. With regard to dry-eye syndrome, rel-
evant conclusions can be drawn since patients who
develop severe dry-eye syndrome are symptomatic
within months after radiotherapy. None of the pa-
tients developed severe dry-eye syndrome and this
observation can be explained by the IMRT beam ar-
rangement used at GUH (figure 2) rather than by
beam modulation itself. The major lacrimal glands
are located at the upper-lateral corner of the orbit
while the other (accessory and tarsal) lacrimal glands
are located in the upper eyelid. The BEV-projection
of 3 or more of the 7 beams, used by the GUH class
solution (figure 2), excludes most of the lacrimal ap-
paratus. In addition, most of glandular tissue is lo-
cated less than 5-7 mm below the skin, in the build-up
region of many of the beams. By this beam arrange-
ment, most of the lacrimal gland apparatus typically
receives a dose well below 30 Gy, which seems con-
sistent with functional sparing (figure 3).
Nasopharyngeal tumors
Lee [27] reported the results of 67 patients with non-
keratinizing (n=34) or undifferentiated (n=33) stage
I-IV nasopharyngeal cancer treated with IMRT (com-
bined with chemotherapy in most patients) between
April 1995 and October 2000. IMRT given by com-
pensators, MLC or MIMiC was used to treat head re-
gion, conventional fields were used to treat the neck.
With a median follow-up of 31 (range 7-72) months,
loco-regional control was obtained in all but 2 pa-
tients; one with a local relapse and one with a fail-
ure in the neck. The 4-year actuarial overall survival
was 88% and the 4-year actuarial distant metastasis-
free rate was only 66%. The authors pointed out
that xerostomia was less than would have been ex-
pected with conventional radiotherapy. The high
local-regional control rate suggests that IMRT pro-
vided good tumor target coverage.
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Figure 3: Dose-effect relationship for severe dry-eye syndrome. With doses of less than 30 Gy to the lacrimal
apparatus, induction of severe dry-eye syndrome was a rare event. A: [42] B: [43] C: [44] D: [45].
Various sites and CUP
Chao described the clinical outcome, with a median
follow-up of 26 months, of IMRT for 165 head and
neck cancer patients from which a subgroup of 126
patients were treated for primary tumours [28]. IMRT
was given for upper neck and head and conventional
AP photon beams for the lower neck. Of the 17/126
patients who had loco-regional relapse or progres-
sion, the site of failure was gross tumour and/or adja-
cent sites in 10 patients (1 patient had also a relapse in
the lower neck region). In 3 patients the site of failure
was the electively irradiated site (n=1) or marginal to
the electively irradiated site (n=2) while in 4 patients
isolated failure occurred in the conventionally treated
lower neck. The main conclusion was that the pre-
dominant tumor failure occurred within clinical tar-
get volume at high prescription dose.
These and other published data provide good ev-
idence that IMRT can reduce side effects in head
and neck cancer. However, most loco-regional re-
lapses still occur in the region that was selected to
receive the highest prescription dose. Chao pointed
out that this may imply the need to identify patients
with radio-resistant tumor sub-volumes (such as hy-
poxic regions) within the tumor [28].
Directions for further improvements
Two main arguments were used in favour of IMRT.
Selective dose-reduction to radiation-sensitive organs
would result in less toxicity. Alternatively, reduc-
tion of the dose to OARs relative to the tumour pre-
scription dose would open a window for dose esca-
lation with the aim to improve local control. Table
2 shows that in the abovementioned IMRT stud-
ies [28, 17, 26, 29] conventional levels of prescrip-
tion doses were used and that dose escalation was
not attempted. In fact, dose prescription to gross tu-
mour or elective sites was performed as in conven-
tional radiation therapy. A homogeneous dose was
prescribed at different dose levels for sub-regions of
the PTV. By using IMRT, the dose could be low-
ered to selected OARs like parotid glands, lacrimal
glands, optic pathway structures, middle ear or tem-
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Figure 4: Biological image-guided intensity-modulated radiation therapy (BG-IMRT) optimization. (A)
Anatomical information remains the basis for conventional PTV definition. (B) Biological imaging provides
radiobiological information as a SI to voxels that is proportional to a radiobiological parameter. (C) Fusing
provides an image where each voxel has a Hounsfield value and SI. (D) BG-IMRT optimization requires the
development of a transformation engine that secures a spatial dose variation in the anatomical PTV (E) as a
function of SI in the PET imaging. D-base: Conventionally applied dose level that encompasses the anatomical
PTV; D+/D++/Dmax: Dose escalation (limited to intra-PTV regions as function of SI values); PTV: Planning
target volume; SI: Signal intensity.
Table 2: Prescription doses (Gy) of intensity-
modulated radiation therapy in head and neck cancer.
Clinical target
volume
Elective Ref.
1st 2nd
70.4 61.2 50.4 [26, 29]
60-70 50-60 - [27]
60-70 - - [17]
70 56 [28]
poral lobes. This resulted in a reduction of the sever-
ity of a specific side effect but the window for dose
escalation remained small, if not inexistent, because
of the presence of the remaining dose-limiting struc-
tures like cartilage, connective tissues, nerve tissues,
bone, the swallowing apparatus or the lymphatic sys-
tem in the large volume treated at high-dose. With
the risk of over-simplification, we could state that
the high-dose volumes are too large for a strategy of
homogeneous dose escalation. We hypothesize that
dose escalation focused to small sub-volumes of the
PTV is feasible. The hypothesis is supported by the-
oretical considerations [14], by results of feasibility
trials using a simultaneous boost technique at Bay-
lor College [31] and at Virginia Commonwealth Uni-
versity [32] and by experience obtained with com-
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bining high-dose or accelerated external beam radio-
therapy or radio-chemotherapy with stereotactic ra-
diosurgery [33] or with brachytherapy [34, 35].
It seems self-evident to direct foci of dose escala-
tion to the regions inside the tumour that are supposed
to be the most radiation resistant [36]. Novel biolog-
ical imaging techniques, mostly based on PET, MRI
and MRS may have the potential to construct three-
dimensional maps of radio-biologically relevant pa-
rameters [37, 38, 39]. These maps can be fused with
high-resolution CT and MRI for treatment design and
optimisation with a strategy of small-volume focused
dose escalation to radiation resistant foci. The strat-
egy for clinical trials of focused dose escalation at
GUH involves the flow of procedures given in fig-
ure 4. Anatomical (CT) information remains the ba-
sis for conventional PTV definition. Biological (PET)
imaging provides radiobiological information as a
signal intensity (SI) to voxels that is proportional to a
radiobiological parameter like hypoxia, proliferation,
intrinsic radiation sensitivity. Fusing provides an im-
age where each voxel has a Hounsfield value (for
computation of absorbed dose) and a SI (for intra-
tumour guidance of the dose distribution). Bio-image
guided-IMRT optimisation requires the development
of a transformation engine that secures a spatial dose
variation in the anatomical PTV as function of SI in
the PET imaging. The D-base indicates a convention-
ally applied dose level that encompasses the anatomi-
cal PTV. Dose escalation (D+, D++, Dmax) is limited
to intra-PTV regions as function of SI values.
The fourth dimension
The current state of the art for planning and evalua-
tion of irradiation treatment of cancer patients is to
work in three dimensions (3D) and to consider the
patient as unmoving and unchanging, that is, images
that are made once prior to therapy are considered
representative for the whole course of treatment. As
a result, the precision of treatment is compromised
by anatomical changes during treatment even if pa-
tient immobilization and positioning can be done ac-
curately.
The problem is illustrated in figure 5. Suppose
that the dose distribution was optimised using pre-
treatment anatomical and biological imaging. This
Figure 5: Biological image-guided optimization. (A)
Based on biological and anatomical imaging imme-
diately before the onset of radiotherapy. This results
in a treatment where the high-dose peaks are accu-
rately focused to the regions of the tumor that showed
the highest signal intensity. This treatment plan may
be appropriate to deliver focused dose escalation as
long as the anatomical and biological image geome-
try remains unchanged (e.g., during the 1st week of
treatment). (B) Tumor response observed at the 4th
week of treatment illustrates that the patient cannot
be considered unchanged for the whole duration of
treatment. The planned dose deposition would focus
dose escalation into the oropharyngeal cavity, which
is obviously useless.
D-base: Conventionally applied dose level that en-
compasses the anatomical planning target volume
(PTV); D+/D++/Dmax: Dose escalation (limited to
intra-PTV regions as function of signal intensity val-
ues).
dose distribution may be suitable in the beginning
of the treatment course. However, after 4 weeks
of treatment when the tumour has regressed, one of
the intended dose peaks coincides with the air of the
oropharyngeal cavity, clearly unlikely to host radia-
tion resistant cells. Figure 5 illustrates that an IMRT
plan based on biological image information can be
applied only during a brief time period. After that pe-
riod, both re-imaging and re-planning need to be per-
formed. This is not trivial since neither the methods
for re-imaging nor the technology to re-optimise the
plan taking into account a delivered dose on a chang-
ing anatomy are available. Therefore we reasoned
that a strategy of focused dose escalation might be
IMRT for head and neck cancer
First
patient
visit
Presentation
and treatment
decisions for
patient at the
MGHNT-GUH
Trial
information
to patient.
First visit
at radiotherapy
department.
Informed consent.
PET
Treatment period
radio-(chemo-)therapy
2 wks post RT:
First control
at radiotherapy
department
Months post radiotherapy:
1 2 3* 4 5 6 7 8 9 10 11 12
CE x x x x x x x x
CT x x* x
MRI x*
CE:
CT:
SF:
clinical examination. * In case of doubt on
Includes clinical evaluation complete remission
of tumour and toxicity scoring. do FDG-PET.
CT-scan
Evaluation of swallowing
function by means of video-recorded
fluoroscopy.
PTV based
on CT/MRI
PTV-PET
PTV-70Gy
PTV-62Gy
PTV-55Gy
Phase I
10 fractions
(Gy/fraction)
2.50
2.16
1.94
1.75
Phase II
22 fractions
(Gy/fraction)
2.16
2.16
1.94
1.75
Total physical
dose
(Gy)
72.5
69.1
62.1
56.0
Total dose
(2 Gy
equivalent)
74
70
62
55
Figure 6: Design of the pilot study: first level of focused dose escalation. Table shows that focused dose
escalation to PTV-PET is performed at 2.5 Gy/fraction during the 2 weeks of Phase I treatment. Abbreviations:
MGHNT-GUH: Multidisciplinary Group on Head and Neck Tumours-Ghent University Hospital; PTV-PET:
planning target volume obtained by a 3 mm isotropical expansion of the automatically contoured lesion defined
by FDG-PET. PTV-70Gy, PTV-62Gy, PTV-55Gy: different planning target volume based on CT and MRI
imaging with prescription doses of respectively 70, 62 and 55 Gy biological (2 Gy equivalent) dose. Inserted
table shows that focused dose escalation to the PTV-PET is performed at 2.5 Gy/fraction during the 2 weeks of
phase I of the treatment.
applicable for a short time period immediately after
imaging. This reasoning was incorporated in a pilot
study described below.
Pilot study of focused dose escalation
The purpose of this study was to apply focused dose
escalation to the GTV in patients with histological
proof of carcinoma of the oropharynx, hypopharynx
or larynx who were referred for primary radiother-
apy or radio-chemotherapy. The design of the study
is shown in figure 6. The radiation treatment was di-
vided in 2 phases: a first phase of 10 fractions fol-
lowed by a second phase of 22 fractions. FDG-PET
image information is used in plan optimisation for the
first phase only. During the second phase of treat-
ment a conventional IMRT treatment is applied. At
the first level of dose escalation, a simultaneous boost
was delivered to a PTV-PET. The PTV-PET was a
3 mm expansion of a GTV-PET that had been auto-
matically delineated based on signal to background
ratio in the FDG-PET image. The technology had
been developed by Grégoire and co-workers [40].
They have shown that this GTV-PET correlated much
better with the macroscopic surgical specimen than
expert-contoured GTVs based on CT or MRI images
(Grégoire, personal communication).
The GTV-PET was also much smaller than the
IMRT for head and neck cancer
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Figure 7: Phase I plan: transverse dose distribution and dose-volume histogram. Due to isotropic expansion of
the respective clinical target volumes, PTV-70, -62 and -55 Gy reach close to the skin surface and are mutually
overlapping. For optimization purposes, subvolumes are created for each of these PTVs In the dosevolume
histogram plots, two histograms are shown for each PTV, one for the whole PTV, the other for the subvolume.
The subvolume is equal to the PTV minus the part of the PTV that is closer than 6 mm to the skin and minus
the overlap region with the PTV planned at a higher dose level. The use of subvolumes for intensity-modulated
radiation therapy optimization and reporting is described elsewhere [41]. PET: Positron emission tomography;
PTV: Planning target volume.
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Figure 8: Sagittal dose distribution: mid-sagittal sec-
tion. PET: Positron emission tomography; PTV:
Planning target volume.
expert-contoured GTVs but still larger than the
macroscopic tumour volume as derived from the sur-
gical specimen. We hypothesized that the PET-based
GTV could be a volume suitable for focused dose es-
calation. A typical dose distribution and DVH ap-
plied during the first phase of IMRT is shown in fig-
ures 7 and 8. Fifteen patients have been included at
the first level of dose escalation. For the second level
of dose escalation, a second PTV-PET will be defined
using a higher PET-signal to background ratio. Opti-
misation aiming at a dose of 3.0 Gy per fraction for
the 10 fractions of treatment phase 1 will is planned.
Expert opinion:
Bilateral neck IMRT was performed for oral cavity,
pharyngeal and laryngeal cancer with functional spar-
ing of salivary glands, reduction of xerostomia and
without increased incidence of recurrences nearby
the spared region. Low rates of recurrences were
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observed in elective nodal sites indicating that PTV
definition and prescription doses were adequate for
elective neck irradiation. Recurrences were mainly
located in the high dose-prescription regions (GTV,
tumor bed), suggesting the need for a selective de-
livery of higher doses to these regions. In sinonasal
cancer, IMRT avoids dry-eye syndrome and may be
used to reduce the incidence of optic neuropathy but
it could not reverse the high failure rates in T4b dis-
ease. For all head and neck sub-sites, planning stud-
ies show equal or improved coverage with IMRT.
In clinical IMRT studies, substantial dose escalation
was not achieved and improved local control by us-
ing IMRT for head and neck cancer cannot be demon-
strated. Progress in biological imaging, mostly based
on PET, may allow us to identify recurrence-prone
regions inside the GTV as targets for focused dose
escalation. With focused dose escalation, the PTV
cannot be considered as spatially invariant during a
long treatment course. Re-planning will be required
which remains a technological challenge.
Five-year view
Radiotherapy with curative intent for head and neck
cancer will gradually be replaced by concurrent
radio-chemotherapy. To limit the toxicity of radio-
chemotherapy while increasing the efficacy of radi-
ation, the high-dose radiation volume will have to
be reduced. Progress in biological imaging, mostly
based on PET and MRS, together with IMRT will al-
low limiting the high dose volume to the recurrence-
prone regions inside the tumor. Biological image-
guided IMRT requires resources and an assembly of
multidisciplinary skills of a magnitude that will not
be present in most cancer centers in Europe. For
imaging and IMRT planning, we expect that the pa-
tient will have to travel to expert centers. The IMRT
plans, developed in these centers, will be sent by net-
work to the referring radiotherapy department as ma-
chine instruction files for robotized equipment. The
actual IMRT treatment can then be performed in a ra-
diotherapy center close to the patients home.
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Key issues discussed in this paper:  
• IMRT was first implemented for re-irradiation of locoregional relapse of HNC, and 
later on for the primary treatment of patients with a HNC arising from the oropharynx 
or oral cavity. 
• The delineation and planning strategies are presented. For the group of patients who 
were treated with IMRT as primary radiotherapy, two consecutive phases were used. 
• Acute toxicity and treatment outcome are reported for the two separate groups of 
patients. The possibility of parotid sparing was explored and confirmed. 
• The importance of clear delineation guidelines is emphasized, as this can have a large 
impact on the possibility of sparing of OARs, like the parotid gland. 
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Abstract
Background and purpose : Intensity modulated radiation therapy (IMRT) offers an opportunity to generate
dose distributions highly conformal to the target volume. Head and neck cancer patients, referred for radio-
therapy, may be good candidates to benefit from IMRT. This paper discusses the clinical implementation of
IMRT for oropharyngeal and oral cavity tumors, and reports the clinical results of the 14 patients treated
with this technique at Ghent University Hospital (GUH).
Patients and Methods : Between May 1999 and May 2001, 14 patients were treated with IMRT at GUH for
oropharyngeal or oral cavity tumors. Two groups of patients can be distinguished. The first group consists
of 8 patients re-irradiated with IMRT for a locoregional relapse. The second group of 6 patients were treated
with IMRT for a primary tumor. For the first group, IMRT was used to treat the relapse by generating a
concave dose distribution, i.e. to combine a homogeneous target re-irradiation with a dose to the spinal cord
as low as possible. For the second group, IMRT was applied in order to achieve a more homogeneous dose
distribution inside the PTV and to preserve parotid gland function.
Results : The majority of the patients of group 1 (6/8) relapsed in field within 4 months after the end of
the re-irradiation, with a median overall survival of 7 months. For group 2, two patients died shortly after
the end of the IMRT treatment, the other 4 patients are free of tumor relapse with a median follow-up of
5 months (1-13 months). The acute toxicity due to radiation was acceptable for both patient groups. Dys-
phagia and pain was more present in group 1. Regarding late complications for the group of re-irradiations
(group 1), no myelitis, carotid rupture or cranial nerve palsy was observed. One patient of group 1 developed
osteoradionecrosis of the mandible and feeding tube dependency was present for another patient. No fatal
late complications were observed in this group. For the first two patients of group 2, sparing of the parotid
function was not a treatment objective. For the other patients of group 2, the mean dose to the contralateral
parotid gland ranged from 17 to 25 Gy, which resulted in a decrease of subjective symptoms of xerostomia
compared to patients treated with conventional radiotherapy.
Conclusions : The implementation of IMRT for oropharyngeal and oral cavity tumors results in a homo-
geneous target irradiation and allows to re-irradiate locoregional relapses with acceptable adverse effects.
Sparing of the parotid gland by IMRT is feasible, although this may be significantly influenced by the de-
lineation method of the elective lymph node regions.
IMRT for oropharyngeal and oral cavity tumours
Introduction
Head and neck cancer patients may be good candi-
dates to benefit from intensity modulated radiation
therapy (IMRT). IMRT offers the opportunity to im-
prove the planning target volume (PTV) dose ho-
mogeneity by omitting photon-electron matchplanes,
and in selected cases, to decrease xerostomia by
sparing one or more of the major salivary glands.
However, due to the complexity of implementing
IMRT for this region, few clinical results are reported
yet, and most of the data consist of very small pa-
tient series [1][3][8][9][10][13][16][22]. IMRT is of-
ten delivered in combination with conventional tech-
niques [15], or its use is restricted to a boost to the
primary tumor region [21].
By May 2001, 85 head and neck patients were
treated with IMRT at Ghent University Hospital
(GUH). Initially, IMRT was the treatment modality
of choice to re-irradiate locoregional relapses or sec-
ond primary head and neck cancers [10]. In a sec-
ond phase, IMRT was applied as primary treatment.
For pharyngeal and oral cavity tumors, the rationale
to use IMRT was to increase the dose homogeneity
inside the target volume and to preserve parotid func-
tion.
This paper discusses a clinical implementation of
IMRT for oropharyngeal and oral cavity tumors.
Patients and Methods
Between May 1999 and May 2001, 14 patients were
treated with IMRT at GUH for oropharyngeal or oral
cavity tumors. Two groups of patients can be dis-
tinguished. The first group consists of 8 patients re-
irradiated with IMRT for a locoregional relapse. The
second group of 6 patients was treated with IMRT for
a primary tumor.
group 1 : IMRT for locoregional relapses
Treatment objectives
For all patients, the dose to the spinal cord by the first
radiotherapy treatment ranged between 40 and 50 Gy,
delivered by 2 Gy fractions (5 days/week). IMRT was
used to treat the relapse by generating a concave dose
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Figure 1: Drawing of a transverse section through the
bottom level of the second cervical vertebral body, il-
lustrating the photon-electron match line (black dot-
ted line), located in the middle of the upper jugular
lymph node chain, outlined in solid black.
distribution, i.e. to combine a homogeneous target
re-irradiation with a dose to the spinal cord as low as
possible.
The maximal dose to the spinal cord imposed
by the IMRT plan was 15 Gy. The PTV dose pre-
scription ranged between 64 and 70 Gy. For the
dose homogeneity within the PTV, the ICRU (Inter-
national Commission on Radiation Units and Mea-
surements) guidelines were followed, i.e. a maximal
underdosage of 5 % and maximal overdosage of 7
%. In case of overlap or close vicinity of the PTV
and the spinal cord, the dose constraint to the spinal
cord was respected, at the cost of the PTV dose ho-
mogeneity. Dose to the mandible was penalized by
plan optimization, but no dose constraints were spec-
ified upfront as treatment objectives.
Planning strategy
Our IMRT planning strategy for locoregional re-
lapses of head and neck cancer is previously re-
ported [9][10]. The IMRT plans consisted of six non-
opposed coplanar 6 MV photon beams, for which
the individual multileaf collimated beamparts (seg-
ments) were optimized by adapting leaf positions and
segment weights [7], using a biophysical cost func-
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Table 1: Selection and dose prescription of lymph node target volumes
lymph node region selection criterion ipsi-bilateral dose (Gy)
Ia if evidence clinical invasion floor of mouth or
region Ib
ipsilateral* 60
Ib target in all cases ipsilateral* 60
II target in all cases bilateral 60
III target in all cases bilateral 50-60**
IV target in all cases bilateral 50-60**
V if clinical evidence invasion regions II or III
or IV
ipsilateral 60
retropharyngeal target in all cases bilateral 60
* : bilateral if tumor crosses the midline
** : 60 Gy if first elective station, 50 Gy if second or third elective station
tion [11]. Treatments were delivered within a time
slot of 15 minutes on an Elekta Sli-plus accelerator.
group 2 : IMRT as primary radiotherapy
Treatment objectives
Conventional radiotherapy for elective node irradia-
tion of head and neck cancer patients at GUH con-
sisted of two lateral fields and an anterior supraclav-
icular field, delivered with a single isocenter tech-
nique [20]. At a dose of 44 Gy, the spinal cord was
blocked, and the target region not covered by the pho-
ton beams was boosted with electron beams. Figure 1
shows the location of the matchplane (dotted line) be-
tween a lateral photon and electron beam in a trans-
verse plane through the body of the second cervical
vertebra. The matchplane is situated in the middle of
the upper jugular lymph node chain. Initially, IMRT
was used to avoid electron-photon matching. In a sec-
ond phase, preservation of the parotid gland function
was also intended.
For the part of the PTV that is located out-
side build-up regions and outside regions where PTV
overlaps with organs at risk (OARs), the ICRU guide-
lines for dose homogeneity were followed. The re-
gion of the PTV that extends close to the skin in the
build-up region, is carefully analyzed. If underdosage
is clinically unacceptable, bolus material is used. A
clinical decision is also made regarding overlap areas
of PTV and OARs. If the OAR function is to be pre-
served, a PTV underdosage restricted to the overlap
zone which is consistent with OAR function preser-
vation, is accepted. When parotid gland function had
to be preserved, the mean dose to the contralateral
parotid gland was limited to 26 Gy. This dose thresh-
old was based on previous data published by Eisbruch
et al. [12].
Current planning strategy
Entrance criteria for patients included
Since December 2000, following entrance criteria are
specified to include patients for IMRT. For oropha-
ryngeal cancer, stages T1-3 N0-2b M0 are included,
for oral cavity cancer, the stages T1-T4 N0-2b M0.
The expected median survival has to exceed 1 year,
and the Karnofsky performance status has to be more
than 50.
Treatment protocol
Table 1 specifies the selection of lymph node target
volumes, and the prescribed dose to these volumes, as
used for the IMRT plans. The terminology for lymph
node regions as proposed by Robbins et al. [19] is
used in the table.
The clinical target volume is 3D-isotropically ex-
panded with a margin of 3 mm to a PTV, to take into
account setup-inaccuracies during treatment delivery.
A reduced PTV, excluding the region within a dis-
tance of 6 mm from the skin outline, is used for plan
optimization and dose prescription. By excluding the
build-up region from the PTV, conflicts during plan
IMRT for oropharyngeal and oral cavity tumours
Table 2: Group 1 : patients treated with IMRT for locoregional relapses
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IMRT for oropharyngeal and oral cavity tumours
optimization and a potential impossibility to achieve
the ICRU guided PTV dose homogeneity are avoided.
Dose is reported for the complete as well as for the
reduced PTV.
Before December 2000, dose prescriptions were
made on a patient-individual basis (patients 1-4 in ta-
ble 3). Since December 2000, a treatment protocol
was applied.
Three PTVs with corresponding dose prescrip-
tions are specified :
PTV-70 :
  the primary tumor and lymph nodes contain-
ing clinical or radiological evidence of disease,
treated to 70 Gy
  the median PTV-70 dose is used for dose pre-
scription
  the tolerated dose range inside this PTV-70 is
66 to 75 Gy
  the 3D-maximum dose has to be located inside
this PTV-70
PTV-60 :
  elective lymph node regions treated to a dose
of 60 Gy
  the selection criterium is specified in table 1
  the median PTV-60 dose is used for dose pre-
scription
  the tolerated dose range inside this PTV-60 is
57 to 65 Gy
PTV-50 :
  elective lymph node regions treated to a dose
of 50 Gy
  the selection criterion is specified in table 1
  the minimum PTV-50 dose is used for dose
prescription (i.e the minimum PTV-50 dose is
50 Gy)
When we elected to spare a parotid gland, it
was a planning goal to keep its mean dose below
26 Gy [12]. The dose constraints for the spinal cord
and brainstem were respectively set to 50 and 60 Gy,
with a maximum daily fraction size of 2 Gy.
The IMRT treatment is delivered in two consec-
utive phases. The first phase consists of 27 fractions
of 1.85 Gy to PTV-50 and 2.22 Gy to PTV-60 and
PTV-70. In a second phase, 5 fractions of 2 Gy were
delivered to PTV-70.
The beam setup consists of six non-opposed
coplanar 6 MV photon beams, for which the indi-
vidual multileaf collimated segments are computer-
generated [6] and optimized by adapting leaf posi-
tions and segment weights [7], using a biophysical
cost function [11]. Treatments are delivered within a
time slot of 15 minutes on an Elekta Sli-plus acceler-
ator.
Patients
Table 2 and 3 list the 14 patients. All of them were
treated with curative intent.
Results
Table 4 reports the clinical results for the 14 pa-
tients. The follow-up was recorded from the end
of the IMRT treatment till the time of analysis (July
2001).
The first 6 patients of group 1 relapsed in field
within 4 months after the end of the re-irradiation.
For patients 4 and 5, residual disease was present at
the end of the IMRT treatment. Patients 7 and 8 of
group 1 are still free of disease. The median overall
survival for the patients of this group (measured as
the time after the end of the treatment) is 7 months.
For group 2, two patients (patient 1 and 2) died
shortly after the end of the IMRT treatment. Patient
1 died one month after the end of the concomittant
chemo-radiotherapy treatment, due to a candida sep-
sis. Patient 2 developed a tumor relapse in the con-
tralateral lymph node region II, which was not treated
by the previous radiotherapy (the patient was treated
before December 2000, and thus not according to
the current IMRT treatment protocol). He died four
IMRT for oropharyngeal and oral cavity tumours
Table 3: Group 2 : patients treated with IMRT for primary lesions
case age* subsite primary TNM staging histology surgery start date dose** parotid sparing
(y) primary grade (G) / chemo radiotherapy (Gy) treatment goal
1 43 tonsil, posterior wall cT4cN2cM0 SCC G2 n / y 24/12/1999 70 no
2 58 retromolar area pT2pN2bM0 SCC G3 y / n 03/02/2000 60 no
3 53 tonsil, tongue cT3cN2bM0 SCC G1 n / n 17/03/2000 70 yes
4 47 tonsil pT2pN1M0 SCC G3 y / n 06/11/2000 66 yes
5 67 tonsil, soft palate pT3pN1M0 SCC G1 y / n 14/12/2000 70 yes
6 61 tonsil pT2pN1M0 SCC G2 y / n 20/03/2001 70 yes
* at time of analysis (July 2001) **dose to the primary tumor site
P P
Figure 2: Dose distribution in a coronal plane of
the IMRT treatment plan for patient 6 of the sec-
ond group, illustrating the intended sparing of the
left parotid gland. The isodose lines, expressed in
Gy, represent the cumulative dose for the two treat-
ment phases. The PTV-50 is coloured in transparent
dark grey, the PTV-60 in transparent light grey and
the PTV-70 in black speckles. The parotid glands are
outlined in white and designated with the capital P.
months after the end of the radiation treatment. Pa-
tients 3-6 are free of tumor relapse, with a median
follow-up of 5 months (1-13 months).
To score the acute toxicity due to radiation, the
Common Toxicity Criteria (CTC) of the NIH (The
US National Institutes of Health) were used (informa-
tion on http://ctep.info.nih.gov/CTC3). Weight loss
was less than 10 % for all patients, except for the sec-
ond patient of group 1 (15 %). Radiation dermati-
tis was mild (dry desquamation) to moderate (patchy
moist desquamation) for 13 patients, and confluent
moist for the first patient of group 1. Pain due to
radiation was more present in group 1. Pain due to
radiation was mild and not interfering with function
for 2 patients, moderate for 8 patients and severe (in-
terfering with activities of daily living) for 4 patients.
Mucositis was mild (erythema) for only 2 patients,
patchy pseudomembranous for 6 patients and conflu-
ent pseudomembranous for 6 patients. Pharyngeal
dysphagia was mild (patient could eat regular diet)
to moderate (requiring predominantly pureed, soft,
or liquid diet) for 12 patients. Two patients suffered
from severe dysphagia, requiring feeding tube and IV
hydratation.
Regarding late complications for the group of re-
irradiations (group 1), no myelitis, carotid rupture or
cranial nerve palsy was observed. Patient 7 of group 1
developed osteoradionecrosis of the mandible. Feed-
ing tube dependency was present for patient 7. All
patients had neck fibrosis and two of them suffered
from hearing loss. No fatal late complications were
observed in this group.
For the first two patients of group 2, sparing of
the parotid function was not a treatment objective.
For patients 3-6, the mean dose to the contralateral
parotid gland ranged from 17 to 25 Gy, which re-
sulted in a decrease of subjective symptoms of xe-
rostomia compared to patients treated with conven-
tional radiotherapy. No functional tests or saliva flow
measurements were performed. Figure 2 shows the
dose distribution in a coronal plane of the treatment
IMRT for oropharyngeal and oral cavity tumours
Table 4: Results of the IMRT treatments for group 1 and 2
category group 1 : relapses group 2 : primaries
case 1 2 3 4 5 6 7 8 1 2 3 4 5 6
common toxicity criteria : peak score (grade)
weight loss 0 2 0 1 0 1 1 0 1 1 1 1 1 0
radiation dermatitis 1 1 2 1 1 2 1 2 3 2 1 1 3 2
pain due to radiation 3 3 3 3 2 2 2 2 2 2 1 1 2 2
mucositis due to radiation 1 3 3 2 2 2 2 2 3 3 2 1 3 3
dysphagia due to radiation 2 3 2 2 2 2 3 1 2 1 1 1 2 1
(second) relapse / survival
relapse yes yes yes yes yes yes no no no yes no no no no
in field relapse yes yes yes yes yes yes no no no no no no no no
time to relapse (months) 1 2 4 0* 0* 4 / / / 1 / / / /
cancer-related death yes yes yes yes yes yes no no no yes no no no no
non-cancer-related death no no no no no no no no yes no no no no no
time to death (months) 12 3 11 7 7 7 / / 1 4 / / / /
* : residual disease
plan for patient 6 of group 2, illustrating the intended
sparing of the left parotid gland.
Discussion
As previously reported [5], the overall survival for
high dose re-irradiations of head and neck cancer re-
mains poor, and is associated with a lower rate of
local tumor control compared to tumors of similar
stage treated with primary radiotherapy. Although re-
irradiations for locoregional relapses are associated
with a poor prognosis, IMRT is a good technique to
combine a high tumor dose with acceptable toxicity
grades. The osteoradionecrosis of the mandible ob-
served in patient 7 of group 1, may be explained by
the high cumulative dose (154 Gy) of both treatment
plans and the use of brachytherapy for the first radia-
tion treatment.
For primary radiotherapy, IMRT allows a higher
dose homogeneity inside the PTV by avoiding
photon-electron matching. Another advantage is the
possibility and feasibility of IMRT to preserve uni- or
bilateral parotid gland function [12][4][23].
A strategy to treat 3 dose prescription levels with
2 consecutive treatment phases reduces the planning
workload and results for the macroscopically invaded
regions and the first elective lymph node stations in a
radiobiological advantage, because of a higher frac-
tion size (2.22 Gy) with shortening overall time [17].
The use of a fixed beam-setup and a fixed set
of parameters for beam segmentation and plan opti-
mization, allows to automate the generation of IMRT
plans and guarantees a plan deliverable within a spec-
ified time slot.
The bottle-neck of the treatment planning process
is the delineation of the clinical target volumes. The
implementation of IMRT for head and neck cancer
has lead to an increased interest in guidelines for de-
lineation of lymph node regions. Especially the defi-
nition to outline lymph node region II may affect, or
even determine the feasibility to preserve the parotid
function by conformally irradiating this lymph node
region. Figure 3 displays the difference in delineation
guidelines for this region in a transverse plane, as pro-
posed by Gregoire et al. [14] (solid white line) and
Nowak et al. [18] (dashed white line). In a coronal
plane, the difference is even more striking, as illus-
trated by figure 4.
The cranial border of lymph node region II, as de-
fined by Gregoire, is the bottom edge of the body of
the first cervical vertebra (C1), whereas Nowak de-
fines the cranial border as the cranial CT-slice (in a
transverse plane) through C1. These differences in
contouring may affect cure rates of the radiation treat-
IMRT for oropharyngeal and oral cavity tumours
1 mandible
4 digastric muscle
3 parotid gland
7 sternocleidomastoid muscle
5 internal jugular vein
1
34
6
7
8
6 internal carotid artery
5
2 medial pterygoid muscle
2
8
8 paraspinal muscles
9
9 vertebral body C2
Figure 3: Transverse CT-slice through the second
cervical vertebral body illustrating two different ap-
proaches to delineate lymph node region II. In white
solid line the delineation as defined by Gregoire et
al., in white dashed line the guidelines proposed by
Nowak et al.
ment, but certainly affect the plantechnical feasibility
to limit dose to a certain volume of the parotid gland.
The validity of the two proposed guidelines needs to
be confirmed in larger patient series. For our IMRT
implementation, we follow the guidelines proposed
by Gregoire, except for the cranial border of lymph
node region II, which we define at the middle of the
body of C1.
Dawson et al. [4] reported the patterns of lo-
coregional recurrence following parotid-sparing ra-
diotherapy. This sparing was achieved by limiting
the dose to the contralateral parotid gland. The supe-
rior extent of the contralateral lymph node region II,
was defined as the axial CT image in which the pos-
terior belly of the digastric muscle crosses the jugu-
lar vein. This corresponds to the superior extent of a
radical neck dissection. The ipsilateral superior ex-
tent was set at the base of the skull. They exam-
C1 C1
C2
C3
parotid
gland
parotid
gland
Figure 4: A coronal reconstructed CT-image through
the cervical vertebral bodies 1, 2 and 3 (C1,C2,C3).
The black lines represent the cranial edge of the tar-
get volume for lymph node region II, as respectively
defined by Gregoire et al. (solid line) and Nowak et
al. (dashed line). The black solid lines with arrows
indicate the craniocaudal extent of the parotid glands.
ined 58 patients, and the eligibility criteria for the
parotid-sparing protocol were patients who required
radiotherapy to the primary tumor and bilateral neck
lymph nodes. Patients with suspicion of contralateral
neck disease were included as long as the jugulodi-
gastric and higher neck nodes did not contain metas-
tases. The median time from treatment to follow-up
was 27 months. They found that the majority of lo-
coregional relapses after parotid-sparing radiotherapy
were in-field, and none of the relapses occurred in
the contralateral high level of lymph node region II.
These data support a rationale to implement IMRT to
preserve salivary gland function by sparing the con-
tralateral parotid gland.
Chao et al. [2] reported 27 patients treated with
IMRT, most of them nasopharyngeal and oropharyn-
geal cases. Bilateral sparing of the parotid glands
was a treatment objective, and the average dose to
the parotid gland was 28 Gy for the postoperative
cases and 30 Gy for the patients receiving IMRT as
definitive treatment. The jugular chain (level II-IV)
was target volume for all cases, but there was no
specification with regard to their lymph node delin-
eation method. Disease free survival rates were not
reported.
IMRT for oropharyngeal and oral cavity tumours
In conclusion, the implementation of IMRT for
oropharyngeal and oral cavity tumors results in a
homogeneous target irradiation and allows to re-
irradiate locoregional relapses to high doses with ac-
ceptable adverse effects. Sparing of the parotid gland
by IMRT is feasible, although this may be signif-
icantly influenced by the delineation method of the
elective lymph node regions. Sparing of the ipsilat-
eral gland remains a topic of debate.
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Key issues discussed in this paper:  
• A group of 39 consecutive patients with sinonasal carcinoma was treated with post-
operative IMRT using a standard class solution. A detailed description of symptoms 
and patient and tumour characteristics is given. 
• Dosimetrical analysis of the IMRT plans is given, using DVHs compiled from the 
whole group. 
• Both acute toxicity and chronic toxicity are assesses and analysed.  
• Local control, disease-free survival and overall survival are analysed for the IMRT 
group, and prognostic factors are identiefied. The IMRT results are compared with a 
historical cohort of sinonasal cancer patients, treated with conventional techniques or 
3D-CRT. 
• A literature review on elective lymph node irradiation in sinonasal is presented. 
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Abstract
Purpose: Carcinoma of the paranasal sinuses is rare. Standard therapeutic modalities consist of surgery
and radiotherapy (RT). Because of the often advanced stage and the vicinity of optic structures, RT-induced
ocular toxicity is a feared side effect of conventional RT. Intensity-modulated radiation therapy (IMRT)
is a relatively new radiation technique, which is implemented with the hypothesis that, compared with
conventional RT, it would result in a lower rate of ocular toxicity for an equal local control (LC).
Methods and Materials: Between 1998 and 2003, 39 consecutive patients received postoperative irradi-
ation by means of IMRT for an adenocarcinoma (n=31) or squamous cell carcinoma (n=8) of the paranasal
sinuses (n=36) or nasal cavity (n=3). T-classification was T2 in 41%, T3 in 15%, T4a in 23% and T4b in
21% of patients. Invasion through the cribriform plate was seen in 11 patients. Orbital invasion was present
in 36% of patients. The delivered dose ranged from 60 Gy to 70 Gy (median 70 Gy). The authors com-
pared the overall survival (OS) and LC with a historical cohort (HC) (n=30), treated with conventional or
3-dimensional conformal RT.
Results: The median follow-up was 31 months. Actuarial OS rates were 68% at 2 years and 59% at 4
years. Actuarial LC rates were 73% at 2 years and 68% at 4 years. Invasion through the cribriform plate
was a significant prognostic factor for LC and OS, with a median time to local disease recurrence of 7
months if present, and a 2-year LC rate of 90% if not present. In the comparison between the IMRT and
the HC groups, no significant differences were found for LC and OS. Acute toxicity was mild. Two patients
developed a decreased vision after RT. No RT-induced blindness was observed.
Conclusion: Postoperative IMRT for sinonasal carcinoma resulted in good LC, with a low acute toxicity
and no RT-induced blindness.
IMRT in sino-nasal carcinoma
Introduction
Carcinoma of the paranasal sinuses or the nasal cav-
ity is a rare disease, representing 5% of all head and
neck tumours, and less than 1% of all malignan-
cies in Flanders in 1998 [1]. The treatment options
for sinonasal carcinoma consist of combinations of
surgery, radiotherapy (RT) and chemotherapy. The
most applied strategy consists of extensive surgery,
followed by RT [2, 3]. The reported 5-year overall
survival (OS) rate varied from 30% to 79% [4, 5].
The wide range in reported treatment results might
rather be a consequence of patient selection, than of
the applied treatment strategy, and hinders the com-
parison between various treatment regimens. A ma-
jor concern in the irradiation of sinonasal carcinoma
is chronic toxicity to the optic pathways. The in-
cidence of RT-induced blindness can be as high as
37% [6, 7, 8], and depends (among other factors)
on irradiated volume, total dose and dose per frac-
tion [9, 10, 11]. Intensity-modulated radiation ther-
apy (IMRT) is a relatively new radiation technique,
offering the possibility to create concave dose distri-
butions [12]. This allows better sparing of the op-
tic structures without compromising the dose in the
target volume (Fig. 1). . Since July 1998, IMRT
has been the standard treatment for sinonasal car-
cinoma at Ghent University Hospital (GUH; Ghent,
Belgium) [13]. The hypothesis for the implemen-
tation of IMRT for sinonasal carcinoma was that it
would result in a decrease in ocular toxicity, with-
out compromising local control (LC). First, we report
on the outcome results and acute and chronic toxic-
ity in a group of patients who received post-operative
RT by means of IMRT. Second, we compared pa-
tients with an adenocarcinoma of the ethmoid si-
nuses, treated postoperatively with IMRT, with pa-
tients treated with conventional RT.
Patients and Methods
Between July 1998 and August 2003, 39 consecutive
patients were treated postoperatively for a histolog-
ically proven adenocarcinoma or squamous cell car-
cinoma (SCC) of the sinonasal cavities by means of
IMRT at GUH. Median age at diagnosis was 62 years
(range 30-78 years). The reported symptoms at the
time of diagnosis were nasal obstruction in 26 pa-
tients, epistaxis in 14 patients, ocular symptoms in
6 patients, swelling of the cheek in 5 patients, and
neurological symptoms in 3 patients. A history of oc-
cupational wood exposure was present in 24 patients,
all of whom had an adenocarcinoma. Two patients
were treated for a recurrence of an earlier tumour
of the paranasal sinuses (1 with ethmoid sinus carci-
noma and 1 with maxillary sinus carcinoma). These
two patients were treated with surgery alone at the
time of the first diagnosis. The (sub)site of the tu-
mour was defined from the epicenter of the tumour
mass, as observed on computed tomography (CT)
and/or magnetic resonance imaging (MRI). In 30 pa-
tients, the subsite of origin was the ethmoidal sinus,
the maxillary sinus in 6 patients and the nasal cav-
ity in 3 patients. Histologic diagnosis was obtained
in all patients, and showed adenocarcinoma in 31 pa-
tients and SCC in 8 patients. All patients were (partly
retrospectively) staged using the 2002 TNM classifi-
cation system [14]. A cross-tabulation among site,
histology and T-classification is shown in Table 1.
Of the patients classified with T4b tumours, all had
invasion of the dura and/or brain. In the group of
patients classified with T4a tumours, 4 patients had
tumour extension through the cribriform plate (CP)
with minimal invasion of the anterior cranial fossa.
Macroscopic extension (with invasion of the external
ocular muscles) into the orbital content was seen in
4 patients. Moderate orbital invasion (invasion of or-
bital fat, without muscle invasion) was present in 7
patients. Invasion of the lamina papyracea was seen
in 3 patients, while bulging (without invasion) of the
medial orbital wall was seen in another 3 patients.
One patient had cervical lymph nodes for which he
received a bilateral neck dissection. In this patient,
the neck was included in the clinical target volume
(CTV). All patients were free of distant metastasis
at the time of diagnosis. The mean time between
surgery and the start of RT was 48 days (range 25-
89 days). The type of surgery was broad resection
(via lateral rhinotomy) in 22 patients, maxillectomy
in 5 patients, functional endoscopic resection in 4 pa-
tients, and craniofacial resection in 8 patients. Three
patients underwent an orbital exenteration as part of
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Figure 1: Dose distributions of a typical intensity-modulated radiation therapy plan for an ethmoid sinus carci-
noma. Dose distributions are shown in a (a) transverse, (b) coronal and (c) sagittal plane. The planning target
volume (PTV) is shown in red. For clarity, the right-sided retina (dark green), optic nerve (light green), and
major lacrimal gland (blue) are depicted in panel (a) and (b). The optic chiasm (light green) is shown in (c).
The dashed lines represent the level at which the other planes are shown. Isodose lines are in gray (Gy).
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Table 1: T-classification per subsite and per histological type.
Ethmoid sinus Maxillary sinus Nasal cavity
Histology T2 T3 T4a T4b T2 T3 T4a T2 T3 T4 Total
Adeno 13 3 5 7 - - - 3 - - 31
SCC - - 1 1 - 3 3 - - - 8
Total 13 3 6 8 - 3 3 3 - - 39
Abbreviations: Adeno: adenocarcinoma; SCC: squamous cell carcinoma
the surgical procedure. Unless stated differently, all
results presented in the “Results” section concern the
39 patients described above.
The historical cohort (HC) consisted of 30
patients, who were irradiated postoperatively for
an adenocarcinoma of the ethmoid sinus between
September 1985 and July 1998 at GUH. Clinical
characteristics, treatment details and outcome of
this group have been reported in more detail else-
where [15]. The 1997 TNM classification [16] was
used, and all patients diagnosed before 1997 were
staged retrospectively. In the HC, there were 2 pa-
tients with a T1, 8 with a T2, 9 with a T3 and 11
patients with a T4 tumour. Three patients had cranial
invasion. This HC was then compared with all pa-
tients with an adenocarcinoma of the ethmoid, treated
with IMRT (n=28). The 1997 T-classification for the
IMRT group was: T1= 0; T2= 13; T3= 4 and T4= 11.
In the IMRT group, all T4 patients (n=11) had inva-
sion through the CP.
Radiotherapy details
All patients were irradiated using IMRT during the
entire RT treatment. The development and clinical
implementation of IMRT for paranasal sinus carci-
noma has been described earlier [13]. The CTV con-
sisted of the resection cavity plus all paranasal si-
nuses which were (partially) invaded or neighbored
invaded cavities. In case of minimal or moderate
orbital invasion, the medial part (up to the rectus
medialis muscle) of the orbit was included in the
CTV. No elective irradiation of the cervical lymph
nodes (ELNI) was performed. A 3-mm isotropic mar-
gin was used for the expansion from CTV to plan-
ning target volume (PTV). The optic structures, like
retina, optic nerve and optic chiasm, were delineated
on planning CT scans and expanded to a planning
risk volume (PRV) with a margin of 2 mm. In re-
gions where the PTV and the PRVs overlap, an under-
dosage of the PTV was tolerated, in order to fulfill the
constraints for the optic structures [13]. Prescribed
end-dose was 60 Gy in 4 patients and 66 Gy in 6
patients. For all subsequent patients, the prescribed
end-dose was 70 Gy (median dose to the PTV), deliv-
ered in 35 fractions. Prescribed dose was not reached
in 2 patients. Of these, 1 patient died after 21 frac-
tions from complications of the craniofacial resec-
tion, and in 1 patient, RT was stopped after 26 frac-
tions because of the histological diagnosis of liver
metastases from a (rapidly evolving) small cell lung
cancer (SCLC).
In the HC, 19 patients were irradiated using a
conventional beam setup (one anterior beam, and two
lateral wedged beams) up to doses of 61 to 70 Gy
(median 65 Gy), with a fraction dose of 1.8 Gy.
In 11 patients, a 3D conformal technique with non-
coplanar beams was used. The prescribed dose in this
group ranged from 54 to 66 Gy (median 66 Gy), and
was delivered in 2 Gy fractions.
Follow-up (IMRT group)
During RT, patients were evaluated clinically at least
weekly. Acute toxicity scoring was done using the
Common Toxicity Criteria (CTC, version 2) of the
US National Institutes of Health (NIH) (information
on http://ctep.cancer.gov/reporting/ctc.html). For the
first 16 patients, no prospective scoring was done, and
only the presence of grade 2 toxicity or higher was
reported in the patient files. Therefore, a distinction
between grade 0 (no symptoms) and grade 1 (mild
symptoms) could not be made. For conjunctivitis,
dry eye, tearing, mucositis, dysphagia and radioder-
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Figure 2: Compiled dose volume histograms (DVHs).
(a,b) Compiled DVHs for the following structures: clinical target volume (CTV; black), planning target volume (PTV; grey), optic
chiasm (brown), ipsilateral (full line) and contralateral (dashed line) optic nerve (orange), and ipsilateral and contralateral retinae
(green). All data concerning optic structures are for the expanded optic structures. DVHs are compiled from the data from the 29
patients that were planned to a dose of 70 Gy. As one of these patients underwent an ipsilateral orbital exenteration, the data for the
ipsilateral optic nerve and retina are averaged over 28 patients. For each structure, the mean (bold line) and the standard error of the
mean (SEM; dotted thin lines) are shown. In (a), the dose at every 1% volume level was calculated for each structure and for all patients.
For each of these volume levels, the mean and the SEM over all 29 patients were calculated. The direction in which the spread around
the mean value should be read is indicated by the arrow. The median, maximal and minimal dose, averaged over the 29 patients whom
were planned to 70 Gy, can be read from this graph. In (b) the volume percentiles at every 1 Gy dose level were calculated for the same
structures as in (a). The mean and the SEM over the 29 patients were calculated for each of the dose levels. Here, the spread around
the mean should be read vertically (as indicated by the arrow). This graph shows the relative volume receiving a specified dose or more
(e.g. on average, 6%  1% of the contralateral retina receives a dose > 50 Gy). (c) Graph showing all individual DVHs (thin grey lines)
for the ipsilateral optic nerve. The full black DVH is calculated as in (a), while the dashed black line is calculated as in (b). This graph
clarifies how these two ways of calculating a compiled DVH yield different results. The DVH indicated with an asterisk ( ) represents
Patient 2 (see Table 5), for whom no attempt was made to spare the ipsilateral optic nerve. (d) Compiled DVHs for the optic nerves
(orange) and the retinae (green) with (full lines) or without (dashed lines) chronic toxicity. DVHs are compiled for all patients without
preexisting ocular disease, who completed their treatment course, and who had > 6 months of follow-up (n=33). DVHs are calculated
according to the method described in (a).
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Figure 3: Overall survival (OS), Disease-free survival (DFS) and local control (LC) for all patients. A timeline
is shown, indicating the time of local ( ), regional () and distant () recurrence.
mitis, a grade 1 score was assigned if no information
was found concerning the specified symptom. For
the subsequent 24 patients, a prospective scoring was
done using a standard form. After completion of RT,
patients were evaluated 1 month after the end of RT,
and then every 3-4 months during the first 2 years
and twice a year thereafter. Chronic ocular toxicity
was prospectively scored according to the Lent/Soma
scale [17]. In case of ocular symptoms, the patient
was sent to an ophthalmologist for further investi-
gation. Furthermore, a routine ophthalmologic ex-
amination was performed in 60% of patients without
symptoms of chronic ocular toxicity. Patients who
did not receive the prescribed radiation dose (n=2),
or with a follow-up of less than 6 months (n=2) were
excluded from the chronic toxicity analysis. No pa-
tient was lost to follow-up.
Statistical analysis
Overall survival (OS), disease-free survival (DFS),
disease-specific survival (DSS) and local control
(LC) were determined using the the Kaplan-Meier ac-
tuarial method. All analyses were calculated from
the first day of RT. Events were defined as fol-
lows: OS: death from any cause; DFS: disease recur-
rence (local, regional or distant) or death from any
cause (whatever came first); DSS: death due to can-
cer progression (local, regional or distant) and LC: lo-
cal disease recurrence. Differences between subcate-
gories were calculated using the log-rank test. A p-
value <0.05 was considered statistically significant.
For all statistical analyses, a standard software pack-
age (SPSS Inc., Chicago, IL) was used.
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Table 2: Summary of the DVH data.
Mean SEM
PTV
Dmed (Gy) 69.7 0.0
V

(%) 87.3 0.9
CTV
Dmed (Gy) 70.0 0.0
V

(%) 95.2 0.6
Optic chiasm
Dmed (Gy) 39.4 1.6
Dmax (Gy) 54.2 1.5
Optic nerve (ipsilateral)
Dmed (Gy) 51.5 1.2
Dmax (Gy) 61.1 0.5
V
Gy (%) 5.3 3.4
Optic nerve (contralateral)
Dmed (Gy) 45.8 1.6
Dmax (Gy) 58.8 0.9
V
Gy (%) 0.6 0.2
Retina (ipsilateral)
Dmed (Gy) 39.4 1.6
Dmax (Gy) 59.0 0.8
V
Gy (%) 8.9 3.3
Retina (contralateral)
Dmed (Gy) 29.6 1.6
Dmax (Gy) 55.9 0.8
V
Gy (%) 1.5 0.4
Abbreviations: Dmed: median dose; V: relative
volume of the specified structure, receiving at least
95% of the prescribed dose; Dmax: maximal dose;
V
Gy: relative volume of the specified structure
receiving more than 60 Gy.
: This is due to one patient (Table 5, Patient 2).
When omitting the patient, the V
Gy for ipsilat-
eral optic nerve is 1.9  0.6%, and the V
Gy for
the ipsilateral retina is 5.9  1.3%.
Results
IMRT planning results
Typical dose distributions for an IMRT plan are
shown in Figure 1. The conformal avoidance of the
optic nerves and retinae is readily visible in panel (a)
and (b). The ability to create concave dose distri-
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Figure 4: Local control by T-classification for all pa-
tients.
butions is best illustrated in panel (b). In a sagittal
plane (panel c), the relative underdosage of the op-
tic chiasm is evident. Figure 2 shows the dosimet-
rical data on the patients treated with an end-dose
of 70 Gy. The contralateral optic structures (retina
and optic nerve) received a lower dose than the optic
structures ipsilateral to the tumour. The underdosage
in the PTV (on average, 12.7% of the PTV received
less than 95% of the prescribed dose) is partly due
to build-up, and partly due to the overlap of the PTV
with the PRVs of the optic structures. A summary of
these DVH data is given in Table 2.
Survival and local control
IMRT group
The median follow-up in survivors was 31 months
(range 9-67 months). The 2 and 4-year actuarial OS
rates were 68% and 59%, respectively. The 2 and 4-
year actuarial DFS rates were 63% and 59%, respec-
tively. The corresponding LC rates were 73% and
68%. Actuarial OS, DFS and LC curves are shown
in Figure 3. DSS rate was 74% at 2 years and 64%
at 4 years. According to T-classification, the LC rate
at 2 years was 100% for T2, 67% for T3 and 70%
for T4a. For T4b lesions, the median duration of lo-
cal control was 6 months. LC per T-classification is
shown in Figure 4 . There was no statistically sig-
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Figure 5: Local control in function of the presence of
invasion through the cribriform plate (CP).
nificant difference in LC between T2, T3 and T4a
lesions. Patients with a T4b tumour had a signifi-
cantly worse LC than patients with a T2 (p<0.001),
a T3 (p=0.013) and a T4a (p=0.021) lesion. Figure 5
shows the LC in function of the presence of invasion
through the CP (with minimal extension into the an-
terior cranial fossa). CP invasion was a significant
prognostic factor for both LC (p<0.001) and for OS
(p<0.001). When only those patients without exten-
sion through the CP (n=27) were considered for anal-
ysis, the LC rate was 90% at 2 years, and 84% at 4
years. For patients who presented with extension of
their tumour through the CP, the median time to local
disease recurrence was 7 months.
At the time of analysis, 25 patients were alive.
Eleven patients had died due to progression of the
sinonasal carcinoma, and three had died due to other
causes: one by complications of the craniofacial re-
section, one by intercurrent disease (exacerbation of
chronic obstructive pulmonary disease) and one by
a second primary cancer (SCLC). Of the 11 patients
who died from sinonasal carcinoma progression, 2
patients died from distant metastasis, but were locally
free of disease. For one patient, the diagnosis of bone
metastasis was made at the end of the RT course,
while in the other patient, brain metastases were di-
agnosed. This was 3 months after retreatment for a
local disease recurrence. One patient died from dis-
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ease due to isolated lymph node recurrence. Eight pa-
tients died due to local disease progression. The tim-
ing of local, regional and distant metastasis is shown
in Figure 3. In total, ten patients developed a local
disease recurrence during the follow-up period. The
characteristics of these 10 patients are summarized in
Table 3.
Comparison between IMRT group and HC
The median follow-up for survivors in the HC was
83 months. OS rates at 2 and 4 years were 65% and
58% for the IMRT group, and 83% and 66% in the
HC (p=0.25). LC rates at 2 and 4 years were 69% and
63% for the IMRT group, and 70% and 63% for the
HC (p=0.72). The LC in the HC and IMRT groups
is shown in Figure 6. In the subselection of patients
without extension through the CP, the 2 and 4-year
OS rates were both 94% for the IMRT group, and
93% and 73% in the HC. This was not significantly
different (p=0.29). For the same subselection, the LC
rates at 2 and 4 years in the IMRT group were 94%
and 86%, and in the HC, this was 78% and 70%, re-
spectively (p=0.28).
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Table 3: Tumour and local disease recurrence characteristics.
T-stage CPI Surgery disease recurrence Location
1 T4b + CFR OF temporal meninges
2 T3 LR BF bottom of orbita
3 T4b + CFR IF frontal lobe
4 T4b + CFR BF optic chiasm
5 T3 LR - orbit, ethmoid, frontal lobe
6 T2 LR IF sphenoid and maxilla
7 T4a + ER IF cranial to CP
8 T4b + CFR - CNS invasion (clinically)
9 T4b + CFR BF frontal lobe
10 T4a + LR IF cranial to CP
Abbreviations: CPI: invasion of cribriform plate (CP); CFR: craniofacial resec-
tion; LR: lateral rhinotomy; ER: endoscopic resection; OF: out-of-field disease
recurrence; BF: border-of-field disease recurrence; IF: in-field disease recur-
rence; CNS: central nervous system.
 Patients are sorted chronologically on the date of start of radiotherapy.
 Intraoperative tearing of the dura.
 Not evaluable.
Table 4: Highest acute toxicity during radiotherapy.
CTC-scaling grade 0 grade 1 grade 2 grade 3
conjunctivitis 0 (0) 23 (59) 15 (38) 1 (3)
dry eye 0 (0) 36 (92) 3 (8) 0 (0)
tearing 5 (13) 24 (62) 9 (23) 1 (3)
blurred vision 34 (87) - 4 (10) 1 (3)
photophobia 35 (90) - 3 (8) 1 (3)
keratitis 36 (92) - 3 (8) 0 (0)
mucositis 0 (0) 21 (54) 11 (28) 7 (18)
dysphagia 7 (18) 21 (54) 11 (28) 0 (0)
radiodermitis 0 (0) 25 (64) 12 (31) 2 (5)
The percentages are given between brackets.
 For blurred vision, photophobia and keratitis, there is no definition of grade 1 in the CTC v2.
 This patient received amiodarone during radiotherapy
Acute toxicity
Acute toxicity scores are summarized in Table 4. One
patient had grade 3 ocular toxicity (symptomatic con-
junctivitis, tearing and photophobia, interfering with
activities of daily living). For this patient, IMRT
treatment had to be interrupted for 2 weeks. Twenty-
one (54%) patients had any ocular grade 2 (symp-
tomatic, not interfering with activities of daily living)
as highest toxicity during RT treatment, and the re-
maining 17 patients (44%) had only grade 1 or lower
ocular toxicity. Conjunctivitis and tearing were the
most frequent ocular grade 2 toxicities seen during
RT, in 38% and 23% of the patients, respectively. In
23 patients (58%), tearing was already present before
the start of RT. The presence of keratitis, blurred vi-
sion or photophobia was only seen in 8%, 13% and
11% of the patients, respectively. None of these three
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symptoms was seen in 30 (77%) patients. One patient
(Table 5, Patient 3) had a retinal detachment 1 month
after the end of RT. Even after maximal therapy for
this retinal detachment, vision remained impaired. It
is unclear if there is a relation between the RT course
and this event. For the analysis of the chronic toxic-
ity, it was considered as induced by RT.
No grade 3 dysphagia was seen. Mucositis was
seen in all patients, but grade 2 and 3 were seen in
< 50% of all patients. The most common site for mu-
cositis was the hard palate, as this is the lower border
of the nasal cavity, and as such included in the CTV
(Figure 1). Grade 3 radiodermitis was seen in 2 pa-
tients (of which one was patient 3 from Table 5).
Chronic toxicity
Vision
Before the start of RT, three patients had a pre-
existing ocular disease. One patient had known re-
tinitis pigmentosa, 1 had preexisting severe hyperten-
sive retinopathy, and 1 patient with tumour-induced
blindness (Patient 2 from Table 5). The patient with
hypertensive retinopathy had no decrease of vision
(DV) over baseline at 15 months after RT, and the pa-
tient with retinitis pigmentosa had a significant DV
(from grade 2 bilaterally before RT to grade 3 11
months after RT). In these patients, it is not clear
if the deterioration of the visual acuity is caused by
the effects of the radiotherapy course, or by the pro-
gression of the underlying ocular disease and, there-
fore, they were excluded from this analysis for vi-
sual impairment. In the remaining 33 patients, no
RT-induced blindness was seen. Table 6 summarizes
data on 5 patients (15%) who developed vision im-
pairment. Figure 2d shows the compiled DVHs for
optic nerves and retinae with or without RT-induced
damage, resulting in vision impairment .
Dry eye and pain
Dry eyes were seen in 10 patients. In three patients,
this caused no pain at all, and was only noted by the
ophthalmologist. In two patients, the dry eyes caused
minimal pain (grade 1). Three patients had grade 2
pain (intermittent and tolerable), and two patients had
grade 3 (Table 5, Patient 2) persistent pain due to dry
eyes. Although these two patients required perma-
nent analgesic therapy, no enucleation was required
to control the pain.
Other ocular toxicity
Twenty patients (50%) had any grade of chronic tear-
ing. This was grade 1 in 9 patients, grade 2 in 7, and
grade 3 in the other 4 patients. In all but one patient,
tearing was also present during RT. When compared
with tearing during the RT period, the chronic tearing
was worse in 3 patients, unchanged in 16 patients,
and was better in 1 patient. Cataracts were seen in
15 patients during the follow-up period. Of these 15
patients, 8 patients already had cataracts before RT,
and it worsened after RT in 1 patient. Three patients
had surgery for their cataract, with a normal vision
after the treatment. This was at 9 months, 4.8 and 5.4
years after the end of RT.
Non-ocular chronic toxicity.
Brain necrosis was seen in 2 patients. In 1 patient,
it was shown on MRI and histologically confirmed.
In the other patient, the localization and the time of
onset, which was synchronous with optic nerve tox-
icity, suggested the diagnosis of brain necrosis (Ta-
ble 5, Patient 1; Figure 7). Both patients are alive at
the time of analysis. Grade 2 xerostomia (partial but
persistent dryness) was present in 5 patients. Grade
2 taste alteration was seen in 6 patients. No chronic
mucosal lesions were noted. Although not scored,
more than half of the patients had nasal crusts, which
were treated by daily nasal irrigations with a physio-
logic solution.
Discussion
IMRT has been used increasingly in many centers
throughout the world. However, for head and neck
carcinoma, there are only few reports on the clini-
cal long-term outcome obtained with IMRT. In the
present report, prospectively collected long-term re-
sults are given for a homogeneous patient group, all
of which were postoperatively irradiated for an ade-
nocarcinoma or SCC of the paranasal sinuses. With
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Table 5: Clinical data of three patients with accumulated chronic toxicity.
Patient subsite T-stage Clinical course
1 ethmoid pT2 Brain necrosis (see Figure 7) and grade 3 visual impairment due
to radiovasculitis
2 ethmoid pT4b Unilateral blindness due to orbital tumour invasion. No attempt
was made to spare ipsilateral orbit. Relapsed at optic chiasm.
Bilateral blindness due to tumour invasion of chiasm. Grade 3
ocular pain after RT.
3 ethmoid pT4a Receipt of amiodarone until one week before RT. Grade 3 acute
toxicity (radiodermitis and mucositis) and retinal detachment one
month after RT, causing grade 3 visual impairment.
 Patients are sorted chronologically on the date of start of radiotherapy. RT: radiotherapy
Table 6: Patients with a radiation-induced decrease of vision.
Pt. Grade Side Time of onset Visual acuity Cause
1 2 bilateral 29 8/10 optic neuropathy
2 2 ipsilateral 6 8/10 optic neuropathy
3 2 ipsilateral 8 8/10 optic neuropathy
4 3 ipsilateral 1 2/10 retinal detachment
5 3 ipsilateral 24 2/10 radiovasculitis + neovascular glaucoma
 Time of onset (in months) was measured from the first day of radiotherapy.
a median follow-up of 31 months, this series is ma-
ture enough to report 2-year LC and survival rates.
The results obtained in other series are summarized
in Table 7. The 2-year OS ranges between 47% and
83%, but most series report a 2-year OS rate of ap-
proximately 70%, which is comparable to the OS rate
observed in the present series. It remains very diffi-
cult to compare results between different series. As
it is a very rare disease, paranasal sinus cancer series
are mostly composed of a multitude of histologies,
and data are often collected retrospectively. Even
the comparison of the treatment results with an HC
from the same institution remains difficult to inter-
pret. When considering all patients, both OS and LC
are slightly (not statistically significant) lower for the
IMRT group, than for the HC. However, there might
have been a patient selection bias since the introduc-
tion of IMRT. As the observed acute toxicity with
IMRT was low, patients with a very advanced stage
of sinonasal carcinoma were treated to high dose,
whereas they would have been treated with a strictly
palliative intention in the pre-IMRT era. Moreover,
in the process of retrieving data on the HC group,
it was clear that the majority of patients who were
deemed to be inoperable in the period from 1985 to
1997 would nowadays undergo surgery followed by
RT. Most probably, this is the reason for the unequal
distribution of the number of patients with invasion
through the CP, which was shown to be an impor-
tant prognostic factor. If only those patients without
extension through the CP were compared, IMRT re-
sulted in a (statistically not significant) higher OS and
LC. However, the follow-up is much shorter for the
IMRT group, and no definitive conclusions can yet
be drawn from this historical comparison.
Invasion through the CP with extension into the
anterior cranial fossa was shown to be an important
prognostic factor for both LC and OS. A median time
to local disease recurrence of 7 months and a me-
dian survival of 8 months was observed in these pa-
tients. In none of these patients, local control was
achieved. In our opinion, these poor results do not
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Table 7: Literature review on treatment results and chronic toxicity.
Series N Period Site Treatment Techn. Dose (Gy) FU OS RIB
(%)
MD;ON
(n)
Enucl.
(n)
Shukovsky [6] 30 ’60-’69 E;NC RT 2D 70-75 - - 30% 7;3 -
Ellingwood [7] 32 ’64-’75 E;NC RT 2D 63-66 - 83 28% 3;0 6
Katz [8] 78 ’64-’98 NC;E RT;SRT 2D 65 - 75 37% -;- 0
Jiang [18] 34 ’69-’93 E SRT;RT 2D 60-63 64 65 9% 1;1 -
Karim [19]  45 ’70-’85 E SRT 2D 64-70 - 70 4% 3;6 -
Tiwari [20]  50 ’75-’94 E SRT 2D 65 - 77§ 2% 8 0
Waldron [21] 29 ’76-’94 E RT;RTS 2D 60 48 53 15% 7 -
Jansen [3] 73 ’77-’96 - SRT;RT 2D 66 66 70 21% 3;3 3
Roa [22] 39 ’86-’92 M SRT;RT 3D 56-68 54 60 0% 0 0
Padovani [23] 25 ’95-’01 E SRT;RT 3D 64-70 25 47 0% 0;1 0
HC 30 ’85-’98 E SRT 2D;3D 66 (60-70) 83 83 10% 0;2 1
IMRT 39 ’98-’03 E SRT IMRT 70 (60-70) 31 69 0% 2;3
Abbreviations: N= number of patients. Site: most prevalent subsite(s) in the series, with E: ethmoid sinuses,
NC: nasal cavity and M: maxillary sinus. Treatment: most prevalent treatment strategies, with RT: radiotherapy,
S: surgery, C: chemotherapy; an arrow () indicates that one modality was followed by the other. Techn.: ra-
diation technique, with 2D: conventional technique (mostly one anterior beam and two, lateral wedged fields);
3D: conformal radiotherapy, in which the shape of the field is based on CT-based target delineation and
IMRT: intensity-modulated radiotherapy. Dose: median (or range) of target dose. FU: Median follow-up (in
months); OS: 2-year overall survival. RIB: radiation induced blindness, expressed as percent of all patients in
the series. MD;ON: radiation-induced maculo-retinal degeneration (MD) or optic neuropathy (ON). Enucl.:
enucleation due to radiation-induced toxicity (e.g. severe dry eye). “-“: not specified;
percentage calculated on the number of evaluable patients (n=60).
 represent data from the same center.
shielding of uninvolved part of the orbita.
§ disease-specific survival
include both patients with blindness and severe visual impairment (not reported separately).
justify the further use of our current treatment pol-
icy (craniofacial resection and post-operative IMRT)
for this subset of patients. Patients should be thor-
oughly informed about the grim prognosis, and the
possible benefit of a treatment should be weighted
against the risk of adverse effects. Besides the current
approach, the patient should be offered the choice
between an experimental treatment strategy within
a clinical (multicentric) trial, or a strictly palliative
treatment. In an investigational treatment approach,
craniofacial resection could be replaced by tumour
debulking using a lateral rhinotomy approach. This
surgical procedure carries less morbidity than the
craniofacial approach, and cannot cause surgical tu-
mour spill in the subarachnoidal space. In our ex-
perience, all recurrences in the patients with inva-
sion through the CP were intracranially, suggesting
a pattern of meningeal spread [15]. There were two
patients with a recurrence at the border of the PTV,
and one patient with a meningeal disease recurrence
outside the PTV (Table 3). This indicates the need
for a broader target volume definition, and we would
propose to delineate an additional CTV including the
subarachnoidal space over the frontal lobes and the
anterosuperior part of the temporal lobes. This sec-
ond CTV could than be irradiated to an elective dose.
Three patients relapsed inside of the PTV, but only
cranial to the cribriform plate. This might indicate
the need for an even higher dose to the PTV that is
constructed around (the surgical bed of) the primary
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tumour. This hypothesis and treatment approach is
a purely radiotherapeutic one, and other approaches
and/or modalities, like systemic [24] or topical [5]
chemotherapy might be indicated. To our knowledge,
this clinical problem has not yet been fully addressed.
At our institution, for paranasal sinus cancer, the
cervical lymph nodes are only treated when they are
clinically (palpation and CT) invaded. In this series
of 39 patients, only one patient presented with cervi-
cal lymph node metastases at the time of diagnosis.
Of the 38 remaining patients, only one patient (with
a squamous cell carcinoma of the maxillary sinus)
developed a regional lymph node metastasis. Thus,
none of the 31 patients in whom an adenocarcinoma
was diagnosed, developed a lymph node recurrence,
while this was 1 out of 8 (13%) for squamous cell
carcinoma. This is consistent with data found in lit-
erature, summarized in Table 8. The prevalence of
positive cervical lymph nodes at time of diagnosis
varies between 0% and 15% [19, 20, 22]. When pool-
ing all patients from the five first series (predomi-
nantly ethmoid sinus cancer, called group I), only 2%
(4/197) had positive cervical lymph nodes at diagno-
sis, whereas this was 12% (32/278) in the five series
with mainly maxillary sinus cancer (further called
group II). The percentage of patients suffering from
a lymph node recurrence during follow-up was 7%
(14/194) in group I, and 12% (33/274) in group II.
For isolated lymph node recurrences, these numbers
were 2% (3/147) and 5% (14/274) for group I and
group II, respectively. It is well described that lymph
node recurrence is associated with a bad prognosis,
despite salvage treatment [3, 4, 26, 27]. These con-
siderations made us change our treatment policy, and
we included elective lymph node irradiation (ELNI)
for T3-4 maxillary sinus carcinoma, as was proposed
by Le et al [26]. An ELNI should include the ipsilat-
eral level Ib and II, as most lymph node recurrences
are located in these lymph node regions [26, 27]. In
ethmoid sinus cancer, and most of all in adenocarci-
noma of the ethmoid sinuses, the incidence of lymph
node recurrence is so low that there is no indication
for ELNI.
Chronic toxicity data were prospectively scored
and collected, and showed visual impairment in 5 of
33 evaluable patients (15%). Three of these were
72 70
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Figure 7: Coronal view of a magnetic resonance im-
age (MRI) showing the zone of brain necrosis (white
arrows) in patient 1 from Table 5. The MRI was ac-
quired two years after the end of radiotherapy. The
planning CT was matched to the MRI, and the dose
distributions were transferred to the MRI. All iso-
doses are in Gy.
grade 2 (with a visual acuity score of 8/10), and
the diagnosis of the underlying optic neuropathy was
based on ophthalmologic examination (fundoscopy,
visual evoked potentials and perimetry) rather than
on symptomatic decrease in vision. Two patients had
grade 3 (decrease in central vision) vision impair-
ment at the ipsilateral eye. Of these, 1 patient was
chronologically the first patient treated with IMRT,
and the IMRT plan was made with a simple optimiza-
tion tool, resulting in an inhomogeneous dose to the
PTV. Moreover, in this first patient, the delineated op-
tic structures were not expanded to account for pos-
sible setup errors. The combination of both resulted
in a high dose region near to the optic structures (Fig-
ure 7). Until now, no radiation induced blindness was
observed. However, follow-up was relatively short.
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Table 8: Literature review on lymph node recurrence.
Series N Site (%)
E/NC/M
Histol (%)
Ad/SCC/O
Initial N+ ELNI Lnn recurr. Isolated
Lnn recurr
Tiwari [20] 50 100/0/0 58/18/24 0 (0%) (no) 2/50 (4%) -
Waldron [21] 29 100/0/0 31/41/28 2 (7%) no 5/29 (17%) 1/29 (3%)
Jiang [18] 34 100/0/0 26/24/50 1 (3%) 2/33 3/31 (10%) 0/34 (0%)
This series 39 77/8/15 79/21/0 1 (3%) no 1/39 (3%) 1/39 (3%)
Karim [19] 45 (E+NC) 51/27/22 0 (0%) no 3/45 (7%) 1/45 (2%)
Roa [22] 39 23/26/59  10/41/62  6 (15%) 10/33 3/39 (8%) 2/39 (5%)
Budihna [4] 46 17/2/81 4/87/9 4 (9%) no 5/46 (11%) 0/46 (0%)
Lavertu [25] 54 11/0/89 0/100/0 7 (13%) no 6/54 (11%) 1/54 (2%)
Le [26] 97 0/0/100 4/60/36 11 (11%) 26/86 8/97 (8%) 7/97 (7%)
Paulino [27] 42 0/0/100 0/100/0 4 (10%) no 11/38 (29%) 4/38 (11%)
Porceddu [28] 60 - 42/53/5 5 (8%) no 7/60 (12%) 1/60 (2%)
Jansen [3] 73 - 19/55/26 8 (11%) no 8/73 (11%) 5/73 (7%)
The series are ordered and grouped by the percent of patients whose tumour originates from the ethmoidal
sinus complex. Abbreviations: N: number of patients. Site: subsite of primary tumour, with E = ethmoid sinus;
NC = nasal cavity and M = maxillary sinus; Histol = Histology of primary tumour, with Ad = adenocarcinoma;
SCC = squamous cell carcinoma and O = other histologies. Initial N+: number of patients with positive lymph
nodes at the time of diagnosis. ELNI: elective lymph node irradiation; the denominator is the number of patients
without positive lymph nodes at the time of diagnosis. Lnn recurr.: lymph node recurrence. “-”: not specified
 the denominator indicates all patients who did not have positive lymph nodes at the time of diagnosis, and
who did not undergo ELNI.
  The sum is not 100 (error in original publication?)
Optic neuropathy typically develops between 2 and
4 years after the end of radiotherapy, but can oc-
cur up to 14 years after treatment [9]. Comparably,
radiation induced retinopathy develops within a pe-
riod of 1.4 to 5 years after radiotherapy [11]. Data
about ocular toxicity after high dose radiotherapy for
sinonasal cancer are summarized in Table 7. In the
patient series in which a large part of the orbital cav-
ity or the optic nerve was irradiated to high doses, the
incidence of radiation induced blindness ranges be-
tween 15% and 40% [6, 7, 8, 21]. Karim et al [19]
showed that irradiation of the whole orbit was un-
necessary in case of minimal to moderate orbital ex-
tension. They found a low incidence of radiation in-
duced blindness (4%) by applying a shrinking field
technique, thus excluding the ocular structures from
the high dose regions. These results were confirmed
by a later series of the same center [20]. Two series
report on the results obtained by 3D conformal irra-
diation of sinonasal cancer. Roa et al [22] and more
recently Padovani et al [23] did not find any radia-
tion induced blindness. Finally, in the HC, 7 patients
developed a decrease of the vision, accompanied by
chronic conjunctivitis. In 1 patient, enucleation of the
eye was necessary to control the pain caused by a dry
eye. One patient developed unilateral blindness due
to optic neuropathy, and 1 patient suffered bilateral
blindness. In total, 3 out of 30 patients (10%) lost vi-
sion at at least one eye in the HC. In conclusion, the
data on LC and ocular toxicity support our hypothe-
sis that IMRT results in a higher uncomplicated local
control in sinonasal carcinoma.
Conclusion
For sinonasal carcinoma, IMRT results in equal local
control and survival features as conventional or con-
formal RT techniques. Both acute and chronic ocular
toxicity were low, and no radiation-induced blindness
was observed. Invasion through the cribriform plate
was an important prognostic factor.
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Key issues discussed in this paper:  
• Despite advanced conformal techniques, like IMRT, local relapse in HNC is still 
frequent, and mostly develops in the high-dose region. This urges for focused dose 
escalation to the regions within the GTV at highest risk for relapse. 
• Biological imaging, like FDG-PET, correlates better to tumour macroscopy than CT- 
and MRI-based delineation, and might indicate tumour regions with a higher intrinsic 
radioresistance, needing higher doses. 
• FDG-PET data were used both in the delineation of the target volumes and in guiding 
the dose escalation. The latter was done using 2 phases, with the dose escalation 
embedded in the first ten fractions. 
• The use of FDG-PET information led to changes in the CTV in 7 out of 20 patients. 
The GTV, delineated on FDG-PET was significantly smaller than the CT-based GTV.  
• The dose escalation to the FDG-PET positive lesion did not result in more complex 
plans, nor in higher doses to the surrounding targets and OARS. 
Positron emission tomography guided dose escalation with
intensity-modulated radiation therapy in head and neck cancer
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Abstract
Background and Purpose: In head and neck cancer, the majority of relapses occur in the gross tumor
volume (GTV). This relapse pattern suggests the need for selective delivery of higher doses to the GTV.
2- fluoro-2-deoxy-glucose positron emission tomography (PET) appears to be more accurate for GTV
definition than computed tomography (CT) or magnetic resonance imaging. This report describes the im-
plementation and planning results of PET-guided intensity-modulated radiation therapy (IMRT) with a dose
escalation, focused on a PET-based GTV (GTVPET).
Materials and Methods: Twenty patients with head and neck cancer were included in a dose escalation
trial. All patients had a planning CT and a PET in treatment position. All target volumes were first delineated
on CT without PET data. Then, CT and PET were fused, and GTVPET was automatically segmented. If
needed, target volumes were enlarged according to PET findings. All target subvolumes were grouped
according to various prescription dose levels. The IMRT treatment (IMRT escal) aimed at a selective dose
escalation to the PTVPET up to 72.5 Gy, and consisted of 10 fractions of phase 1 (containing the dose
escalation) and 22 fractions of phase 2. The IMRTescal was evaluated using median dose (Dmed) and
indices for range for PTVs and dose constraints for organs at risk (OARs). The selectivity of dose escalation
for the PTVPET was evaluated by comparing the IMRTescal to a virtual “conventional” IMRT treatment
(IMRTconv), which consisted of 32 fractions of phase 2 plan.
Results: GTVPET was 45% smaller than the CT-based GTV (GTVCT). PET resulted in an adaptation
of target volumes in 7 patients. The multiple dose levels, prescribed as D med to the various PTVs, could be
planned within 0.5 Gy in nearly all patients. Comparing IMRTescal with IMRTconv showed that selectivity
of dose escalation was secured with respect to OARs and PTVs.
Conclusions: The use of PET had an impact on target volumes in one third of the patients. Dose es-
calation of GTVPET to 72.5 Gy using two phases was feasible on planning and delivery, and was highly
selective since it did not increase dose to the OARs.
PET guided IMRT dose escalation
Introduction
In conformal radiotherapy, like intensity-modulated
radiation therapy (IMRT), three-dimensional (3D)
imaging is directly used to shape beam outlines and
sometimes to modulate beam intensity as function of
3D anatomical information. Clinical use of confor-
mal radiotherapy serves 2 main objectives. First, se-
lective reduction of the dose to radiation-sensitive or-
gans may result in less toxicity and results of case
series indeed suggest that conformal avoidance of
radiation-sensitive structures like parotid or lacrimal
glands, optic or auditory pathways has resulted in
less morbidity [10]. Reduction of dose to sensitive
organs relative to the tumor prescription dose could
be exploited to reach the second objective: improved
loco-regional control by dose escalation [10]. Case
studies of conformal radiotherapy show that the ma-
jority of relapses occur in the gross tumor volume
(GTV) or tumor bed receiving the highest prescrip-
tion dose, and less often in electively irradiated ar-
eas [2, 6]. This pattern of relapse suggests that tar-
get definition and prescription doses are appropriate
for electively irradiated regions to which prescription
doses of 40-50 Gy, 50-60 Gy and 60-70 Gy are typ-
ically applied for low, intermediate and high proba-
bility of microscopic invasion respectively. Prescrip-
tion doses to the region of the GTV are of the same
order or slightly higher than for the high-risk elec-
tive regions. For some tumor sites, the feasibility and
safety of dose escalation has been demonstrated us-
ing brachytherapy [16], stereotactic radiosurgery [19]
and IMRT simultaneous boost techniques [20]. In
all these techniques, dose was escalated to small vol-
umes. Neither the criteria to define the boost volume,
nor the dose/volume/toxicity relationships for boost-
ing small volumes are known. We decided to use 2-
 fluoro-2-deoxy-glucose positron emission tomog-
raphy (FDG-PET, further referred to as PET) imag-
ing for the definition of the boost volume. Daisne et
al showed that in pharyngo-laryngeal squamous cell
cancer, the GTV that had been automatically delin-
eated based on the FDG-PET data (GTVPET), cor-
related better with the macroscopic surgical spec-
imen than expert-contoured GTVs based on com-
puted tomography (CT) or magnetic resonance imag-
ing (MRI) scans [5]. We reasoned that this PET le-
Table 1: T- and N-stage for the 20 patients, according
to the UICC TNM classification [18].
T2 T3 T4a T4b All
N0 1 2 1 - 4
N1 1 4 - - 5
N2b 1 2 - - 3
N2c 2 - 1 3 6
N3 - 2 - - 2
All 5 10 2 3 20
sion might be a suitable target subvolume for dose
escalation inside the expert-contoured highest-dose
planning target volume (PTV).We clinically imple-
mented focused dose escalation, based on PET, and
report on the planning results of the first escalation
step.
Materials and Methods
Patient description
Twenty patients were enrolled in the first level of this
dose escalation trial. Inclusion criteria for the trial
were: (1) histological diagnosis of a squamous cell
carcinoma (SCC) arising from the hypopharynx, the
oropharynx or the larynx (for larynx, only T
 
N

or
Tany N were included); (2) the patients did not un-
dergo surgery of the primary tumor as a part of their
treatment; (3) the patients were free of lung metas-
tases (assessed by CT). Patients who had previously
been irradiated in the head and neck region were ex-
cluded from the trial. All patients gave their written
informed consent to enter the study protocol, which
was approved by the local ethics committee. Of the
twenty patients included in the trial, 8 patients had
a SCC of the larynx, 6 patients had a tumor arising
from the hypopharynx and another 6 patients had an
oropharyngeal tumor. All patients were staged ac-
cording to the UICC TNM classification [18](see Ta-
ble 1).
Delineation of target volumes and organs at
risks (OARs)
Planning CT and PET scan were both acquired in
treatment position, immobilized with a thermoplas-
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tic mask. All anatomical structures were delineated
on the CT before PET information was made avail-
able. A summary of target structure definitions is
given in Table 2. The GTV was delineated based
on the planning CT (GTVCT), using complementary
diagnostic imaging (CT and/or MRI) but not PET.
The clinical target volume (CTV) containing the mi-
croscopic extension locally around the GTVCT was
manually delineated based on the idea of compart-
mental tumor spread [13], resulting in the primary
CTV (pCTVCT). All lymph node regions (LNRs)
were contoured separately [12].
The PET acquisition was done on a Siemens Ex-
act HR+ camera (CTI-Siemens, Knoxville, USA),
operating in 3D-mode, i.e. septa retracted. Imag-
ing began 60 minutes after iv injection of 185-259
MBq (5-7 mCi) FDG. Emission scans were first ob-
tained at two bed positions, with a 3.9-cm overlap,
covering an axial field of view of 26,675 cm. The
duration of the emission scans was 10 minutes each.
Transmission scans (5 min each) were then obtained.
The data were transferred to a dedicated workstation
and reconstructed using a fully 3D iterative algorithm
(attenuation-weighted-OSEM), without rebinning of
the data. Images were reconstructed with correction
for random, normalization, scatter and attenuation.
Pixel size in the final image was 2.5, 2.5 and 2.4 mm
in the x, y and z direction, respectively. The PET le-
sion (GTVPET) was automatically segmented based
on the source-to-background ratio [4]. The CT and
PET transmission scan were coregistered using Pin-
nacle (Philips Medical Systems, Milpitas, CA). Af-
ter the CT/PET fusion and the segmentation of the
GTVPET, a final GTVunion was made by the addi-
tion of GTVCT and GTVPET. The pCTV was com-
posed from the pCTVCT and - if needed - extended
to encompass the GTVunion with a margin for mi-
croscopic extension.
CTV subvolumes (pCTV and all the separate
LNRs) were grouped according to the dose prescrip-
tion levels in CTV
	
, CTV

, CTV

and CTV


, as
explained in Table 2. A 3 mm margin was applied for
the expansion from CTV to PTV for all CTV volumes
and for the expansion of GTVPET to PTVPET.
In order to avoid ambiguous demands to the opti-
mization algorithm, subvolumes of each PTV were
**
* *
*
*
Figure 1: Transverse plane of planning CT from a pa-
tient with a tumor originating from the oropharynx.
The automatically delineated PET lesion (GTVPET)
is indicated by the speckled area. Dotted lines rep-
resent manually delineated structures, with gross tu-
mor volume (GTVCT) in yellow, the clinical target
volume around the GTVCT (pCTVCT) in orange,
lymph node regions (LNRs) in black and spinal cord
in green. Full lines represent the expanded struc-
tures, with the PTV
	
in red, the PTV


in blue and
the expanded spinal cord in green. The dashed lines
and shaded areas represent the optimization struc-
tures PTV
	 optim (red) and PTV
 optim (blue).
PTV

 optim results from PTV
 using the subtrac-
tion of a 6 mm build-up region (indicated by the hol-
low arrows) and excluding the PTV
	
with a margin
of 6 mm (shown by the asterisks). In the same way,
PTV
	 optim is made by subtracting the PTVPET
(not shown) from PTV
	
with the same margin. The
beam directions are indicated by the six arrows.
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Table 2: Overview of target structure definition.
Structure Name Description
GTVCT GTV as delineated on the planning CT without PET information
GTVPET GTV, automatically segmented on PET based on the source-to-
background ratio
GTVunion GTV constructed by the addition of GTVCT and GTVPET.
pCTV CTV containing GTVunion and microscopic extension locally
around GTVunion
CTV
	
CTV consisting of CTV subvolumes with macroscopic tumor:
pCTV and LNRs with clinically positive and unresected lymph
nodes
CTV

CTV containing resected LNRs with pathologically positive
lymph nodes with capsular rupture
CTV

CTV containing resected LNRs with pathologically positive
lymph nodes without capsular rupture
CTV


CTV containing elective LNRs: no clinical evidence of disease
but at risk for microscopic invasion
Abbreviations: GTV: gross tumor volume; CT: computed tomography; PET: positron
emission tomography; CTV: clinical target volume; LNR: lymph node region.
constructed using in-house developed software [9].
From each PTVD (D = prescription dose for a given
PTV), a PTVD whbu (whbu: without build-up) was
created by subtraction of a 6 mm build-up region.
All PTVs to which a dose higher than D Gy was
prescribed were subtracted from PTVD whbu with a
margin of 6 mm. The part of PTVD whbu, which
remains after the subtraction procedure(s) is called
PTVD optim. This procedure secures priority rank-
ing for the PTVs to which the highest dose was pre-
scribed. The method of delineation and creation
of target subvolumes is illustrated in Fig. 1. The
contoured OAR set consisted of spinal cord, brain-
stem, parotid glands, mandible and thyroid cartilage.
Spinal cord was expanded with a 5 mm margin, while
a 3 mm margin was used for brainstem. The other
OARs were not expanded.
Planning procedure
The treatment consisted of 2 consecutive phases
for which separate plans were made. Dose es-
calation to the PTVPET was embedded in the
phase 1 plan. Ten fractions were delivered according
to this phase 1 plan. The phase 2 plan, without dose
escalation, was given for 22 fractions. Both plans
were IMRT plans, using multiple prescription dose
levels simultaneously for the different target volumes.
The technique is referred to as simultaneous inte-
grated boost (SIB) [20, 15]. Details about dose pre-
scription per plan are given in Table 3. These doses
represent the median dose (Dmed) to a PTVD optim
that was requested from the optimization algorithm.
In practice, both the phase 1 plan and the phase 2 plan
were optimized to 69.1 Gy to the PTV
	 optim (this
is as if the plan would virtually be given 32 fractions),
and rescaled to 1 fraction (see Table 3). This strategy
enabled us to use the same biological optimization
parameters for OARs for both plans.
A class solution, consisting of 6 coplanar pre-
defined beam directions, was used for all patients.
For each beam direction, segments were generated
by the anatomy-based segmentation tool [7]. Seg-
ment outlines and weights were optimized based
on a bio-physical cost function [8]. Several cycles
of optimization were executed, until the planning
goals/constraints were reached/respected. For all
PTVD whbu, the partial volume receiving less than
95% of the prescribed dose (V
	

) had to be less
than 5%. For the PTV to which the highest dose was
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prescribed (for the phase 1 plan, this was PTVPET,
while for phase 2 plan, this was PTV
	
), the partial
volume receiving more than 107% of the prescribed
dose (V
 
) had to be less than 5%. The inho-
mogeneity factor U
	
   x D  DDmed
, with D

the nd percentile dose and D
	
the th percentile
dose, had to be less than 12% for PTVPET and for
PTV
	 optim. For all PTVs with a lower prescription
dose (66 Gy, 62 Gy and 56 Gy), the maximal homo-
geneity depends on the dose prescriptions and con-
straints to neighbouring structures. For this reason,
we choose not to impose a homogeneity criterium to
PTV

, PTV

and PTV


or their respective opti-
mization subvolumes.
The partial volume of the expanded spinal cord
receiving more than 50 Gy (V

Gy) had to be less
than 5%. If there was a conflicting situation be-
tween PTV underdosage (V
	

) and the V

Gy
for spinal cord, priority was given to the latter. Spar-
ing of the contralateral parotid was only performed
in those cases were the contralateral LNR II and III
were free of lymph nodes that were clinically suspect
for tumoral invasion. Fourteen patients fulfilled this
criterium (7 left and 7 right parotids). The planning
goal for parotid sparing was a Dmed less than 27 Gy.
Evaluation endpoints
The volumes of the following structures were
recorded: i) the GTVCT ii) the GTVPET, iii) the
mismatch volume GTVPET only, which is the par-
tial volume of the GTVunion that is only con-
toured using PET and iv) the mismatch volume of
GTVCT only, which is the part of the GTVunion
that is only contoured by the expert. Also, the in-
fluence of the PET information on the CTVs was
recorded.
Statistics regarding the number of segments and
the monitor unit (MU) efficiency of the phase 1 and
the phase 2 plans were computed. MU efficiency
was calculated per patient by dividing the number
of MUs needed for one fraction by the prescription
dose (i.e. 250 cGy for phase 1 plans and 216 cGy for
phase 2 plans).
The effect of dose escalation to the PTVPET on
the other subvolumes and on the OARs was evalu-
ated by comparing clinically relevant indices between
the summed plans (IMRTescal) and the conventional
IMRT treatment (IMRTconv). The IMRTescal was
made by summing 10 fractions of phase 1 plan
with 22 fractions of phase 2 plan. The hypothet-
ical IMRTconv was composed of 32 fractions of
phase 2 plan, which is the plan without dose esca-
lation. For each target volume PTVD , the Dmed,
V
	

, U
	
, the minimal dose (Dmin) and the
maximal dose Dmax were evaluated. The th and

nd dose percentile were used as surrogate for Dmin
and Dmax, respectively [20]. For the expanded spinal
cord, the V

Gy and the Dmax were reported, while
for the parotid glands the Dmed and the VGy are
given. Results are presented as the mean   standard
deviation. For all statistical comparisons, a paired
Student t test was used. All tests were two-tailed.
A p-value < 0.05 was considered significant.
Dose-volume histograms (DVHs) of phase 1 and
phase 2 plans were compiled for the whole group
of patients using the following method: for all pa-
tients, the volume percentiles at every 2 cGy dose
level between 0 and 270 cGy were computed from the
calculated fraction dose distribution for the relevant
anatomical structures. For each of these dose levels,
the mean and standard error of the mean (SEM) over
all the patients were calculated. Compiled DVHs
were then plotted using this mean volume percentile
and SEM value.
Results
Target volume adaptations
The mean GTVCT volume was 17.4   13.8 cc,
while for the GTVPET, this was 9.7   8.4 cc
(p = 0.026). When looking at the regions covered
by GTVPET but not by GTVCT, the mean abso-
lute volume of GTVPET only was 2.7   2.6 cc
(19.3   14.9% of GTVunion volume). The reverse
mismatch structures GTVCT only had a mean vol-
ume of 10.4   9.8 cc, representing 45.7   25.6%
of the volume of GTVunion. The volume of the
GTVPET was larger than that of the GTVCT in
6 patients. The average volume of the pCTV was
104.9   41.2 cc. In 8 patients, PET imaging gave
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Table 3: PTV dose prescription levels.
phase 1 plan phase 2 plan TPD (Gy) NID
Gy (Gy)
PTVPET 2.50 [80.0] 2.16 [69.1] 72.5 78.3
PTV
	 optim 2.16 [69.1] 2.16 [69.1] 69.1 72.5
PTV
 optim 2.06 [65.9] 2.06 [65.9] 65.9 67.2
PTV
 optim 1.94 [62.1] 1.94 [62.1] 62.1 60.9
PTV

 optim 1.75 [56.0] 1.75 [56.0] 56 51.1
Numbers represent dose (in Gy) per fraction. Numbers between square brackets rep-
resent the dose (in Gy) to which the plans were optimized. TPD: Total physical dose
(in Gy) represents the dose that was actually delivered to the patients, which consists
of 10 fractions according to phase 1 plan, and 22 fractions according to the phase
2 plan. The several PTVs are explained in the text and in Table 2. NID
Gy: Nor-
malized Iso-effective Dose (in Gy) for 2 Gy fractions, calculated according to Lee
et al [14] with  =10 Gy, =0.035 Gy  and a potential doubling time of 4 days.
Treatment time was estimated as n


with n the number of fractions.
additional information about the tumor extent. In
one patient with a pathologically enlarged retropha-
ryngeal lymph node on CT, a second retropharyn-
geal lymph node at the contralateral side was found
by PET. As the retropharyngeal LNR was already in-
cluded in the CTV
	
, this additional finding did not
alter the target volumes. In the 7 other patients, PET
information led to adaptations of the CTV. In 3 of
these, the pCTV was only marginally adapted after
PET information was available. However, in one pa-
tient, PET imaging showed FDG activity at the con-
tralateral side of the tumor imaged on CT and seen at
endoscopy. This finding was confirmed on repeated
endoscopy. The average volume of the pCTVCT in
these 4 patients was 117.8  46.3 cc, while, using the
PET information, the pCTV became 138.3  34.1 cc.
In the 3 other patients, additional lymph nodes were
seen on PET scan that were not suspect by previous
diagnostic interventions. One patient shifted from
cN0 to cN1, another patient reached cN2b instead
of cN1. In the third patient, a lymph node that was
suspect on CT but negative on fine needle aspiration
cytology was clearly positive on PET scan.
Planning results for IMRTescal
The planning results of IMRTescal are summarized
in Table 4. The achieved Dmed to the PTVs were all
within acceptable range around the Dmed that was
required from the optimization. The underdosage
constraint for PTVPET and PTV
	 whbu were met
in all but one patient. In this patient, the PTVPET
was partly lying in the build-up region (V
	

for
PTVPET whbu was 0%). For PTV	 optim, the plan-
ning did not fulfill the constraint for avoiding under-
dosage in 2 patients (V
	

of 5.3% and 5.8%). The
V
	

constraint for PTV

 optim was not met in
half of the patients. No overdosages were seen in the
PTVs.
Comparison IMRTconv vs IMRTescal
Results of the comparison between IMRTconv and
IMRTescal are summarized in Table 4. Dose esca-
lation to the PTVPET results in a higher dose to the
surrounding PTV
	
, but did not significantly affect
dose to other structures. No statistically significant
differences were found for spinal cord, parotid gland
(spared and unspared) and mandible. For thyroid car-
tilage, the Dmean was 65.8   3.6 Gy for IMRTconv
and 66.6   4.1 Gy for IMRTescal (p = 0.508), while
the Dmax was 69.7   1.5 Gy and 71.7   2.5 Gy
(p = 0.347). For the subselection of the patients
with a primary tumor of the larynx or hypopharynx
(n = 14), the Dmax of the thyroid cartilage was sig-
nificantly higher in the IMRTescal (72.6   0.7 Gy)
than in IMRTconv (70.1   0.4 Gy) (p < 0.001). The
Dmean for thyroid cartilage in this group of patients
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Figure 2: DVHs compiled from the data of the
whole patient group for phase 1 plan (a) and
phase 2 plan (b). The method of the DVH compi-
lation is described in the Materials and Methods sec-
tion. The represented dose (in cGy) is the dose given
per fraction. For each structure, the mean   the stan-
dard error of the mean (dotted lines) of the relative
volumes is represented. For each target structure, ex-
cept for PTVPET, both the PTVD (solid thin lines)
and the PTVD optim (dashed bold lines) are shown.
The DVHs for PTV

and PTV

are compiled from
the 6 and 4 patients respectively for whom this PTV
dose level existed. The data for the spared parotid
are compiled over the 14 “spared” parotids. The surr
structure is the region at least 30 mm away from
PTV
	
and at least 20 mm from PTV


.
was not significantly different, being 67.3   1.6 Gy
for IMRTconv and 68.4   2.1 Gy for IMRTescal
(p = 0.158).
Comparison of the phase 1 and the
phase 2 plans
The phase 1 IMRT plans were not more com-
plex than the phase 2 IMRT plans. The aver-
age number of segments, used in the final plan,
was 40.2   7.1 for phase 1 plans and 37.3   6.3
for phase 2 plans (p = 0.180). The total num-
ber of MUs for the delivery of one fraction was
481.5   81.0 for phase 1 plans and 407.0   37.5 for
phase 2 plans (p < 0.001). However, the MU effi-
ciency for phase 1 plans (1.92   0.32 MU/cGy) and
phase 2 plans (1.88   0.17 MU/cGy) was not signif-
icantly different (p = 0.616).
A comparison of the compiled DVHs between
the phase 1 and phase 2 plans is shown in Fig. 2.
Besides the (intended) difference for PTVPET, and
the subsequent higher doses in the parts of the other
PTVs that lie in vicinity of the PTVPET, no ma-
jor differences are visible between phase 1 plan
(Fig. 2a) and phase 2 plan (Fig. 2b). The V
 

for PTV
	 whbu was 36.0   14.7% in phase 1 plan.
For PTV
	 whbu, there was a significant correla-
tion between the ratio of the volume of PTVPET
over the volume of PTV
	 whbu and the V 
 for
PTV
	 whbu (product-moment coefficient of correla-
tion R = 0.818, p < 0.001).
Fig. 3 shows the dose distribu-
tions of phase 1 plan for a patient with a tumor of
the oropharynx.
Discussion
IMRT offers a high control over the distribution of
dose within the patient. It enables the conformal spar-
ing of OARs on the one side, and the escalation of
dose to the target volume on the other side. The dif-
ferent fraction sizes within one plan offer a combina-
tion of radiobiological advantages over conventional
radiotherapy, like higher/lower dose per fraction to
the tumor/OARs, and result in (slightly) accelerated
treatments [20]. Theoretically, IMRT allows dose es-
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Table 4: Summary of the dose volume histogram (DVH) data showing averages   SD.
IMRTconv IMRTescal Constr. violation p-value
PTVPET (volume: 25   16 cc)
Dmed (Gy) 69.0  0.6 72.4  0.4 2/20 <0.001
Dmin (Gy) 66.8  2.1 70.3  2.1 - <0.001
Dmax (Gy) 70.5  0.9 73.6  0.6 - <0.001
U
 
(%) 5.4  3.4 4.6   3.0 1/20 0.468
V

(%) 0.7  1.6 0.6   1.5 1/20 0.728
PTV
whbu (volume: 202  76 cc)
Dmed (Gy) 68.8  0.1 69.6  0.6 - <0.001
Dmin (Gy) 65.7  1.1 65.9  0.8 - 0.456
Dmax (Gy) 70.5  0.5 73.0  0.4 - <0.001
U
 
(%) 7.0  2.0 10.2  1.2 2/20 <0.001
V

(%) 2.2  1.9 1.9   1.4 0/20 0.463
PTV
optim (volume: 140  64 cc)
Dmed (Gy) 68.8  0.1 69.0  0.2 0/20 <0.001
Dmin (Gy) 65.7  1.0 65.6  0.8 - 0.652
Dmax (Gy) 70.3  0.4 71.1  0.6 - <0.001
U
 
(%) 6.6  1.9 8.0   1.4 0/20 0.016
V

(%) 2.2  2.1 2.4   1.8 2/20 0.743
PTV
whbu (volume: 372  132 cc)
Dmed (Gy) 56.9  1.4 56.9  1.4 - 0.920
Dmin (Gy) 51.9  2.1 52.4  1.5 - 0.395
Dmax (Gy) 69.1  0.9 70.1  1.6 - 0.016
U
 
(%) 30.2  4.3 31.1  4.3 - 0.504
V

(%) 5.2  4.6 4.0   3.2 6/20 0.339
PTV
optim (volume: 272  102 cc)
Dmed (Gy) 56.0  0.3 56.0  0.2 2/20 0.579
Dmin (Gy) 51.5  2.3 52.0  1.6 - 0.385
Dmax (Gy) 61.2  2.2 60.8  1.7 - 0.568
U
 
(%) 17.3  7.5 15.6  5.5 - 0.439
V

(%) 6.8  5.8 5.2   4.0 10/20 0.341
spinal cord
V
Gy (%) 0.9  1.4 0.5   0.8 0/20 0.232
Dmax (Gy) 45.8  3.9 45.3  3.8 - 0.673
parotid (sparing)
Dmed (Gy) 20.2  10.6 19.5  8.5 1/14 0.838
Dmean (Gy) 24.1  7.5 23.3  5.7 - 0.780
V
	Gy (%) 42.6  15.5 41.2  13.0 - 0.795
parotid (no sparing)
Dmed (Gy) 55.1  8.7 54.5  8.8 - 0.817
V
	Gy (%) 86.4  15.5 86.4  15.9 - 0.995
mandible
V
Gy (%) 14.2  17.1 13.7  17.1 - 0.931
Dmax (Gy) 63.3  6.0 63.0  6.1 - 0.881
IMRTconv: total treatment without dose escalation (32 fraction of phase 2 plan). IMRT escal: total treat-
ment with dose escalation (10 fractions of phase 1 plan + 22 fractions of phase 2 plan). Constr. violation:
number of patients for whom a specified constraint was violated in the IMRT escal treatment.
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Figure 3: Fraction dose distribution for a patient with
a tumor of the oropharynx in a transverse (a) and
sagittal (b) view. The PTVPET is indicated by a thick
grey line, while the PTV
	
is shown in a black line.
Isodose lines are in cGy.
calation up to   80 Gy (as a maximal dose) to the
GTV without major influence on the dose to the sur-
rounding structures [21]. The boost volume should
ideally reflect that part of the tumor with the highest
intrinsic radio-resistance. The macroscopic tumor -
approximated on CT by the GTVCT - is very hetero-
geneous with respect to radiobiological properties,
like clonogenic cell density, proliferation rate and hy-
poxia. FDG uptake might express some of these bi-
ological properties. It has been shown that patients
with a head and neck tumor showing a higher uptake
of FDG have a worse local control than the patients
with a lower FDG uptake [1]. In conclusion, there
are two main reasons to select FDG-PET in order to
determine the boost volume: (1) high FDG uptake
correlates with worse local control; (2) FDG-PET-
based target delineation correlates better with tumor
macroscopy than CT-based delineation and results in
smaller volumes. The use of FDG-PET scans for the
delineation of the tumor volume in head and neck has
been investigated by several authors. Ciernik et al [3]
used coregistered PET/CT in the radiotherapy treat-
ment planning of 12 head and neck patients. In their
report, the GTV (including possible lymph nodes)
changed by more than 25% in 6 out of 12 patients.
Moreover, the inter-observer variability of the GTV
delineation significantly decreased by the use of PET.
Geets et al [11] found a reduction of 40% in GTV by
FDG-PET when compared to CT-based GTV delin-
eation. In the present report, we found a GTVPET
that was 45% smaller than the GTVCT, confirming
the data of Geets et al. Scarfone et al [17] studied the
influence of FDG-PET scan on the target volumes in
6 head and neck cancer patients. In their series, the
GTV (as defined on CT only) was adapted in 5 out of
5 analyzable patients after coregistered PET/CT data
were available and nearly 20% of the GTVPET was
located outside of the GTVCT.
The dose escalation to the PTVPET in the IMRT
planning did not increase the complexity of the IMRT
plans. The same class solution with 6 beam direc-
tions could be used, and the number of segments did
not significantly increase. Except for thyroid car-
tilage in the patients with laryngeal and hypopha-
ryngeal tumors, dose escalation to the PTVPET did
not alter the dose to the surrounding OARs. Wu et
PET guided IMRT dose escalation
al [20] reported on a dose escalation study in which
the dose was escalated to the GTV, as defined on CT.
They found that dose escalation, using a simultane-
ous integrated boost IMRT technique was feasible,
and did not hamper parotid sparing. They found a
homogeneity of   7% in the GTV, which is compa-
rable to the U
	
of 4.6% we observed. In the re-
port by Wu et al, boost dose was integrated over the
whole treatment, by giving a higher dose/fraction ev-
ery fraction. Although we also used the SIB planning
technique (with different fraction sizes for different
target structures), we choose to give the dose esca-
lation during the first 10 fractions. Current state of
the art planning systems are designed to use invariant
anatomy for a treatment plan. Images used for plan-
ning are considered representative for the entire dura-
tion of treatment for which the plan was made. How-
ever, anatomical changes during fractionated treat-
ment schedules of several weeks for head and neck
cancer are known to occur frequently. These changes
may involve tumor as well as OARs but the common
practice of delineation and dose prescription seems
robust against changing anatomy. In conventional
radiotherapy, homogeneous doses are prescribed to
PTVs that contain generous margins around known
or suspected disease. Thereby, the risk for tumor
to move out of the PTV margin is low, especially
if the tumor is regressing during the course of treat-
ment and the dosimetric effects of motion inside the
PTV are low when dose homogeneity is high. How-
ever, when using a conformal dose distribution inside
the PTV, like dose escalation to a subvolume, motion
may seriously affect the tumor dose. In our appli-
cation of focused dose escalation, any motion of the
tumor tends to lower the dose it receives. For these
reasons, we elected to use a focused dose escalation
plan only for the st phase of treatment. For the nd
phase of treatment, it appears logical to perform re-
imaging and re-planning. The re-planning however,
is not a trivial task if anatomy has changed since
it has to take into account a previously given non-
homogeneous dose, delivered to a different anatomy.
None of our planning systems is capable to secure
dose integration of two or more plans with a chang-
ing anatomy in-between. For these reasons, we used
the pre-treatment imaging for the planning of both
phases of treatment, the st phase involving focused
dose escalation while for the nd phase a more ro-
bust conventional IMRT plan with homogeneous pre-
scription doses to large (pre-treatment) volumes was
made. “Biological imaging” (BI)-guided IMRT is a
relatively new research area for improving treatment
results of radiotherapy. Although it has been shown
to be feasible, several improvements can be made on
different levels. A closer integration of the biologi-
cal image into the planning system seems a logical
next step for BI-guided IMRT. The dose escalation in
this study was applied to a contour that was generated
by clipping on a certain PET signal value. PET sig-
nal values within the GTVPET can still vary substan-
tially. We are currently investigating the feasibility of
direct incorporation of the PET signal intensity into
the planning procedure.
In conclusion, twenty patients were treated within
a dose escalation protocol. The use of PET informa-
tion altered the target volumes in approximately one
third of the patients. The GTV defined on PET was
significantly smaller than the GTV that was delin-
eated using CT only. Dose escalation to the PTVPET
was performed in the first 10 fractions, and resulted
in a total physical dose of 72.5 Gy to the PTVPET.
This dose escalation did not influence the complex-
ity of the IMRT treatment and was highly selective to
PTVPET, as the dose to the other PTVs and organs
at risk was not significantly higher due to the escala-
tion.
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Key issues discussed in this paper:  
• Theoretically, IMAT is indicated in these anatomical situations in which a PTV is 
wrapped concavely around an OAR with a large radius. 
• The anatomy-based approach for segmentation, developed at GUH, has favorable 
characteristics for the transition from IMRT to IMAT. 
• An IMAT class solution was developed for whole abdominopelvic radiotherapy, and 
clinically implemented for ovarian carcinoma. 
• A PGD experiment on an anthropomorphic phantom showed good agreement between 
the calculated and measured dose distributions for the PTV. All clinically imposed 
constraints were met in the PGD-measured dose distribution for the PTV and OARS.  
• Compared to the best available 3D plan, IMAT resulted in a higher homogeneity in 
the PTV, and a lower mean and median dose the kidneys (dose-limiting OARS). 
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Abstract
Purpose: Whole abdominopelvic radiation therapy (WAPRT) is a treatment option in the palliation of
patients with relapsed ovarian cancer. With the conventional techniques, kidneys and liver are the dose and
homogeneity limiting organs. We developed a planning strategy for intensity modulated arc therapy (IMAT)
and report on the treatment plans of the first five treated patients.
Materials and methods: Five consecutive patients with histologically proven relapsed ovarian cancer were
sent to our department for WAPRT. The target volumes and organs at risk (OAR) were delineated on 0.5 cm
thick CT slices. The clinical target volume (CTV) was defined as the total peritoneal cavity. CTV and
kidneys were expanded with 0.5 cm. In a preset range of   Æ interspaced gantry angles, machine states were
generated with an anatomy based segmentation tool. Machine states of the same class were stratified in
arcs. The optimization of IMAT was done in several steps, using a biophysical objective function. These
steps include weight optimization of machine states, leaf position optimization adapted to meet the maximal
leaf speed constraint, and planner-interactive optimization of the start and stop angles. The final control
points (machine states plus associated cumulative monitor unit counts) were calculated using a collapsed
cone convolution/superposition algorithm. For comparison, two conventional plans (CONV) were made,
one with two fields (CONV2), and one with four fields (CONV4). In these CONV plans, dose to the
kidneys was limited by cerrobend blocks. The IMAT and the CONV plans were normalized to a median
dose of 33 Gy to the planning target volume (PTV). Monomer/polymer gel dosimetry was used to assess the
dosimetric accuracy of the IMAT planning and delivery method.
Results: The median volume of the PTV was 8306 cc. The mean treatment delivery time over four patients
was 13.8 minutes. A mean of 444 monitor units was needed for a fraction dose of 150 cGy. The fraction of
the PTV volume receiving more than 90% of the prescribed dose (V
 
) was 9% higher for the IMAT plan
than for the CONV4 plan (89.9% vs 82.5%). Outside a build-up region of 0.8 cm and 1 cm away from both
kidneys, the inhomogeneity in the PTV was 15.1% for the IMAT plans and 24.9% for the CONV4 plans
(for CONV2 plans, this was 34.9%). The median dose to the kidneys in the IMAT plans was lower for all
patients. The   percentile dose for the kidneys was significantly higher for the IMAT plans than for the
CONV4 and CONV2 plans (28.2 Gy vs 22.2 Gy and 22.6 Gy for left kidney, respectively). No relevant
differences were found for liver. The gel-measured dose was within clinical planning constraints.
Conclusion: IMAT was shown to be deliverable in an acceptable time slot and to produce dose distributions
that are more homogeneous than those obtained with a CONV plan, with at least equal sparing of the OARs.
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Introduction
The treatment options for most patients with relapsed
ovarian cancer are palliative. For patients who re-
lapse within 12 months after platinum-based sched-
ules, second or third line chemotherapy is often used,
but the response rates average between 10% and
30% [1].
A difficult problem to palliate is bowel obstruc-
tion. Surgery may be attempted but the disease is
often multifocal making palliative resection impossi-
ble. In reports of Redman [2] and Krebs [3] , 10% to
15% of patients died within 8 weeks after surgery and
35% to 38% had no clinical benefit. The results of
chemotherapy for bowel obstruction are disappoint-
ing. In a report by Abu-Rustum [4] , a response
was observed in only one of 18 patients treated with
chemotherapy for bowel obstruction. Radiation ther-
apy seems to compare favorably to second or third
line chemotherapy, with symptom response rates be-
tween 63% and 79% with a median duration between
4 and 9 months [5, 6, 7]. Given the pattern of spread
of ovarian cancer, whole abdominopelvic radiation
therapy (WAPRT) could be the radiation technique
of choice, eventually with a boost to sites of gross
tumor.
Maximum tolerated dose levels to the whole kid-
ney are often set to 20 Gy or less. When the kidneys
are blocked from radiation, conventional techniques
result in underdosage of the peritoneal regions in the
blocked areas.
We investigated the potential of Intensity Modu-
lated Radiation Therapy (IMRT) to spare kidneys and
liver. For reasons described in the discussion sec-
tion, we selected Intensity Modulated Arc Therapy
(IMAT) [8] as the most appropriate IMRT-technique
for WAPRT.
This paper describes the results of the transla-
tional research that was performed to bring IMAT
into the clinic for WAPRT. We report on treatment
planning and delivery for the first five patients treated
with IMAT-WAPRT. The clinical results of the phase
I study will be reported elsewhere.
Materials and methods
Delineation of target volumes and OARs
Between November 2001 and October 2002, 5 pa-
tients with a relapse of a histologically proven adeno-
carcinoma of the ovary were treated by IMAT. All pa-
tients signed informed consent for IMAT to the whole
abdomen. A planning CT-scan was performed with
the patient lying supine, with both arms resting under
the head. The upper border of the scanned volume
was located 10 cm cranial to the diaphragm, while
the lower border was defined as 10 cm caudal to the
obturator foramina. 0.5 cm thick sequential CT-slices
were acquired without contrast enhancement. Clin-
ical Target Volume (CTV) was defined as the total
peritoneal cavity, with the inclusion of iliac and para-
aortic lymph node regions. A 0.5 cm rim of liver, ad-
jacent to the peritoneum, was also included into the
CTV. The upper CTV boundary was defined by the
highest CT-slice on which the diaphragmatic dome
was visible, and the most caudal drawing of the CTV
was on the level of the bottom of the obturator foram-
ina. A Planning Target Volume (PTV) was made by
a 3D expansion of the CTV with a margin of 0.5 cm
in all directions. The kidneys and the liver (further
called OARs: organs at risk) were drawn as visu-
alized on CT, and the kidneys were expanded with
5 mm (kidney_exp_5mm), to account for setup inac-
curacy and organ motion. PTV and OARs overlap,
which would result in a conflicting requirement from
the optimization algorithm. A similar problem arises
with those parts of the PTV in the build-up region.
Both problems were solved by defining subvolumes
inside the PTV which are used as optimization vol-
umes (PTV_optim). PTV_optim was nowhere closer
than 0.8 cm to the skin surface or 0.5 cm to the ex-
panded kidneys. A surrounding structure was made
by subtracting the PTV from the total scanned vol-
ume of the patient. This structure (sur_0cm) was
used to avoid hot spots outside of the PTV. A gen-
eral description of the use of PTV subvolumes and
surrounding structures for IMRT plan optimization is
found elsewhere [9].
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Table 1: Details about the IMAT treatments.
isocenters arcs control points monitor units delivery time (min.)
Patient 1 1 11 73 568 < 20
Patient 2 1 7 + 1 SW 110 387 11.6   2.5
Patient 3 1 7 + 1 SW 78 378 15.3   3.6
Patient 4 2 7 + 1 SW 99 528 18.1   3.6
Patient 5 1 6 + 1 SW 148 359 13.5   1.3
For the first patient, no systematic measurements were done concerning the delivery time. The
monitor units are for one fraction of 150 cGy. SW= Sliding Window.
IMAT planning procedure
Generation of machine states by ABST
An anatomy based segmentation tool (ABST) was
developed at our institution to create segments for
step-and-shoot IMRT [10]. For IMAT planning
ABST is used to create an initial set of segments,
which we will call machine states. A machine state
is described by a set of machine parameters that
uniquely define the beam incidence, aperture and
photon beam quality. After definition of the isocenter
location and with the collimator, table top and isocen-
ter rotations at zero degrees, ABST generated ma-
chine states per  Æ of gantry rotation. Restriction of
the range of gantry angles was needed to avoid beams
traversing metal components of the couch before en-
tering the patient. The couch on the linear accelera-
tor (Elekta, Crawley) used for the IMAT treatments
has two C-arms, which can be positioned at one of
the Æ discrete angles. The largest range of possi-
ble gantry angles was obtained by setting the arms at

Æ
, measured from their lateral position (Fig. 1).
For patients 2, 3 and 5, a class solution was used,
implying that the initial machine states were gener-
ated using a fixed set of parameters, including start
and stop gantry angles, widths of the segments and
conformal avoidance structure. The arcs used by the
class solution are shown in figure 1. For patient
4, where the cranio-caudal extend of the PTV was
42 cm, a second isocenter was defined 12 cm from the
first isocenter in caudal direction. Only a longitudi-
nal table shift is required to perform the transition be-
tween the two isocenters. An additional "pelvic arc"
was made around a structure called PTV_pelvis, with
the L5-S1 intervertebral space as the upper border.
The collimator was rotated by Æ, to have the leaf
movements in the cranio-caudal direction and allow
for feathering in the junction region [11].
For each gantry angle, ABST generates multiple
machine states which only differ by apertures of the
multileaf collimator (MLC). Each beam’s-eye-view
(BEV) projection of a MLC aperture covers a part of
the PTV at one side of the anatomical structure that
is to be avoided. A margin of 0.8 cm around the PTV
is used to account for penumbra. For each gantry
angle, the machine states differ from each other by
the degree of coverage of the BEV projection of the
PTV. For a detailed description of ABST, we refer
to De Gersem et al. [10]. These machine states are
useful to create intensity levels that increase with de-
creasing distance to the anatomical structure that is
to be spared. It was shown by Brahme and oth-
ers [12, 13] that such intensity profiles are useful to
create homogeneous dose distributions to a concave
PTV which conformally avoid anatomical structures
at risk. The machine states were stratified in classes,
the first class consisting of machine states with the
largest area of MLC aperture; the second class con-
sisting of machine states with the second largest area
of MLC aperture and so on. Due to the algorithm
inside ABST which creates MLC apertures avoiding
anatomical structures with -in this case- smooth sur-
faces, MLC apertures, which belong to the same class
of machine states, do not differ much from one gantry
angle to the next, their angular separation being only
 
Æ
. Hence, the leaf travel required when moving from
one gantry angle to the next is small for machine
states of the same class which is preferable for dy-
namic transitions as in IMAT.
For patients 2-5, an additional posterior “sliding
window” intensity modulated beam with a Æ col-
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Figure 1: Class solution for the IMAT plan. A transverse plane through the patient can be appreciated, with the
PTV, the left kidney (LK) and the right kidney (RK). The arcs are depicted by circle segments. Abbreviations:
S0R LK: Arc composed by the machine states covering the total BEV projection of the PTV passing the right
side of the LK. S0L RK: Arc composed by the machine states covering the total BEV projection of the PTV
passing the left side of the RK. S1R LK: Arc composed by the machine states covering a 3 cm wide area of the
PTV at the right side of the LK. S1L RK: Arc composed by the machine states covering a 3 cm wide area of
the PTV at the left side of the RK. The metal C-arms are shown as the grey squares, respectively in their most
lateral position (asterisk) for the sliding window, and in their Æ position (+ sign). The large dashed arrow
represents the beam direction for the delivery of the sliding window (SW). Machine states for one arc (S0R
LK) are shown every Æ, from  Æ to Æ. The thick grey lines represent the jaw position, each small white
bar stands for one leaf.
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limator rotation was used. For this beam, the table
bars were put on their most lateral position. Due to
the position of these metal bars, and the impossibility
to prescribe arcs traveling over the  Æ gantry point,
the range for posterior arcs is very limited. Therefore,
a sliding window IM-beam with static gantry angle
was preferred to boost the most posterior region of
the PTV. The control points for this sliding window
were made manually. For patient 4, the most caudal
isocenter was selected for this sliding window beam.
Creation and optimization of control points
The machine instruction file to deliver arc therapy
with dynamic MLC consists of a sequence of control
points (Fig. 1). A control point is defined as a ma-
chine state plus a monitor unit count (MUC) value.
Delivery of a sequence of control points implies that
the prescribed machine state has to be reached at
the MUC value for each control point. The transi-
tion from a control point to the next is slaved by the
MU counter, each parameter (leaf positions, jaw po-
sitions and gantry angle) that changes between two
control points is linearly interpolated as function of
the MUC value. The beam is paused if the control
software detects that a machine parameter is outside
tolerance to the (linearly interpolated) position pre-
scribed by the machine state. Control point optimiza-
tion involves the machine states - and more precisely
the leaf positions - as well as the MUC values and
is done by a Segment Outline and Weight Adapt-
ing Tool (SOWAT) [14], modified for IMAT pur-
poses (SOWAT-IMAT). The main difference between
SOWAT and SOWAT-IMAT resides in the maximal
leaf velocity (MLS) constraints. After the control
point generation and after each leaf position opti-
mization cycle, a leaf velocity constrainer (LVC)
adapts leaf positions of all control points to obey
maximum leaf speeds, minimum distances to op-
posed and diagonally opposed leaves and maximum
leaf position extends (method unpublished). MUCs
are optimized for each step, a step being defined as
the transition from one control point to the next. The
objective function on which the optimization is done
is a biophysical model and has been described and
discussed elsewhere [15, 16].
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Figure 2: Picture representing the angular delivery
rate. One “virtual” arc (dashed line) as well as three
deliverable arcs (solid lines) are shown. The “virtual”
arc is not deliverable on the Elekta linac. The deliver-
able arcs approximate the optimized virtual arc. The
final angular delivery rate (W) of the deliverable arcs
is optimized as described in the text.
Transformation to deliverable arcs
As a result of SOWAT-IMAT, n machine states and
n-1 weights are obtained. These weights are numbers
of monitor units that have to be delivered while the
machine moves from one control point to the next.
Apart from leaf and jaw travel, such motion involves
a  Æ gantry rotation. Because the Elekta SL-series of
linear accelerators was designed to deliver arcs with
a gantry rotation speed directly proportional to the
dose rate, the number of monitor units delivered per
degree (angular delivery rate) must remain constant
over the whole arc. This condition is not secured by
SOWAT-IMAT. In fact, the (requested) angular deliv-
ery rate may be different for each  Æ-sector of gantry
rotation. This problem is solved by splitting each arc
which features a variable angular delivery rate into
multiple overlapping arcs each with a constant angu-
lar delivery rate (Fig. 2). This procedure also pro-
vides the start and stop angles of the delivered arcs.
The plan is finalized by a SOWAT-IMAT optimiza-
tion cycle which involves optimization of leaf posi-
tions and the angular delivery rate (equal for all sec-
tors of the arc in order to keep the angular delivery
rate constant within each arc).
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Dose prescription and computation
The prescribed dose was 33 Gy (median dose in the
PTV), given in 22 fractions. Except for the first pa-
tient, IMAT plans were accepted using the follow-
ing clinical criteria: less than 5% of the PTV vol-
ume was allowed to receive more than 107% of the
prescribed dose, and more than 95% of the volume
of PTV_optim had to receive more than 90% of the
prescribed dose; less than 5% and 20% of the kid-
neys_exp_5mm should receive more than 30 Gy and
25 Gy, respectively, while the median dose had to be
lower than 18 Gy; the median liver dose was con-
strained to 30 Gy. After clinical constraints were met
by the optimization procedure, a final dose compu-
tation was performed for 18 MV with the collapsed
cone convolution/superposition algorithm from Pin-
nacle [Philips Medical Systems, Best, The Nether-
lands]. A final optimization of the MUs of all arcs
was done using the results of this dose computation.
The value of a MU is such that 100 MUs correspond
to 1 Gy at reference depth (5 cm for 6 MV and 10 cm
for 18 MV) for a 10x10 cm field and a source-detector
distance of 100 cm.
IMAT treatment delivery
For each arc, a prescription file containing the se-
quence of control points and related monitor units is
generated and networked to an SLiPlus 18 MV linear
accelerator (Elekta, Crawley, UK). The IMAT treat-
ment is delivered in local service mode using pro-
totype dynamic control software (Elekta, Crawley,
UK), operating as described before [17]. Delivery
of dynamic prescriptions is not possible in clinical
mode on the Elekta linear accelerators. The local ser-
vice mode is operated in the same interlock class as in
clinical mode. Thereby, tolerances used by the linac’s
control system are the same as for clinical mode.
Conventional plans
For each patient, two different conventional (CONV)
plans were made. The first plan was the widely used
“AP/PA” technique, using an anterior and a poste-
rior field (CONV2). A second plan used 4 beams
(CONV4), anterior, posterior and two lateral fields.
The field margins were drawn with a 1 cm margin
around the PTV in all directions. Kidney blocks cov-
ered the BEV projection of the kidneys with a margin
of 0.5 cm. For the CONV2 plans, the posterior field
was duplicated in 2 segments, an open segment and a
segment where kidney blocks were inserted. Respec-
tively, 6 MV and 18 MV photons were used for the
anterior and posterior field. For the CONV4 plans,
all four fields were duplicated in 2 segments each,
an open segment and a segment with kidney blocks.
Here, 18 MV photons were used for all fields.
Optimization of the relative segment weights was
done by the planner, to reach a median dose to the ex-
panded kidneys between 18 and 20 Gy. Median dose
to the liver was constrained to 30 Gy. Dose computa-
tion was done with the same collapsed cone convolu-
tion/superposition algorithm.
Treatment evaluation.
Delivery time, defined as the time between the start
of the first arc and the end of the last arc or sliding
window, was measured for patients 2-5. Additionally,
the setup time was measured from the entrance of the
treatment room by the patient to the start of the first
arc. This includes the time necessary to acquire portal
images and correction of the patient position.
Comparison of dose distributions obtained with
the CONV2, CONV4 and the IMAT plan were done
after normalizing the median dose of the PTV to
33 Gy. To evaluate the dose homogeneity in the target
volumes, an inhomogeneity factor U
 
was defined
as the difference between the th percentile dose
(D

) and the th percentile dose (D

), divided by
the median dose (Dmed). We preferred to use the D
and the D

above the maximum and minimum dose,
because an underdosage was allowed in the region
close to the kidneys. Other endpoints for the target
volumes were the first percentile dose (as a surrogate
for minimum dose), the th percentile dose and the
ratio of volume of the target structure receiving more
than 95% of the prescribed dose (V

) over the total
volume. For the parallel-element organs kidney and
liver, the Dmed was used. The DVHs were recon-
structed for the 5 patients, by calculating the mean
dose and the standard error of the mean at every 5%
volume level. The paired Student  -test was used. All
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tests were two-tailed and  < 0.05 was considered as
a statistically significant difference.
Dosimetric verification of the IMAT treat-
ment.
Monomer/polymer gel dosimetry was used for 3D
dose verification of the whole IMAT procedure.
A de-oxygenated hydrogel infused with acrylic
monomers forms the basis for this dosimetric tech-
nique [18]. Highly reactive radicals, formed by ra-
diolysis during irradiation of the gel, initiate a poly-
merization reaction. The amount of polymer formed
is related to the absorbed dose. Formation of polymer
clusters in the water-equivalent gel increases the lo-
cal spin-spin relaxation rate (R2), a typical magnetic
resonance (MR) contrast parameter. Therefore, MR
imaging (MRI) can be used to visualize the amount of
polymer formed and subsequently the dose distribu-
tion in the gel. With monomer/polymer gel dosime-
try, it is possible to obtain absorbed dose information
in 3D with high spatial accuracy [19]. For a more de-
tailed review on this subject, the reader is referred to
De Deene et al. [20].
A Barex (Cifra, Chateau Thierry, France) cast
was vacuum molded on the abdominal region of
the Rando phantom (Alderson Research Laborato-
ries, Stamford, CT). At our laboratory, the maxi-
mum amount of monomer/polymer gel that can be
produced in one batch is 10 liter. Hence, the en-
tire volume irradiated with IMAT can not be veri-
fied by one gel dosimetry experiment. We chose to
limit the phantom geometry to that part of RANDO
containing the (dosimetrically most interesting) re-
gion around the kidneys. Supports on the cranial
and caudal side, marker lines and placement of fidu-
ciary markers (Medtronic, Louisville, USA) on the
surface facilitated a reproducible positioning of the
gel phantom during CT scanning, IMAT delivery and
MRI (Fig. 3). Three supplemental Rando slices were
placed alongside the phantom on the cranial and cau-
dal side during CT scanning and treatment delivery,
to ascertain full scatter conditions in the gel upon irra-
diation. Spiral CT scans (Siemens Somatom Plus 4,
Erlangen, Germany) of the gel-filled phantom were
transferred to the planning system. Volumes of in-
terest (kidneys, liver and PTV) from the first pa-
Figure 3: Adapted Rando phantom as used for the
gel dosimetry. At each side of the Barex cast, three
Rando slices were added to obtain full scatter con-
ditions. Tape is attached to the phantom to draw
laser lines in transverse, sagittal and coronal refer-
ence planes. Seven markers are attached to the phan-
tom on the laser lines to facilitate positioning. The
transverse plane indicated in the middle of the barex
phantom is 13.5 cm cranial to the treatment isocen-
ter. A barex screw is used to close the phantom at the
place where the gel was inserted, visible left to the
sagittal plane.
tient were transferred to the CT data set. For this
setup, an IMAT plan was made by using the meth-
ods as described above. This resulted in a plan with
6 arcs and one sliding window. To cover the maxi-
mum response range of the gel while avoiding gradi-
ent dependent non-linearities in dose response [21],
the monitor units were multiplied with a factor five,
thus giving a median dose of 7.5 Gy to the PTV. For
calibration purposes, gel-filled test tubes were irra-
diated to known doses (0 - 10 Gy, every 1 Gy) to
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establish a dose-R2 relationship. The gel dosimeter
and test tubes were scanned together in the body coil
of a 1T MR system (Expert, Siemens, Erlangen, Ger-
many). A 26-spin-echo sequence was applied with
a (Carr-Purcell Meiboom-Gill) CPMG RF pulse en-
coding scheme and equidistant echo spacing (TE =
40 - 1080 ms). The phantom was scanned in 33 ad-
jacent transverse slices, each with a slice thickness
of 5 mm. A field-of-view of 320 mm and image
resolution of 128128 resulted in an in-plane reso-
lution of 2.5 mm. Ideally, a homogeneous unirradi-
ated gel phantom should produce identical R2 read-
ings throughout the entire volume when scanned with
MRI. A homogeneity study was done on the IMAT
phantom filled with a blank gel and the MRI proto-
col was adjusted to minimize R2 variations related
to temperature deviations and radiofrequent inhomo-
geneities.
A linear regression was used to describe the dose-
R2 relationship. The gel-measured dose grid was
transferred to the planning system and scaled to the
prescription dose (33 Gy), which allowed the com-
parison of measured and computed DVHs of the dif-
ferent structures inside the abdominopelvic phantom,
truncated to the volume of the gel-phantom. Low’s
-index [22] was calculated in 3D (dose difference
criterion = 7.5%, distance-to-agreement = 5 mm),
as a guide to pinpoint significant deviations between
the computed and measured dose matrix. A -index
above 1 indicates that the specified tolerances are not
met.
Results
The median volume of the PTV in the five patients
was 8306 cc (range 5717 - 9054 cc), and the me-
dian of the cranio-caudal length which had to be cov-
ered was 36 cm. Details on the treatment plans and
delivery times are shown in table 1. Mean delivery
time over patients 2-5 was 13.8 minutes (range 9.5 -
24.5 minutes). Less than 30% of the given fractions
had a delivery time exceeding 15 minutes. Of these,
50 % were seen in patient 4, who had two isocen-
ters, necessitating entrance of the treatment room to
perform a cranial shift of the patient. For one patient
(chronologically the last), the setup-time was mea-
sured over all the fractions, and showed a mean of 8
  2.9 minutes. Though actively asked for, no patient
complained about the rotating gantry. As an example,
the obtained intensity profiles for patient 5 are shown
in figure 4.
Dose Volume Histogram analysis and dose
distributions
The DVH data for the five patients are summarized
in Table 2 and graphically displayed in figure 5. For
both the CONV4 and IMAT plans, there is a large
variation in minimal dose (represented by D
 
) in the
PTV (range 0.2 - 26.1 Gy), resulting from the PTV
extending outside the skin in one patient. When con-
sidering the PTV without a build-up region of 8 mm
(PTV_whbu), the very low doses that are the result
of the ICRU PTV definition rather than of the plan-
ning technique, are eliminated (range of D
 
: 19.5
- 26.9 Gy). The homogeneity in the PTV_whbu is
better for the IMAT plan than for the CONV4 plan
(U
 
is 20 % and 32% respectively; p = 0.01). Due
to the strong dose constraint to the expanded kidneys,
and due to the possibility to generate concave dose
distributions, we expected an underdosage in the PTV
in the region around the kidneys. For the PTV_optim,
the mean (and the standard deviation) of the V

was
78.4% (  2.2%) for the CONV4 plan, and 88.9% ( 
5.1%) for the IMAT plan (p = 0.01). For the V

,
these values were 87.7% (  3.0%) and 95.8% ( 
3.5%) for the CONV4 and the IMAT plan, respec-
tively (p = 0.02). The comparison between the IMAT
plan and the CONV2 plan (Table 1) shows a signif-
icant increase in homogeneity (expressed by U
 
)
for the PTV as well as for PTV_optim by the IMAT
plans.
The median dose to the kidneys was lower for the
IMAT plan in all patients, when compared to both
CONV plans. The maximal doses to the kidneys were
significantly higher for the IMAT plan than for the
CONV plans, as can be seen in figure 5. For the
liver, no significant differences were found between
the IMAT and the CONV plans. The higher homo-
geneity by the use of lateral beams in the CONV4
plans yielded a higher dose to the liver.
Dose distributions for the first patient are shown
in figure 6. The sparing of the kidneys by the IMAT
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Figure 4: (a) Intensity profiles (rescaled) for the delivered plan of patient 2. The CT slice through the isocentric
plane is shown, with the dose distribution in Gy. The PTV (dotted line) extends outside the scanned volume
(asterisks). (a) Intensity profiles, generated at a range of gantry angles from  Æ to  Æ, are plotted around
the CT-slice. (b) Intensity profiles for the gantry at 	Æ, 	Æ and for the posterior beam, delivered as a
sliding window ( Æ).
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Table 2: Summary of the DVH data showing averages   standard deviations.
IMAT CONV2 p-value CONV4 p-value
PTV
V

(%) 82.2   6.5 76.8   5.2 0.11 73.6   5.9 0.01
V

(%) 89.9   5.7 80.1   4.6 0.01 82.5   6.1 0.01
V
 
(%) 2.7   3.4 6.4   3.3 0.18 7.2   4.41 0.05
D
 
(Gy) 19.0   10.8 16.4   9.1 0.09 16.6   9.3 0.10
D

(Gy) 35.8   0.9 36.1   0.6 0.53 36.5   0.9 0.02
U
 
(%) 28.1   15.8 42.3   7.9 0.03 34.4   10.9 0.10
PTV_optim
D
 
(Gy) 27.0   2.8 21.7   0.9 0.02 24.5   1.2 0.12
U
 
(%) 15.1   5.8 34.9   2.5 < 0.01 24.9   4.1 0.01
Left kidney (expanded)
Dmed (Gy) 16.1   3.6 19.9   0.6 0.11 19.4   0.4 0.11
D

(Gy) 28.2   1.3 22.6   0.8 < 0.01 22.2   0.4 < 0.01
Right kidney (expanded)
Dmed (Gy) 13.6   3.9 19.3   1.5 0.02 18.6   1.1 0.02
D

(Gy) 26.0   2.9 22.8   1.0 0.02 22.2   1.0 0.08
Liver
Dmed (Gy) 24.4   6.3 22.8   10.1 0.44 29.2  2.0 0.09
Abbreviations: IMAT: Intensity modulated arc Therapy; CONV2: conventional plan with an
antero-posterior and a postero-anterior field; CONV4: conventional plan with 4-field technique;
PTV: planning target volume; PTV_optim: PTV without build-up region of 0.8 cm and with the
exclusion of the expanded kidneys with an extra margin of 5 mm;V

, V

and V
 
: the partial
volume (percent) receiving more than 95%, 90% and 107% of the prescribed dose; D

and D
 
:
Dose given to 99% and 1% of the volume, respectively; U
 
: inhomogeneity factor, defined as


D
 
D


Dmed
, with D

the  percentile dose; D

the  percentile dose andDmed the median
dose.
plan does not produce underdosages in the cone of
the PTV lying anteriorly to the kidney, in contrast to
the CONV2 plan (Fig. 6b and 6e). This underdosage
is largely, but not completely, resolved in the CONV4
plan, at the cost of higher liver dose (Fig. 6c and 6f).
The dose distributions also illustrate that the maximal
doses to the kidneys were higher in the IMAT plans
than in the CONV plans, as there is a steep circular
gradient around the kidneys.
Dosimetric verification.
Volumes of total and truncated structures are com-
pared in table 3.
The DVHs for the truncated structures of both the
computed plan and the results of the dosimetric mea-
surements are shown in figure 7a. The median gel-
measured dose in the PTV was 1% lower compared
to the calculations. The median gel-measured dose
for the liver was 16% higher (18.9 Gy compared to
16.4 Gy). For the right kidney, median measured dose
was 13% lower than predicted by the dose calcula-
tions. All planning constraints were met in the mea-
sured dose distribution (Fig. 7a). A volume histogram
was made using the computed -indexes for the total
measured volume and for each relevant (truncated)
structure (Fig. 7b). The -index was higher than 1
for 8.1% of the total measured volume (Table 3). The
-index for the left and right expanded kidneys was
higher than unity in 8.3% and 19.6% of the volumes
respectively. Dose was outside tolerance in 1.9% vol-
ume of the liver part within the gel phantom. For
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Figure 5: DVHs compiled from the data of the five patients. Solid lines and bold dots represent the IMAT plans
(mean   standard error of the mean). Dashed lines and circles represent the 2D plans. (a-c) DVHs of the IMAT
and CONV2 plans. (d-f) DVHs of the IMAT and CONV4 plans. (a) + (d) DVHs of PTV and expanded left
kidney. (b) + (e) DVHs for PTV_whbu and expanded right kidney. (c) + (f) DVHs of PTV_optim and liver.
PTV, 1.2% of the volume had a -index above 1. An
example of a computed and a measured dose distri-
bution is shown in figure 8a and 8b, respectively, to-
gether with a the iso- line at value 1 (Fig. 8c).
Discussion
Intensity modulation gives the possibility to gener-
ate concave dose distributions. This is a major ad-
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Figure 6: Dose distributions for patient 1, showing the delivered IMAT plan in a transverse (a) and sagittal (d)
plane, and the conventional comparison plans in (b) + (e) for the CONV2 and (c) + (f) for the CONV4 plan.
Isodose values are in Gy. The PTV is delineated with a dotted line. The kidneys (LK: left kidney and RK: right
kidney) are delineated by dashed lines, while the liver (L) is circled by a dashed-dotted line. The dotted straight
line in (a) and (d) indicates the transection planes in (d-f) and (a-c), respectively.
vantage in the treatment of cases where the PTV is
wrapped around a dose limiting OAR, e.g. in the head
and neck region. For planning cases where the ra-
dius of curvature of the concavity of the intended iso-
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Table 3: Total volumes of contoured structures, volumes of the parts of these structures inside the gel phantom
and relative volumes of these parts. Percentage volumes of the truncated structures that have a -index above
unity are shown in the last column.
Structure Volume (cc) Volume in gel-
phantom (cc)
Partial volume in
gel-phantom (%)
Volume(  )
(%)
PTV 6943.2 2060.9 29.7 1.2
PTV_optim 6574.8 1907.9 29.0 0.4
Left kidney (expanded) 370.8 337.5 91.0 8.3
Right Kidney (expanded) 283.6 254.4 89.7 19.6
Liver 1471.6 1459.0 99.1 1.9
Scanned volume 18653.8 8330.7 44.7 8.1
dose lines is rather small, a beam setup with a limited
number of incidences is sufficient. Stein et al. [23]
demonstrated this for prostate cancer where the dose
distribution concavity is generated around the rec-
tum. However, when the internal radius is increasing
with equal distance to OAR(s) inside the concavity,
an increasing number of beam incidences is needed
to avoid underdosage in parts of the PTV while main-
taining the same OAR sparing, as demonstrated in
figure 9. The fastest way to deliver a very large num-
ber of incidences is arc therapy. Therefore, IMAT
was selected in our department as a delivery method
only for those situations where intensity modulation
is needed together with sparing of OARs of medium
and large sizes. Next to WAPRT, the same planning
problem can be encountered in e.g. rectal cancer (and
more broadly in pelvic irradiation), malignant pleural
mesothelioma and breast cancer.
We compared the planning results of the IMAT
plan with a 2-field and a 4-field conventional plan.
By applying IMAT, we could improve homogeneity
(U
 
) by 49% in the PTV_whbu in comparison with
the CONV2 plan, and by 37% compared to CONV4.
Furthermore, the median dose to the kidneys was
lower in all patients. A recent report found that func-
tionality defects (estimated using static scintigraphy)
were correlated with the dose and volume of the ir-
radiated kidney [24]. In that dose-effect curve, the
risk of any scintigraphic changes for an irradiation of
10 to 30% of the renal volume to doses between 20
and 30 Gy is estimated to be between 10 and 40%.
The five patients described in our report were all in
this range (Fig. 5). However, in their series, no pa-
tient had clinical symptoms of nephrotoxicity nor any
rise in serum creatinine levels. Considering the dose
distribution to the liver, no relevant differences were
found between IMAT and CONV.
The doses measured with gel dosimetry were
within clinical planning constraints, although large
differences can be seen on the DVHs (Fig. 7) for the
right kidney and the liver. For the kidney, a lower
dose was measured than computed, while for liver
the opposite was seen. Only a small part (1.9%)
however of the liver had a -index above one. For
PTV, DVHs of measured and computed dose distri-
butions showed no relevant differences. Also only a
low volume part of the PTV had a -index more than
one (1.2%). Both results validated the IMAT delivery
in the PTV. The relatively large fractions of left and
right kidney with a -index more than one (8.3% and
19.6%, respectively) can have multiple reasons. As
the kidneys are most of the time shielded by leaves
only and not by the backup diaphragms, calculation
errors of leaf transmission have a high impact on the
computed doses to these structures. Inaccuracy of
computed output factors of fields with high offsets,
setup errors both at the irradiation of the gel and at
the dose acquisition by MR further can contribute to
differences seen between measurements and calcula-
tions and will be investigated.
Hong et al. [11] describe the planning results
for WAPRT using static gantry IMRT with five in-
cidences. The delineation of the target volumes and
OARs were quite similar to those described in this
report. Their treatment planning goal differs by the
use of the unexpanded kidneys as OARs. The mean
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Figure 7: (a) Dose volume histograms of the computed (solid lines) and gel-measured (dashed lines) dose for
the contoured volume inside the gel. C1-6: clinical constraints, with C1: more than 95% of the volume of the
PTV_optim has to receive more than 90% of the prescribed dose; C2: less than 5% of the PTV may receive
more than 107% of the prescribed dose; C3: less than 5% of the expanded kidneys may receive more than
30 Gy; C4: less than 20% of the expanded kidneys may receive more than 25 Gy; C5: median dose to the
expanded kidneys should be lower than 18 Gy and C6: median dose to the liver should be lower than 30 Gy.
(b) Volume histogram using the computed -index. The thick line represents the total measured volume.
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Figure 8: Dose distributions in the middle transverse plane of the Barex cast (figure 3) for the IMAT plan, (a)
as calculated with the collapsed cone convolution/superposition algorithm from Pinnacle and (b) as measured
by monomer/polymer gel dosimetry. For (a) and (b) isodoses are shown at 3 Gy intervals. (c) Iso- line for
 = 1. PTV: planning target volume (dotted line). The liver is indicated with a dashed-dotted line, the kidneys
with a dashed line.
V

of the PTV was 83.5% for the static IMRT,
while it was 82.2% in our study. However, in the
report by Hong et al., the overlap with the kidneys
was excluded from the PTV. When we look at the
PTV_optim, which also excludes the overlap region,
the mean of the V

was 88.9%. These data reflect
that the dose homogeneity in the PTV is similar for
both planning techniques. The mean dose to the kid-
neys is also in the same range in both reports. In
the report of Hong et al., a mean of 1442 MUs was
needed for a fraction of 150 cGy, where IMAT re-
sulted in 444 MUs on average for the same dose. Due
to the design of the Varian MLC for which Hong’s
implementation was intended, a split of the intensity
modulated fields was necessary, which gives rise to a
higher number of MUs. Hong did not report on de-
livery time.
IMAT with dynamic multileaf collimation was
first described by Yu [8]. Yu initially reported on
an IMAT planning methodology using inverse plan-
ning (Peacock by NOMOS Corporation). Optimized
beam fluences were "decomposed" to multiple super-
imposing fields. In the inverse planning strategy de-
scribed by Yu, the intend is to generate control points
that are compliant with the MLS-constraint with re-
gard to the previous control point of the arc. If such a
decomposition can’t be found, Yu described a soften-
ing of the MLS-constraint with selection of a lower
nominal dose rate. The Elekta SLi-18 picks a nom-
inal dose rate from a set of discrete values (32, 65,
130, 260 or 520 MU/minute) so that the gantry speed
is as close as possible to 156Æ/minute (range: 104 -
208Æ/minute). We were unable to apply Yu’s method
as we could not influence the selection of this nomi-
nal dose rate without elimination of safety interlocks.
In our implementation, the MLS-constraint is han-
dled using a combination of anatomy-based segmen-
tation and the LVC. For volumes of interest at max-
imum 12.5 cm of a cranio-caudal axis through the
isocenter, it can be proven that the lateral position of
their projected outlines in BEV between two adjacent
incidences, interspaced by eight degrees, can in the
worst case only differ 2.0 cm when beam divergence
is not taken into account. As the Elekta MLC has
a possible overtravel distance up to 12.5 cm for all
leaves, and leaf speeds are sufficient to move 2.0 cm
each 8 degrees of arc rotation, the conformal avoid-
ance of OARs within the above-mentioned regional
constraint is always possible. For volumes of interest
as the PTV that do not fit within the 12.5 cm cylin-
der, anatomical boundaries in BEV can have higher
lateral shifts. For volumes within 20.0 cm of the lon-
gitudinal axis, this can amount up to 3.5 cm, which
is however only obtained in the worst case scenario.
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Figure 9: Demonstration of the need for more incidences as the inner radius of a concave PTV is increasing,
if the same homogeneity and OAR sparing is wanted and for the same distance between PTV and OAR. The
concave PTV is shown in a solid grey line, the circular OAR in dotted black line, the borders of the beams in
dashed fine black lines, the 70% dose level in solid black line and the 30% dose level in a dashed-dotted black
line. These dose levels were defined relative to the maximum dose of one beam. The isocenter is located in
the middle of the OAR. Beam weights were set equal, and attenuation was not taken into account. The profile
function used was described earlier [14]. (a) A concave PTV with a small internal radius. Three beams (gantry
angles Æ, Æ and  Æ) are sufficient to obtain a 40% dose difference between the PTV and the OAR. (b)
The same beam setup for a PTV with a larger internal radius and the same distance between OAR and PTV,
with equal sparing of the OAR, produces underdosages (grey areas) in the PTV.(c) This can be avoided by the
increase of incidences (	Æ and Æ). Note that due to the higher number of beam portals, beam aperture could
be reduced without PTV underdosage.
By beam divergence, larger lateral shifts can occur.
Where the MLS-constraint would be violated in the
process of machine state generation, it was resolved
by the LVC. Recently, the first clinically delivered
planning results of IMAT were published [25][26]. In
both reports, a planning strategy was used in which
the outlines of the machine states were based on pa-
tient anatomy. The initial reports, using anatomy
based segmentation could indicate that the inverse
planning method described by Yu [8] is hard to im-
plement in clinical practice. To deal with the problem
of MLS, they had to insert a wedge in (some) arcs in
order to increase the number of MU per degree of arc
rotation [26]. In our opinion, wedges are superfluous
in IMAT planning, as this procedure decreases MU-
efficiency and as the leaf speed problem can be solved
by optimization methods.
The clinical implementation of IMAT for this site
was a challenge for other than plan-technical reasons
too. The setup procedure was strongly influenced
by the combination of the large target volume and
the limitations of the Elekta table. The C-arms can
only be set in a non-horizontal position (Æ) if the
table is sufficiently extended longitudinally towards
the gantry drum. The distance in caudal direction
between the isocenter and metal components of the
support system in this extended position is maximally
26.4 cm. As the PTV has a median height of 36 cm,
repositioning range in cranio-caudal direction using
the table shift possibility was restricted. This is a
problem that however equally occurs when a static in-
cidence technique would be used, unless care is taken
to only generate segments that can be delivered with
the bars in either the most lateral or medial position.
For a PTV of the above-mentioned sizes, this will in
practice lead to a restriction of possible gantry an-
gles, or delivery of the treatment in two parts (one for
each bar position). During the planning process, the
maximal arc range was used, taking a 2 cm margin
between table bars and field aperture in lateral direc-
tion into account. Repositioning using the motorized
table shift system in this direction was therefore re-
stricted to an uncommonly small range. As a conse-
quence, the table had to be set to predefined lateral
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and longitudinal positions, after which the first posi-
tioning is done by shifts of the patient relative to the
table. The support system capabilities were used to
correct for the last millimeters of the patient setup.
A shorter setup time could be achieved by use of a
appropriately designed carbon fiber table top.
To implement IMAT (8 patients so far) in the
same routine clinical practice as IMRT (in total 362
patients, 120 in 2002, which is   10 % of our pa-
tientload), further automation is necessary on several
points. The transition of virtual to deliverable arcs
is a time-consuming manual operation. Although a
class solution can aid the planner towards a final arc
setup, constraints on the modulation of the angular
delivery rate during optimization would reduce the
problem. Full automation of this procedure would be
optimal. Start and stop angle optimization can fine-
tune converted arcs. The conversion of arcs with a
non-constant angular delivery rate could be avoided
by a variable gantry speed. This could enhance plan-
ning quality, reduce the number of arcs and the deliv-
ery time, together with a decrease of planning com-
plexity by elimination of the conversion and elimi-
nation of local minima induced by the discretization.
Although the Elekta linac has by its rotation mech-
anism excellent mechanical possibilities to achieve
this, Elekta was not yet able to implement a variable
angular delivery rate for IMAT.
Conclusion
We clinically applied five IMAT treatment plans for
WAPRT. IMAT was validated dosimetrically and was
shown to be deliverable in an acceptable time slot and
to produce dose distributions that are significantly
more homogeneous at the PTV than those obtained
with a CONV plan. Our anatomy based segmenta-
tion strategy offered a feasible solution in view of the
leaf speed constraint. Although the planning is still
time consuming, we think this can be solved by adap-
tations to the patient couch, the control software of
the linear accelerator and the planning software, in-
tervention of which each has the potential to improve
the quality of the IMAT plans.
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Abstract
Purpose: Optimization of radiation techniques to maximize local tumour control and minimize small
bowel toxicity in rectal cancer requires proper definition and delineation guidelines for the clinical target
volume (CTV).
Materials and methods: Seven reports were analysed to assess the incidence and predominant location
of local recurrences in rectal cancer. The distribution of lymphatic spread was analysed in another 10 reports
in order to record the relative frequency and location of metastatic lymph nodes in rectal cancer, according
to the stage and level of the primary tumour.
Results: The mesorectal (MS), posterior (PPS) and inferior pelvic subsite (IPS) are mostly at risk for
local recurrences, while lymphatic tumour spread proceeds mainly in three directions: upward along the
superior rectal artery to the inferior mesenteric nodes, lateral into the internal iliac lymph nodes and in a few
cases downwards into the external iliac and inguinal lymph nodes. The risk for recurrence or lymph node
involvement is related to the stage and the level of the primary lesion, resulting in more IPS recurrences and
lateral lymphatic seeding in low seated tumours and increased risk of lateral lymphatic spread in advanced
stage malignancy. According to the results, we propose guidelines for inclusion of the tumour, the MS and
the PPS into the CTV in all cases. The IPS is at risk if 1) the surgeon aims a sphincter saving procedure
and the tumour is located within +/- 6 cm from the anal margin or 2) the tumour invades the anal sphincter
and an abdominoperineal resection (APR) is necessary. Concerning the lymph node regions, the mesorectal
lymph nodes and the lateral lymph nodes are mostly at risk and should be included into the CTV for all
patients. We did not find solid evidence to include the external iliac nodes in the target volume, except in
these cases where anterior organ involvement is highly suspected. The inguinal lymph node group is not at
risk in rectal cancer patients.
Conclusion: Definition and delineation guidelines are necessary to optimize radiation treatment and de-
fine the best therapy according to the primary tumour characteristics. Based on a review of articles reporting
on the incidence and predominant location of local recurrences and the distribution of lymphatic spread in
rectal cancer, we defined guidelines for inclusion of the most critical pelvic subsites and lymph node regions.
CTV for rectal cancer
Introduction
Since the introduction of total mesorectal excision
(TME), a significant decrease in local recurrence rate
has been observed in resectable rectal cancer [1]. The
use of radiotherapy, either pre- or postoperatively, de-
creases the local recurrence rate and improves sur-
vival in locally advanced rectal cancer [2, 3, 4].
Chemotherapy has shown to enhance the efficacy
of pelvic radiation [5]. While postoperative radia-
tion allows patient selection based on histopatholog-
ical tumour characteristics, recent data demonstrate
the superiority of preoperative radiation [6]. More-
over, preoperative chemoradiation allows downsiz-
ing of low seated rectal tumours which may result in
more sphincter preservation [7]. Based on the results
of prior randomised trials [3, 8], radiation therapy to
a dose of 45-50 Gy in 1.8-2 Gy per fraction, com-
bined with 5-FU chemotherapy is the current stan-
dard pre-operative schedule in T3 (and/or positive
lymph nodes, further N+) tumours in many European
centres.
Indeed, high-risk patients (T3-T4, N+) still suffer
from local relapse rates in up to 33% with trimodality
treatment [9]. In these selected patients improvement
in treatment may be achieved with higher preopera-
tive doses with or without altering the fractionation
of radiotherapy, and integrating novel chemothera-
peutic and molecular targeted agents with radiosen-
sitizing properties. Mohiuddin et al. [10] treated pa-
tients with escalating doses of preoperative radiother-
apy, resulting in a global improvement in overall lo-
cal control and survival. However, further dose esca-
lation is limited due to normal tissue toxicity. Dose
limiting toxicities originate mainly from irradiation
of the small bowel and the normal rectal tissue result-
ing in a 15 to 40% grade III-IV diarrhoea, depend-
ing on the scoring system, type of surgery, adjuvant
chemotherapy, and other factors such as comorbid-
ity [11, 12]. Chronic small bowel radiation toxicity
is irreversible and can be life threatening, requiring
surgical interventions [13].
In radiotherapy, multiple beam set-up, cus-
tomized blocking, and the use of a special open table
top or belly-board device, shifting the small bowel
out of the treatment field can limit the volume of
small bowel treated [13]. In rectal cancer, intensity-
modulated radiation therapy (IMRT) and intensity-
modulated arc therapy (IMAT) can be used to spare
the small bowel around which the planning target
volume (PTV) is located in a horseshoe shape [14].
However, as these techniques introduce dose gradi-
ents close to the PTV (Figure 1), proper definition
and delineation of the clinical target volume (CTV)
is required to avoid underdosage of regions that could
possibly harbour cancer cells. Some studies are pub-
lished on guidelines to define and delineate the CTV
in rectal cancer [15, 16, 17, 18, 19], but they all give
recommendations for two-dimensional treatment por-
tals, rather than for three-dimensional (3D) treat-
ments like IMRT or IMAT.
In this paper we analyse reported data on the
predominant locations and frequency of local recur-
rences and lymph node involvement in rectal cancer
to propose a definition of the CTV for rectal cancer
and guidelines for its delineation.
Materials and Methods
Literature search strategy
Medline (http://www.pubmed.com) was searched for
the following title terms:
((rectum or rectal or colorect* or rectosigm* or
sigmo*) and (cancer or adenocarcinoma or carci-
noma or neoplasm*) and (recurrence or failure or
relapse or recurrent or spread or node or lymph or
lymphatic) and (local or locoregional or regional or
pelvic)) up to September 2005 (note: the “*” depicts
a “wildcard”).
This yielded 406 hits. A selection was made
based on the titles, excluding all articles dealing with
prostate cancer, diagnostic techniques for recurrent
rectal cancer, treatment of recurrence or follow-up
strategies for rectal cancer. Only publications in En-
glish, French or German were retained. After this
first selection, 114 articles remained, of which the ab-
stracts were read, and only those articles that were ex-
pected to give precise anatomical information about
the location of the recurrence or pathologic lymph
nodes, more detailed than pelvic or local, were re-
tained. This yielded 22 articles. From these 22 ar-
ticles, the full text version was retrieved, and only
4 of these 22 articles gave satisfactory information
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Figure 1: Dose distribution in a transverse plane for a conventional plan (2 lateral wedged beams and 1 posterior
beam) at the left side, and an intensity-modulated radiotherapy (IMRT) plan at the right. The ability of IMRT
to spare small bowel [14] is clearly visible. Note that the conventional plan is more robust against less accurate
delineation of the clinical target volume (CTV) than the IMRT plan. In the latter approach, an erroneous CTV
definition will lead to underdosage of regions possibly containing tumour cells.
on the precise location of recurrence and a clear de-
scription of the number of patients at risk. By ex-
tensive cross-referencing, 18 articles were eventually
retained [17;20-36]. Of these, one article [17] was
withdrawn from the final analysis in account of less
reliable information, based on CT findings only, com-
pared to histologically proven data.
Definitions
In an attempt to compare the results of the remaining
17 articles, we defined the names of the pelvic areas
that seemed most at risk for local recurrence or lymph
node spread, aiming at the greatest common divisor
of all described areas as discussed in the individual
articles.
Pelvic region
Five subsites were defined as the predominant areas
at risk for local recurrence: the mesorectal subsite
(MS), the posterior pelvic subsite (PPS), the lateral
pelvic subsite (LPS), the inferior pelvic subsite (IPS)
and the anterior pelvic subsite (APS).
  The MS encompasses the mesorectum, defined
as the adipose tissue with lymphovascular and
neural structures, encapsulated by a fascia, the
so-called perirectal fascia (Figure 2d). The MS
is cylindrical with cone shaped tips in cranial
and caudal direction, starting at the level of the
sacral promontory, at the origin of the supe-
rior rectal artery (SRA) and ending at the level
where the levator ani muscle inserts into the
rectal wall.
  The PPS covers mainly the presacral space: a
triangular area, posteriorly enclosed by the pre-
sacral fascia (Waldeyers fascia), and anteriorly
by the perirectal fascia. This volume is best
seen on magnetic resonance imaging (MRI),
and contains the median and lateral sacral ves-
sels, the lymphatics of the presacral chains, the
anterior branches of the sacral nerves and the
inferior hypogastric plexus [37].
  The LPS includes the lateral pelvic side walls.
  The IPS consists of the anal triangle of the per-
ineum, containing the anal sphincter complex
with the surrounding perianal and ischiorectal
space.
  The APS contains all pelvic organs that are lo-
cated ventrally from the MS.
The results of the different studies were obtained
via retrospective analysis [23, 30, 32], follow-up se-
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ries [20, 24, 34] and findings at planned second-look
operations [21]. Table 1 shows the risk of local re-
currence per pelvic subsite. For the IPS, the distri-
bution of recurrences was further subdivided for pa-
tients whom underwent an abdominoperineal resec-
tion (APR).
Lymph node regions
To assess the risk of lymph node involvement, we
analysed all articles discussing the distribution and
frequency of pathological lymph nodes at primary
diagnosis, based on histopathological examination
at primary surgery [22, 25, 26, 27, 28, 29, 31, 33,
35, 36]. Data on lymph node invasion are gener-
ally from Japanese studies, as extended pelvic lym-
phadenectomy evolved to become the standard treat-
ment for low-lying rectal cancer in some centres in
Japan [38, 39].
We defined five lymph node regions (LNRs): the
mesorectal lymph nodes (MLN), the upward lymph
nodes (ULN), the lateral lymph nodes (LLN), the
external iliac lymph nodes (ELN) and the inguinal
lymph nodes (ILN). Each LNR was chosen in accor-
dance to the main lymphatic drainage pathways of the
rectum. The MLN is, similar to the MS, defined as
the mesorectal tissue enclosed by the perirectal fas-
cia, containing the perirectal nodes with their affer-
ent and efferent vessels. The ULN encompasses all
lymphatic tissue along the SRA and inferior mesen-
teric artery (IMA). Lymphatic spread to the LLN is
defined as involvement of the lymph nodes along the
middle rectal, the obturator and the internal iliac ves-
sels. The lymph nodes along the external iliac artery
and superficial inguinal lymph nodes are classified as
ELN and ILN, respectively. Table 2 shows the risk of
lymph node involvement per LNR. For the LLN, the
risk of lymph node invasion was analysed according
to T-stage and level of the primary tumour. A sep-
arate analysis for high and low-seated tumours was
also made for the incidence of ELN and ILN involve-
ment.
Results
Pelvic subsites at risk for local recurrence (Ta-
ble 1)
Mesorectal subsite (MS)
Only two articles report on the incidence of recur-
rence in the MS in patients that underwent sphincter
saving surgery. The first study [30] reports on 46 pa-
tients with a local recurrence, initially operated with
a low anterior resection in the pre-TME era, where a
blunt dissection was performed with a distal tumour
free border of at least 2 cm. Thirty-four patients had a
recurrence originating from the perirectal tissue and
in 7 patients the recurrence was considered as true
anastomotic. In the second article [32], the MS was
not totally removed in patients that were operated
on before 1985, while after this date, diathermy dis-
section allowed excision of the perirectal fascia. Of
all patients that underwent sphincter saving surgery
(468 patients, with or without partial or TME), 15
patients developed a recurrence in the MS, with 8 re-
currences in the perirectal tissue. The incidence of
anastomotic recurrences (as a percentage of locore-
gional sites involved) ranged between 10 and 21%,
depending on the definition of a true anastomotic re-
currence [23, 24, 30, 34].
Posterior pelvic subsite (PPS)
For the PPS, data on recurrences in the presacral
space [20;23], posterior pelvis [21], or both [34] were
considered. The results were merged, as most of the
posterior relapses include presacral disease [34]. If
all patients from retrospective studies are considered
(3 studies, n=254), then 22% of these patients had a
recurrence in the PPS. Looking at all patients suffer-
ing from a recurrence (5 studies, n=435), 49% had in-
volvement of the PPS. A recent publication reported
on the location of recurrent rectal cancer in 123 pa-
tients with the help of a CT based 3-D data file sys-
tem. They also found that local relapse was mainly
situated in the PPS [19].
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Table 1: Local recurrence per pelvic subsite at risk.
Subsite Pt.
group
Author Ref. No. at
risk (n)
Any rec.
(n)
Rec. in
subsite (n)
Risk for
rec. (%)
Involv in
rec. (%)
PPS All Gilbertsen [20] 89 32 14 16 44
Mendenhall [23] 90 40 18 20 45
Gunderson [18] 75 48 25 33 52
Hruby [34] - 269 127 - 47
Wiig [30] - 46 27 - 59
partial sum 254 - 57 22 -
total sum - 435 211 - 49
LPS All Gilbertsen [20] 89 32 1 1 3
Mendenhall [23] 90 40 4 4 10
Gunderson [18] 75 48 13 17 27
Killingback [32] 468 34 24 5 70
Hruby [34] - 269 30 - 11
Wiig [30] - 46 25 - 54
partial sum 722 - 42 6 -
total sum - 469 97 - 21
IPS All Gilbertsen [20] 89 32 5 6 16
Mendenhall [23] 90 40 4 4 10
Gunderson [18] 75 48 14 19 29
McDermott [24] 934 191 30 3 16
Hruby [34] - 269 15 - 6
partial sum 1188 - 53 4 -
total sum - 580 68 - 12
APR Gilbertsen [20] 89 - 5 6 -
McDermott [24] 100 - 24 24 -
total sum 189 - 29 15 -
APS All Gilbertsen [20] 89 32 13 15 40
Mendenhall [23] 90 40 6 7 15
Gunderson [18] 75 48 21 28 44
McDermott [24] 934 191 23 2 12
Hruby [34] - 269 29 - 11
Wiig [30] - 46 12 - 26
partial sum 1188 - 63 5 -
total sum - 628 104 - 17
Abbreviations: PPS: posterior pelvic subsite; LPS: lateral pelvic subsite; IPS: inferior pelvic subsite;
APS: anterior pelvic subsite; APR: abdominoperineal resection; Pt.: patient; Ref.: reference; rec.:
recurrence; Involv: Involvement of specified subsite. The number of patients at risk for a recurrence
are listed in the 5th column, and were extracted from the studies who gave enough information on the
patient population at risk. The “partial sum” is the sum over these studies, for the patients at risk, the
subsite-specific recurrences and the risk for recurrence in the specified subsite.
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Table 2: Lymph node involvement per lymph node region.
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Lateral pelvic subsite (LPS)
The LPS was only vaguely defined in the articles that
were reviewed, as lateral pelvic wall or just lateral.
For our analysis, both descriptions were considered
as locations for recurrences that are related to the lat-
eral pelvic wall. Six percent of all patients in these
series had invasion of the LPS as a part of their dis-
ease relapse. When only considering patients with
a local recurrence (n=469), the LPS was involved in
21% of the patients.
Inferior pelvic subsite (IPS)
Information on IPS recurrence was found in 4 reports,
including 1188 patients. All papers were retrospec-
tive analyses. The overall risk of developing a recur-
rence in the IPS was more than 4%. In one study,
the risk of IPS recurrence was calculated in relation
to the tumour site, being 8% for tumours located less
than 6 cm from the anal margin and 3% for tumours
located between 6 cm and 11 cm above the anal mar-
gin. For tumours located higher than 11 cm from the
anal margin, no recurrences were observed in the IPS
[24]. When all patients with an APR were considered
(2 studies, 189 patients), 15% developed a recurrence
in the IPS. Furthermore, IPS involvement was seen
in 12% of all patients suffering from a recurrence.
Höcht et al. came to a similar conclusion although no
absolute numbers were reported in their publication
[19]. These data clearly indicate that the IPS is es-
pecially at risk for local recurrence in those patients
with a low seated tumour and patients that underwent
an APR because of a low seated tumour.
Anterior pelvic subsite (APS)
Recurrences involving one of the following organs:
vagina, bladder, prostate, seminal vesicles, urethra,
uterus were classified as APS recurrences. APS re-
currences were found in only 5% of the patients at
risk for local recurrence. In patients with a pelvic
recurrence, involvement of the APS was observed in
17%.
Lymph node regions at risk (Table 2)
Eight reports on lymphatic spread in patients with
rectal cancer were analysed in order to compute the
relative frequency and location of metastatic lymph
nodes in rectal cancer. We also assessed the sites of
lymph node metastases in relation to those aspects of
the primary tumour that can be documented before
surgery.
Mesorectal lymph nodes (MLN)
In 44% of all available rectal cancer patients, at least
one positive node in the MLN was found. The MLN
were involved in 87% of the patients with positive
pelvic lymph nodes, showing the importance of this
group. Information on correlation with T stage was
too scarce for analysis. Morikawa et al. [26] pro-
vided detailed information on longitudinal perirectal
lymphatic spread. In caudal direction, no lymphatic
spread was found more than 4 cm away from the tu-
mour. In cranial direction, positive lymph nodes (in
the MLN) were found up to 10 cm above the primary
tumour (8%), while above 10 cm, the risk was less
than 2%.
Upward lymph nodes (ULN)
In two articles, upward spread is defined along the
SRA and the IMA, reported as one entity [22;33].
Other authors only classify the lymph nodes along
the IMA in this group [27;31]. In one study up-
ward spread is not further specified [26]. Three
articles make a distinction between positive lymph
nodes along the peripheral and the root of the IMA,
the majority being located along the peripheral IMA
[27;33]. The incidence of positive lymph nodes in the
ULN was found to be 27%. Looking only at patients
with positive lymph nodes in any site, 54% of these
patients had lymph node metastases in the ULN.
Lateral lymph nodes (LLN)
Throughout the available articles, the definition of the
LLN varied, going from lymph nodes along the inter-
nal iliac artery [31], to nodes along the internal il-
iac artery, the middle rectal artery, and the obturator
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Figure 2: Transverse view through 6 selected levels from cranial (a) to caudal (f) direction. Images are T2
weighted magnetic resonance images. Abbreviations: B: bladder; C: coccyx; EIA: external iliac artery; EIV:
external iliac vein; EOM: external obturator muscle; GM: gluteus maximus muscle; IMA: inferior mesenteric
artery; IOM: internal obturator muscle; IT: ischial tuberosity; LAM: levator ani muscle; OA: obturator artery;
P: promontory; PiM: piriform muscle; PM: psoas muscle; Pr: prostate; R: rectum; S: symphysis pubis; SGA:
superior gluteal artery; SRA: superior rectal artery; T: tumour; U: ureter. The two arrows in (a) indicate the
sacro-iliacal joint. The black asterisk in (b) indicates a suspect lymph node along the SRA.
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Figure 3: Transverse computed tomography slices through the levels corresponding to those in Figure 2. The
abbreviations are explained in the caption of Figure 2. The posterior pelvic subsite (PPS) is indicated by the
dashed line. The lymph node regions that are to be included in the clinical target volume (see text for details)
are delineated by the dotted lines. The mesorectal subsite (MS) is shown by the full black line, while a grey
dashed line indicates the inferior pelvis subsite (IPS; only visible in (f)). In (b), the white asterisks indicate
suspect lymph nodes. In (f), the prostate is delineated by the full white line.
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artery [22;25;28;33], to even larger groups, includ-
ing nodes along the common iliac artery [27] and the
external iliac artery [29;35;36]. One article did not
clearly define the LLN [26].
For all patients at risk (6 studies, n=2230), the
incidence of LLN invasion was 13%. When look-
ing at the patients with positive lymph nodes, the risk
doubles up to 27%. The main clinical significance is
seen in advanced stage and low seated tumours. Six
studies give detailed information on T stage, showing
5% positive LLN in T1-T2 tumours, 14% in T3, and
18% in T4 tumours. In high seated tumours, we doc-
umented a risk for positive LLN in 4%, whereas in
tumours of the middle and lower part of the rectum
this risk was up to 18%. Steup et al. [33] reported on
a relative large number of positive lymph nodes at the
level of the obturator artery (6%), the majority being
attributable to tumours located below the peritoneal
reflection.
External iliac lymph nodes (ELN) and inguinal
lymph nodes (ILN)
Two articles reported on lymph nodes along the ELN.
In these retrospective analyses, positive lymph nodes
in the ELN were found in 4% when considering the
whole patient group, and in 9% when only taking
into account the patients with positive lymph nodes.
Nearly all positive lymph nodes in this group orig-
inate from tumours located close to the anal mar-
gin, resulting in a higher percentage for patients with
middle or low seated tumours and/or those that un-
derwent an APR (7%, versus non-existing for pa-
tients with an anterior resection and/or high seated
tumours). Regarding the ILN, 3 articles provide data
on 1028 patients, showing only a 1% risk of positive
ILN. When looking at the data from Hojo et al. [22]
and Steup et al. [33], all positive lymph nodes in the
ILN were associated with low seated rectal tumours.
Delineation guidelines (Figures 2 and 3)
Taking into account the results in the Table 1 and 2,
we defined delineation guidelines for the CTV for
rectal cancer patients, including the most critical sub-
sites and lymph node groups. To decide whether a
subsite or lymph node group was critical for inclusion
into the CTV, an arbitrary limit was set to 10% overall
risk for recurrence or lymph node involvement. Sev-
eral pelvic subsites partly cover lymph node groups
and vice versa. Therefore, we only describe the most
relevant subsites and LNRs.
Mesorectal subsite (MS) and mesorectal lymph
nodes (MLN)
As this area is highly at risk for lymphatic spread,
it must be included in the CTV. Its circumferential
boundary (perirectal fascia) is best visualized on MRI
(Figure 2d) and can sometimes be identified on CT
scan. The lower border is located at the level where
the levator ani muscle inserts into the rectal wall. The
upper border is situated at the peritoneal fold, where
the peritonealized rectum starts and bends anteriorly
to form the recto-sigmoid. We propose to take the
bifurcation of the IMA into the sigmoid artery and
the SRA as the upper limit of the MS [40]. The ante-
rior border is defined by the Denonvilliers fascia. The
prostate/seminal vesicles/bladder in men and the pos-
terior vaginal wall/uterus in women define this bor-
der. The lateral border below the dentate line is the
levator ani muscle, which makes a funnel around the
distal rectum. Above the dentate line, the piriform
muscle bounds the perirectal fascia on both sides.
The retro-rectal fascia forms the anatomical posterior
border and lies alongside the PPS.
Posterior pelvic subsite (PPS)
Parallel to the mesorectum, the PPS is highly at risk,
independent of tumour location and should therefore
always be part of the CTV. The PPS corresponds
mainly to the presacral space, a triangular strongly
curved volume, which posteriorly faces the sacral
concavity. Bounded anteriorly by the perirectal fas-
cia, it extends laterally towards the lateral borders
of the sacrum where it encounters the posterior limit
of the LLN. Its apex is directed caudally and corre-
sponds to the coccyx, while the sacral promontory
delineates its base. The anterior border that coincides
with the posterior border of the mesorectal subsite is
difficult to spot on CT images. Therefore, we pro-
pose to delineate this region by use of MRI or, if not
available, take an arbitrary maximal margin of +/- 1
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cm ventrally from the sacral bone as anterior border
[41]. On the images where there is direct visual con-
nection of the presacral space with the sacral neuro-
foramina, the CTV should be expanded posteriorly to
include the sacral neuroforamina.
Inferior pelvic subsite (IPS)
We suggest including the IPS in the irradiated volume
when 1) the surgeon aims a sphincter saving proce-
dure and the tumour is located within +/- 6 cm (de-
pends on the centre) from the anal margin or 2) the
tumour invades the anal sphincter and an APR is nec-
essary. This area includes the ischiorectal fossa and
the internal and external anal sphincter (Figure 3f),
with the penile bulb/vestibular bulb as anterior bor-
der. The deeper part of the ischiorectal fossa, located
above the transverse septum and bounded laterally by
the internal obturator muscle and the ischium, is en-
tirely at risk. We propose to extend this lateral bor-
der to the superficial/perianal part of the ischiorectal
fossa. The posterior border can be drawn at the level
of the gluteal muscle and coccyx. If the IPS is not
at risk for subclinical disease, the external and inter-
nal sphincter with the surrounding ischiorectal fossa
should not be included in the CTV.
Lymph node regions
Table 2 clearly shows that the LNRs at risk depend on
the level of the primary lesion. For tumours located
in the upper part of the rectum (high seated tumours
or more than 10 cm above the anal margin), the lym-
phatic spread is mainly in the upward direction along
the SRA to the nodes along the IMA, while tumours
in the middle and lower part of the rectum addition-
ally drain in the lateral direction into the internal iliac
nodes. Lesions that extend to the anal canal tend to
spread to the inguinal nodes [18]. If the primary tu-
mour spreads beyond the perirectal fascia and invades
adjacent structures or organs, nodal drainage extends
via the lymphatics of the involved organ (prostate,
vagina, uterus, and bladder). This includes the ELN
if there is anterior organ involvement and the ILN if
the lower third of the vagina is involved [18]. We
propose to include the MLN, the ULN and the LLN
into the CTV for all patients. Taking into account the
results of Steup et al. [33], the obturator nodes can be
omitted if the lesion is located more than 10 cm above
the anal margin. These guidelines are in correspon-
dence with Arcangeli et al. [15]. We did not find solid
evidence to include the ELN in the target volume,
except in these cases where anterior organ involve-
ment is highly suspected. The LLN is triangular in
shape with the internal iliac artery in the centre, and
becomes enlarged caudally around its different vis-
ceral branches. The tip is located at the bifurcation of
the common iliac arteries (Figure 3a). Anteriorly, the
ureter bounds this volume, while the posterior limit
reaches the lateral edge of the sacroiliac joint. Infe-
riorly, we propose to delineate this LNR until the ob-
turator artery enters the obturator canal (Figure 3e).
The lateral wall is lined superiorly by the ischium,
then by the medial surface of the piriform muscle
and the levator ani muscle more caudally. The me-
dial wall of the LLN extends towards the plane of the
perirectal fascia. This area contains in the adipose
tissue surrounding the internal iliac vessels most of
their posterior parietal and visceral branches but also
the lymphatic pathways of the middle main pelvic
pathway, the proximal part of the posterior presacral
pathway, the efferent pelvic nerves of the hypogastric
plexus and the origin of the sciatic nerve. The upward
spread in rectal cancer runs along the SRA into the
nodes along the IMA [37]. The IMA originates from
the aorta, 3 to 4 cm cranial to the aortic bifurcation.
Considering the whole IMA as CTV is in our opin-
ion unwanted, as it has been shown that para-aortic
irradiation to elective doses does not result in an im-
proved disease free survival, and was associated with
higher toxicity [42]. We propose to take the promon-
tory as the cranial border for the ULN.
Discussion
In this article, delineation guidelines are defined after
a detailed analysis of the literature, combining pub-
lished data on the frequency and distribution of local
recurrences and positive lymph nodes in rectal can-
cer patients. These guidelines should help the clin-
ical implementation of conformal radiotherapy tech-
niques, like IMRT or IMAT, in rectal cancer.
Some caveats, however, have to be formulated.
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Even the selected articles are sometimes difficult to
compare in account of diverse, incomplete or even
non-existing definitions of pelvic subsites and lymph
node groups, obscurity about the surgery performed
(definition of curative surgery, the extension of lym-
phadenectomy (fields and lymph node groups in-
cluded)), the use of adjuvant therapies, number of pa-
tients in studies, collection of data (prospective, ret-
rospective), definition of recurrences, assessment of
recurrences (clinical, radiological, histopathological:
biopsy or autopsy proven, or findings at second look
operations), and differences in the method of record-
ing: number of recurrences versus number of patients
with a recurrence per subsite. This problem is re-
flected in the heterogeneity of the data, as can be seen
in Table 1. Therefore, these guidelines should be con-
sidered as a starting point, and need to be confirmed
by prospective observations.
It should also be noted that a distinction be-
tween a nodal and pelvic relapse is difficult to iden-
tify in clinical analysis and even in second-look se-
ries some of the relapses coded as lateral or poste-
rior were undoubtedly due to relapse within the lym-
phatics or replaced internal iliac nodes or presacral
nodes rather than tumour bed relapse. Two articles
[20;30] report on the incidence of local disease re-
currence alone without distant metastases, while the
other studies record both local recurrence only or in
combination with distant relapse [23;24;32;34]. We
should, however, realize that once a patient develops
distant metastasis, the local disease status is often less
carefully verified because of limited therapeutic rele-
vance. Local recurrence in those patients will only be
discovered by chance or in case of symptoms, except
in the study of Gunderson where initially planned
single or multiple second look operations were per-
formed [21;30].
Recurrences in the MS are mostly reported before
the introduction of TME. Various articles reported on
the importance of the MS as a predominant subsite
for local tumour spread, both in lateral and longitudi-
nal direction. Moreover, removing the total mesorec-
tum resulted in a significant improvement of local
control. Nevertheless, during preoperative radiother-
apy, the mesorectal subsite can hide viable tumour
clonogens available for metastasis and should there-
fore be covered by the CTV. Although difficult to
discriminate from a MS recurrence, anastomotic re-
currences originate from contamination with cancer
cells during operation, while MS recurrences start in
remaining circumferential mesorectal tissue (in pa-
tients operated with a partial mesorectal excision or
in the pre-TME era). In one article, the authors as-
sumed that the recurrence was anastomotic if the tu-
mour volume was larger on the mucosal side than in
the perirectal tissue, and, on the other hand, a recur-
rence starting in the perirectal tissue was assumed to
have a relative small volume in the rectal wall [30].
The relative high incidence in some series (Hruby et
al. 21%) could be a reflection of a broader defini-
tion of a true anastomotic recurrence, but suggest that
great care must be taken to avoid peroperative soiling.
The level of the primary tumour is an important
factor relative to the mode of spread in rectal can-
cer. Still, a large variation exists in the definition of
low-seated, middle seated and high-seated tumours
exist, blurring the analysis. The majority of the au-
thors define the peritoneal reflection as the anatomi-
cal boundary between high seated and low seated tu-
mours, based on a biological barrier between lym-
phatic pathways. The location of the peritoneal re-
flection has been described in anatomy texts as 7.5
cm from the anal margin in males and 5.5 cm in fe-
males. The source of this information was not refer-
enced, but presumably stemmed from cadaveric dis-
sections. Some authors have proposed the anatomic
reference of the second rectal valve as the location of
the anterior peritoneal reflection [43].
We only found solid evidence of a higher inci-
dence of lymph node involvement in the ELN group
in low seated tumours. Data on involvement of the
ELN group in tumours that invade adjacent structures
are scarce because of the inoperable state of these
highly advanced lesions. Nevertheless, it is gener-
ally believed that the CTV should include the ELN
group in tumours with invasion of adjacent organs on
the basis of the lymphatic drainage pattern from those
organs.
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Conclusion
Definition and delineation guidelines are necessary to
optimize radiation treatment and define the best ther-
apy according to the primary tumour characteristics.
The CTV should encompass the tumour, the MS and
the PPS in all cases. The IPS is at risk if 1) the sur-
geon aims a sphincter saving procedure and the tu-
mour is located within +/- 6 cm (center-dependent)
from the anal margin or 2) the tumour invades the
anal sphincter and an APR is necessary. We pro-
pose to include the MLN, the ULN and the LLN into
the CTV for all patients. We did not find solid ev-
idence to include ELN in the CTV, except in these
cases where anterior organ involvement is highly sus-
pected. The ILN are not at risk in rectal cancer pa-
tients.
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Key issues discussed in this paper:  
• In rectal cancer, radiotherapy is standard treatment option. The main dose-limiting 
organ is the small bowel. Intensity modulation is a possible method to minimize small 
bowel toxicity. IMAT was selected due to the large inner radius of the PTV. 
• An additional IMAT planning tool was implemented, in order to facilitate the 
extraction of deliverable arcs out of the preliminary arcs with variable ADR. 
• An IMAT class solution for rectal cancer was developed, consisting of 3-6 arcs, and 
resulting in a delivery time of 5 to 10 minutes. 
• IMAT was tested against 3D-CRT, and was found to result in a lower dose to the 
small bowel, at the cost of a slightly larger inhomogeneity in the PTV. 
• A series of PGD experiments showed good agreement between measured and 
calculated dose in the PTV, and confirmed the sparing of the small bowel. IMAT 
delivery was shown to be as accurate as 3D-CRT delivery. 
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Abstract
Purpose: In rectal cancer, combined radiotherapy and chemotherapy, either pre- or postoperatively, is
an accepted treatment. Late small bowel (SB) toxicity is a feared side effect and limits radiation-dose
escalation in a volume-dependent way. A planning strategy for Intensity Modulated Arc Therapy (IMAT)
was developed and IMAT was clinically implemented with the aim to reduce the volume of SB irradiated at
high doses and thus reduce SB toxicity. We report on the treatment plans of the first seven patients, on the
comparison of IMAT with conventional 3D planning (3D) and on the feasibility of IMAT delivery.
Methods and Materials: Seven patients, who were referred to our department for pre- (n=4) or postop-
erative (n=3) radiotherapy for rectal cancer, gave written consent for IMAT treatment. All patients had a
planning CT in prone position. The delineation of the clinical target volume was done after fusion of CT
and MRI, with the help of a radiologist. For the IMAT plan, arcs were generated using an anatomy-based
segmentation tool. The optimization of the arcs was done by weight optimization (WO) and leaf position
optimization (LPO), both of which were adapted for IMAT purposes. The 3D plans used one posterior and 2
lateral wedged beams, of which the outlines were shaped to the beam’s eye view projection of the planning
target volume (PTV). Beam WO was done by constrained matrix inversion. For dose volume histogram
analysis, all plans were normalized to 45 Gy as median PTV dose. Polymer Gel Dosimetry (PGD) on a
humanoid phantom was used for the validation of the total chain (planning to delivery). IMAT treatments
were delivered by an Elekta SliPlus linear accelerator using prototype software with the same interlock class
as in clinical mode.
Results: The IMAT plan resulted in 3 to 6 arcs, with a mean delivery time of 6.3 minutes and a mean of
456 monitor units (MU) for a 180 cGy fraction. The minimal dose in the PTV was not significantly different
between 3D and IMAT plans. Inhomogeneity was highest for the IMAT plans (14.1%) and lowest for the
3D plans (9.9%). Mean dose to the SB was significantly lower for the IMAT plans (12.4 Gy) than for the 3D
plans (17.0 Gy). The volume of SB receiving less than any dose level was lower for the IMAT plans than
for 3D plans. Integral dose was lower in the IMAT plans than for the 3D plans (respectively 244 J and 262 J
to deliver 45 Gy). Differences between the PGD measured dose and the calculated dose were as small for
IMAT as for 3D treatments.
Conclusion: IMAT plans are deliverable within a 5-10 minute time slot, and result in a lower dose to the
SB than 3D plans, without creating significant underdosages in the PTV. PGD showed that IMAT delivery
is as accurate as 3D delivery.
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Introduction
The use of radiotherapy, either pre- or postoper-
atively, in addition to systemic chemotherapy, de-
creases the local recurrence rate and improves sur-
vival in rectal cancer [1]. Randomized trials of pre-
operative radiation and surgery versus surgery alone
showed a radiation-dose dependent reduction of local
failure in the combined modality arm, with a halving
of the local recurrence rate at biologically effective
doses of  30 Gy [2]. Pre-operative radiation therapy
to a dose of 40-45 Gy in 1.8-2 Gy per fraction, usu-
ally combined with 5-fluoro-uracil-based chemother-
apy is the standard schedule in many European cen-
ters.
Although some reports suggest further improve-
ment in local control for higher doses, especially
in high-stage rectal cancer [3, 4], acute and chronic
small bowel (SB) and rectal toxicity [5] seem to limit
further dose escalation. For small bowel, reported in-
cidences of acute grade III-IV diarrhea vary between
15% and 40%, depending on grading systems, type
of surgery, administration of adjuvant chemotherapy
and other variables like co-morbidity [6, 7]. Chronic
SB radiation toxicity is irreversible and can be life-
threatening. Actuarial 5-year estimates of severe
chronic SB toxicity vary between 7 and 42% [8, 9]
at doses of 45-50 Gy. The incidence of both acute
and late SB toxicity is related to the volume of SB
in the treatment fields [6, 7, 9]. Several possible
methods have been examined for minimizing the por-
tion of SB in the treatment field. For a review of
these different techniques, the reader is referred to
Letschert [10]. A new possibility to reduce the vol-
ume of SB irradiated to high doses consists of In-
tensity Modulation (IM). IM offers the possibility to
spare an Organ At Risk (OAR) lying in the concavity
of a Planning Target Volume (PTV). This anatomical
relationship occurs in rectal cancer, where SB is par-
tially surrounded by the CTV, consisting of the rec-
tum and its draining lymph node regions. Because of
the large internal radius of the concave PTV in rec-
tal cancer, a large number of beam directions may
be favorable [11]. With arc therapy, the number of
beam directions is infinite, and thus Intensity Modu-
lated Arc Therapy (IMAT) [11, 12] might be a logical
approach to this clinical problem. The goals of this
manuscript are:
 to present our planning strategy and first expe-
rience of IMAT for rectal cancer;
 to report the results of a planning comparison
between conventional radiotherapy (3D) and
IMAT;
 to validate the IMAT delivery method using
polymer gel dosimetry.
Methods and Materials
Delineation
Between February 2003 and November 2003, 7 pa-
tients with a histologically proven adenocarcinoma
of the rectum were treated with IMAT. All patients
signed an informed consent for inclusion in this fea-
sibility study, approved by the local ethics commit-
tee. Some clinical data of these patients are shown
in Table 1. A planning computed tomography (CT)
was performed with the patient in prone position. For
patient 5, 6 and 7, a bellyboard was used (Sinmed,
Reeuwijk, The Netherlands). CT slice thickness was
0.3 cm, and the scanned volume extended from the
third lumbar vertebra down to 10 cm caudal to the ob-
turator foramina. No contrast enhancement was used.
No attempts were made to reduce variation of blad-
der filling. All patients underwent diagnostic mag-
netic resonance imaging (MRI), which was electron-
ically fused with the planning CT. This was done us-
ing the landmark method of the Oncentra Treatment
Planning System (Nucletron B.V., Veenendaal, The
Netherlands). In those patients who were sent for
pre-operative radiotherapy, the gross tumor volume
(GTV) was delineated using the fused CT-MRI. The
fused CT-MRI was also used for the delineation of all
other target subvolumes. These included the follow-
ing structures: rectum , mesorectal space, presacral
space and the lymph node regions along the com-
mon iliac (up to and including the level of the first
sacral vertebra), the internal iliac, the superior rectal
and the internal obturator vessels. In patients with a
tumor lying 6 cm or less from the anal verge, the per-
ineal area was also included. The contouring of these
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Table 1: Patient and planning description.
timing Volsb
  (cc)
IMAT 3D
#
arcs
#
MUs
CDT
(meanSD)
DRDT # MUs
(W/UW)
DRDT
Pt 1 pre 234.4 5 526 5.8  0.4 5.4 389/109 2.8
Pt 2 pre 29.7 6 508 9.4  0.3 7.6 350/87 2.4
Pt 3 post 22.6 6 421 7.5  0.3 6.3 302/92 2.3
Pt 4 post 8.9 4 476 5.5  0.3 5.5 187/153 2.6
Pt 5 pre 145.8 3 529 3.4  0.0 3.5 304/100 2.5
Pt 6 pre 0.8 5 392 5.8  0.1 5.5 363/92 2.4
Pt 7 post 146.3 4 337 5.6  0.7 4.8 211/144 2.6
The seven patients (Pt) are ordered chronologically. Timing is the order of radiotherapy in relation to the
surgery, in which “pre” stands for pre-operative radiotherapy, and “post” for post-operative radiotherapy.
Volsb
  
= the volume of small bowel receiving more than 90% of the target prescription dose in the 3D plan.
IMAT= Intensity Modulated Arc Therapy. For IMAT the number of arcs is given, as is the total number of
monitor units (MUs) for a fraction of 180 cGy. Both clinical delivery time (CDT) as dummy run delivery time
(DRDT) is given. All time measurements are given in minutes. For the 3D plans, MUs are split up in the
wedged (W) and unwedged (UW) part.
target subvolumes was done together with a radiolo-
gist (PS). Due to the fact that the internal motion of
the different target subvolumes is different [13], the
rectum was expanded anisotropically with 1.5 cm in
the antero-posterior direction, and with 0.5 cm in the
cranio-caudal and lateral directions. All other subvol-
umes were expanded isotropically with 0.5 cm. All
unexpanded subvolumes were summed to form the
CTV, while all expanded subvolumes were summed
to the PTV.
The OARs that were contoured were bladder and
SB. All SB loops were delineated individually up to
the CT slice through the middle of the fourth lum-
bar vertebra. Structures provided to the optimization
algorithm included the PTV, bladder, SB, and three
structures generated to aid the optimization towards a
desirable solution. A first optimization aid structure
was made by subtracting the PTV and an additional
margin of 0.6 cm from a 1 cm expansion of the SB,
resulting in the structure "small_bowel_exp_optim".
Other optimization aid structures were rim_2_cm (=
all tissue between 0 and 2 cm around the PTV) and
surr (= all tissue more than 2 cm from the PTV). For
a discussion about the use of these optimization aid
volumes, the reader is referred to De Neve et al. [14].
The anatomy-based segmentation tool (ABST) [15]
needs an OAR of which the projection on the isocen-
tric plane is larger than the PTV projection in the
direction perpendicular to the direction of the leaf
motion. For this reason, a segmentation structure
(segm_str) was made, consisting of SB and bladder,
elongated in the cranio-caudal direction when neces-
sary. Per patient, the same target structures and OARs
were used for both plans.
IMAT planning procedure
The IMAT planning procedure has been described
in more detail previously [11] and is summarized in
Figure 1. Machine states (MSs) are generated using
ABST every 8Æ within the deliverable range. This de-
liverable range consists of beam directions in which
the radiation beam does not traverse metal compo-
nents of the couch before entering the patient. In
the case of the Elekta SLiPlus couch, the largest de-
liverable range is obtained by positioning the metal
C-arms of the couch on 120Æ or 150Æ, as measured
from their lateral position. Considering the relative
position of the isocenter to the table and the PTV ge-
ometry, possible gantry angels ranged from -136Æ to
136Æ. Thus, no arcs were irradiating the patient from
below the couch (anterior to the patient). The ABST
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Figure 1: IMAT planning flowchart. Abbreviations: ADR: angular delivery rate. aSOWAT: arc-therapy mod-
ification of segment outline and weight adaptation tool. CCC/S: collapsed cone convolution/superposition
calculation algorithm. MS: machine state. A MS is described by a set of machine parameters that uniquely
define beam direction, aperture, photon beam quality. After MS generation, MSs of the same class are then
ordered into arcs. These arcs are given as input to aSOWAT. This is our optimization tool, which was adapted
for IMAT purposes. aSOWAT starts with a check of the leaf velocities in the transition from one MS to the next.
If necessary, leaf positions are adapted in order to meet this constraint. Then, the actual optimization starts with
the optimization of the monitor units (MU) per step, in which a step is defined as the transition from one MS
to the next. A factor is included in the bio-physical cost function to restrict the MU per degree variation (ADR
constraint). When a user-defined number of cycles have been executed, aSOWAT is terminated, and the new
MS outlines are saved. This is followed by the interactive extraction of deliverable arcs with constant ADR.
After all deliverable arcs have been extracted, these are given as input to aSOWAT, but with optimization of the
total number of MUs per arc instead of per step. Finally, a dose calculation with the CCC/S algorithm is done,
and the plan is evaluated by the clinical staff.
resulted in (maximally) 4 classes of MSs per beam
direction, differing from each other only in the cov-
erage of the PTV (Figure 2). All adjacent MSs of
the same class were sorted based on the gantry an-
gle to form an arc (Figure 2), thus resulting in four
arcs. These initial arcs were the input of the optimiza-
tion, which is done by our in-house developed seg-
ment outline and weight adaptation tool (SOWAT),
modified for IMAT purposes (aSOWAT) (Figure 1) .
aSOWAT optimizes the leaf positions of each MS and
the monitor unit (MU) values of each step, in which
a step is defined as the transition from one MS to
the next MS. Additional to the previously described
IMAT planning strategy, a factor has been added to
the objective function to obtain a fluent angular de-
livery rate (ADR). This factor takes into account the
first and second derivative of the ADR, approximated
using the first and second finite differences of the MU
values of each step. This first aSOWAT optimiza-
tion results in arcs with a non-constant ADR, further
called virtual arcs, which are presently undeliverable
on the Elekta SLiPlus linac. These virtual arcs how-
ever help to select the start and stop gantry angles of
the final, deliverable arcs, for which the ADR has to
be constant. The fluently modulating ADR facilitates
this extraction of deliverable arcs. To obtain a time-
efficient treatment, the number of arcs has to be kept
low. Consequently, a one step extraction of deliver-
able arcs would impose a very rough discretization of
the optimized ADR. A more efficient procedure was
IMAT for rectal cancer
Gantry 0
Gantry 8
S0L S1L S0R S1R
Gantry 16
PTV
segm. str.
MS outline
Figure 2: Anatomy-based arc generation shown in beam’s eye view (BEV). Abbreviations: PTV: planning
target volume. Segm. str.: segmentation structure. MS: machine state. S0L: MS covering the total BEV
projection of the PTV passing at the left side of the segmentation structure. S1L: MS covering a 2 cm wide area
of the PTV at the left side of the segmentation structure. S0R: MS covering the total BEV projection of the
PTV passing at the right side of the segmentation structure. S1R: MS covering a 2 cm wide area of the PTV at
the right side of the segmentation structure. The ABST-generated machine states are shown for three adjacent
beam directions (gantry angles 0Æ, 8Æ and 16Æ). The horizontal position shows how the different classes (S0L,
S1L, S0R and S1R) were generated per gantry angle. In the vertical direction, the ordering per arc can be
appreciated. As can be seen, the BEV projection of the PTV and the segmentation structure does not differ
much when the gantry is rotated over 8Æ. The S1R MS for the gantry on 16Æ was not generated, because the
width of the S0R MS was less than the user-defined 2 cm for the S1R MS. This means that the S1R arc will end
at a gantry angle of 8Æ.
implemented as follows: each arc is separately (and
manually) extracted from the ADR graphs displayed
on the planning computer. After each extraction of a
deliverable arc, the MUs of all deliverable arcs are re-
optimized, together with the remnant ADR of the vir-
tual arcs. During this short optimization, a factor in-
cluded in the objective function favors the MUs of the
deliverable arcs with respect to the ADR of the vir-
tual arcs. Each extraction transfers MUs from the vir-
tual to the deliverable arcs. By downforcing the rem-
nant ADR, only the important parts of the virtual arcs
remain to be extracted in the next deliverable arcs.
When the remnant ADR falls to zero by optimiza-
tion, the extraction procedure is finished. The plan
is finalized by an aSOWAT optimization cycle, con-
sisting of optimization of the leaf positions of the fi-
nal arcs, and optimization of the ADR per (extracted)
arc instead of per step, which is equivalent to opti-
mization of the total MU-count of an arc (to be de-
livered at a constant ADR). A final dose computation
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was done for 18MV using the collapsed cone convo-
lution/superposition algorithm from Pinnacle (Philips
Medical Systems, Best, The Netherlands), which was
used for all (IMAT and 3D) plans. Dose distributions
of arcs were approximated by computing dose at the
 
Æ interspaced MSs. For this, the MUs of each step
were equally split and attributed to the two defining
MSs. Thereby, the number of MUs assigned to the
first and last MS is the number of MUs of the arc
divided by twice the number of steps. The MUs as-
signed to the other MSs is the number of MUs of the
arc divided by the number of steps. Except where
explicitly mentioned, all presented results on IMAT
calculated dose distributions are based on this  Æ dis-
cretization.
A last MU optimization per arc was done using
the results of the final dose computation. Finally,
a prescription file was generated for each arc, and
networked to a an Elekta SLiPlus 18 MV linear ac-
celerator. The IMAT treatment was delivered in lo-
cal service mode using prototype dynamic software
(Javelin, Elekta), with the same interlock class as
used in clinical mode.
Conventional planning
The conventional plan consisted of two lateral beams
and one posterior beam, as described earlier. The out-
lines of the beams were shaped conformally around
the PTV with a margin of 0.8 cm, using multileaf
collimation. All beams consisted of a wedged and
an unwedged part. The weight optimization was done
using constrained matrix inversion (CMI) [16]. It was
proven previously that CMI resulted in a better plan
than achieved by human planners, given that all rele-
vant structures are included in the objective function.
The following structures were used in the optimiza-
tion algorithm: PTV, SB and surr. The last structure
was added to avoid unacceptable overdosage outside
the PTV.
Treatment evaluation
Treatment delivery time, defined as the time between
the start of the first arc and the end of the last arc,
was measured for all patients for nearly all fractions.
Apart from these clinical time measurements, dummy
run delivery time measurements were done for all
plans. For the IMAT plans, this was done on Javelin,
while for the 3D plans, this was done on the RT Desk-
top (RTD) linac control software from Elekta. Total
time was measured, as well as beam-on time, time
for automatic setup and time for system checks. For
the different planning techniques, the total number of
MUs needed to deliver a 180 cGy fraction, were also
compared.
For dose volume histogram (DVH) analysis, all
plans were normalized to a median dose of 45 Gy in
the PTV. Target dose homogeneity was evaluated us-
ing an inhomogeneity factor   ( =   
 

with 

the dose below which 99% of the PTV volume was
treated ,
 
the dose below which 1% of the PTV vol-
ume was treated, and 

the median PTV dose).
Furthermore, the 

and 
 
(used as a surrogate
for maximum and minimum dose, respectively), and
the % volume of the target structure receiving more
than 95% of the prescribed dose over the total vol-
ume (V

) were compared. For SB, the mean dose
(

), the % volume receiving more than 90% of
the target prescription dose (

), and the % volume
receiving more than 15 Gy (
 	
) were evaluated.
Finally, the integral dose (



) given to the patient
was approximated as 



with 

the total
scanned volume. The dose deposition efficiency fac-
tor (DDEF) was calculated by dividing the integral
dose to the PTV (


	

) by 



. DVHs were re-
calculated for the group of 7 patients. For all relevant
structures of all patients, the volume percentiles at
every 0.25 Gy dose level from 0 to 50 Gy were com-
puted from the calculated dose distribution. For every
dose level, the mean and standard error of the mean
(SEM) was calculated. In order to characterize the
different plans in their ability to spare SB, dose "vol-
ume difference" histograms (DVDH) were made. A
DVDH represents the difference (between two plans)
of the % volume receiving specified doses. DVDHs
were constructed by calculating the mean (over the
seven patients) of difference in % volume receiving
a specified dose. These points were calculated every
0.25 Gy between 0 and 50 Gy. For all statistical com-
parisons, a paired Student t test was used. All tests
were two-tailed and p < 0.05 was considered statisti-
cally significant.
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Dosimetric verification
Polymer gel dosimetry (PGD) was used for dose
verification. The basis of this dosimetric tech-
nique resides in a polymerization reaction of acrylic
monomers within a hydrogel. The reaction is initi-
ated by highly reactive radicals, that are formed by
radiolysis during irradiation. The amount of poly-
mer formed is related to the absorbed dose, and can
be quantified by MRI. Detailed information on PGD
can be found elsewhere [17, 18, 19]. A homogeneity
study was done to validate PGD for the use of large
volumes, and is described elsewhere [20]. A Barex
(Cifra, Chateau Thierry, France) cast was vacuum
molded on the pelvic region of the RANDO phantom
(Alderson Research Laboratories, Stamford, USA).
Three supplemental RANDO slices were placed cra-
nially and caudally to the Barex phantom to have
full scatter conditions in the gel during irradiation.
CT scans (Siemens Somatom Plus 4, Erlangen, Ger-
many) of the gel-filled Barex phantom were trans-
ferred to the planning system, and the volumes of
interest of a patient case were transferred to the CT
set. For this setup, a 3D and an IMAT plan were
made as described earlier, and a prescription was
made giving a median dose of 7.5 Gy to the PTV.
This ensured the maximal response range of the gel,
while avoiding saturation effects in the gel. Both
techniques were dosimetrically verified using PGD.
For the IMAT plan, two measurements were done.
First, the plan was delivered in arc therapy mode,
thus with dynamic gantry (IMATd). In a second ex-
periment, the prescription was delivered in a discrete
way, i.e. as a static gantry IMRT with gantry posi-
tions every 8Æ (IMATs). The latter delivery reflects
how the plan is calculated. By comparing both re-
sults, the effects of the interpolation from discrete,
8Æ-interspaced, gantry positions to arcs can be seen.
For each experiment, gel-filled test tubes were irra-
diated to doses between 0 and 10 Gy (every 1 Gy)
for calibration purposes. The dose distributions, as
measured in the gel, were transferred to the plan-
ning system. For the transfer of the gel-measured
dose distributions, the following positioning proce-
dure was followed: on both the planning CT and the
MRI (used for PGD), the content of the Barex cast
(=the gel) was automatically contoured. The center
of volume (COV) of both structures was positioned
onto each other. Rotations were avoided by using
laser line positioning on the CT scanner and position-
ing lines on the MRI scanner. The measured dose dis-
tribution was converted to the prescription dose based
on the planned versus delivered monitor units. As a
consequence, the comparison of converted dose dis-
tributions is an absolute dosimetry comparison. The
DVHs of all relevant structures, which were clipped
to the volume of the gel phantom [11], were com-
puted both for the calculated and the measured dose,
and compared. Low’s -index [21] was calculated in
3D (dose difference criterion = 5%, distance to agree-
ment = 5 mm) and -volume histograms (-VH) were
reconstructed.
Results
Treatment plan and delivery
Details on the delivered IMAT plans are summarized
in Table 1. Three to six arcs were used in the IMAT
plans. Mean clinical delivery time was 6.3 minutes
(range 3.2-12.8 minutes) over all fractions and all
patients. For the dummy run delivery, the mean to-
tal delivery time was 5.5 minutes (range 3.5-7.6) for
the IMAT plans, and 2.5 minutes (range 2.3-2.8) for
the 3D plans (p<0.01). When considering beam-on
time only, this was 3.81.0 minutes for IMAT and
1.40.2 minutes for the 3D delivery (p<0.01). Time
for system checks was 1.3 min for the IMAT deliv-
ery on the Javelin, and 0.4 min for the 3D plans on
the RTD. For the IMAT plans, the number of MUs
needed for a fraction of 180 cGy varied between
337 and 529 MUs (mean 456 74 MUs ) . For
the 3D plans, this varied between 340 and 498 MUs
(mean 41256 ). This difference was not signifi-
cant (p=0.16).
DVH analysis and dose distributions
The compiled DVH data for the 7 patients are sum-
marized in Table 2, and graphically displayed in Fig-
ure 3. The minimal dose in the PTV was not signifi-
cantly different. Inhomogeneity, however, was lower
for the 3D plans (9.9%  1.5) than for the IMAT
plans (14.4%  3.1). This difference was significant
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Table 2: Summary of the DVH data, showing the mean  the standard deviation.
3D IMAT p
PTV


(%) 97.5  1.4 95.7  2.0 0.16

 
(%) 0.0  0.0 0.2  0.3 0.13


(Gy) 46.6  0.1 47.3  0.5 <0.01

 
(Gy) 42.1  0.6 40.9  1.3 0.12
  (%) 9.9 1.5 14.1  3.1 0.03
Small bowel


(Gy) 17.0  7.7 12.4  4.6 0.02


(%) 19.1  6.5 6.6  2.3 0.04

 	
(%) 45.6  8.2 33.0  5.6 0.04
Bladder


(Gy) 34.6  6.8 18.2  2.7 <0.01




(J) 262.1  64.5 244.0  47.6 0.24
DDEF (%) 20.7  0.1 22.2  0.1 0.21
Abbreviations: 3D = conventional plan (three beam directions), with conformal portals; IMAT = Intensity
Modulated Arc Therapy plan; PTV = Planning target volume; 

, 

and 
 
= partial volume (%) receiving
more than 90%, 95% and 107% of the prescribed dose, respectively; 
 
and 

= the first and the 
percentile dose;   = inhomogeneity factor, defined as   	
 

, with 

the median dose; 

= mean
dose. 



= the integral dose defined as the mean dose in the total volume multiplied by its volume. 



was calculated for the total treatment dose (=45 Gy). DDEF = Dose deposition efficiency factor, defined as
 

	

 


.
p-values represent the result of a two-tailed paired t test.
(p=0.03). Maximal dose in the PTV was 46.6 Gy
for the 3D plans, and 47.3 Gy for the IMAT plans
(p<0.01). For the CTV, the inhomogeneity for the
3D and IMAT plans was 6.3% and 8.1% (p=0.06).
The mesorectal space, surrounding the rectum, re-
ceived a slightly higher dose in the IMAT plans than
in the 3D plans, with a maximal dose of 47.0 Gy vs
46.3 Gy (p=0.01). In the 3D plans, no part of the
mesorectal space received a dose higher than 107%
of the prescribed dose, while the 
 
was 0.1% for
the IMAT plans. This difference was not significant
(p=0.1). For SB, the 

was 45.5 Gy for the 3D
plans and 41.5 Gy for the IMAT plans. Mean dose
to the SB was significantly lower for the IMAT plans,
as was the 
 	
and the 

. The absolute vol-
ume of SB receiving more than 15 Gy was 158 cc
(range 21-327 cc) in the 3D plans, and 128 cc (range
13-305 cc) in the IMAT plans. The absolute 

was
84 cc (range 1-234 cc) and 27 cc (range 0-58 cc) for
the 3D and IMAT plans, respectively. Figure 4 shows
the DVDH for SB, PTV and surr for 3D plans com-
pared to the IMAT plans. This illustrates that the vol-
ume of SB receiving any dose is lower for the IMAT
plans. The differences in relative volume between
3D and IMAT plans for SB were significant between
13.5 and 42.5 Gy. For the PTV, the DVDH shows the
underdosage and overdosage caused by IMAT when
compared to 3D. Between 42.25 and 45 Gy, 1-5% of
the volume of the PTV receives less by IMAT than by
3D. The bladder received a significantly lower dose
in the IMAT plans, with a relative reduction of nearly
50% in Dmean. The dose to the surr was lowest for
the IMAT plans, with a mean 

	
of 9.0% and
4.4% for the 3D and IMAT plan, respectively . This is
also reflected in the average DDEF, which was 20.7%
for the 3D plans and 22.2% for the IMAT plans. This
difference was not significant, but shows that IMAT
is at least as efficient as the 3D technique in dose de-
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Figure 5: Dose distributions for Patient 5, showing the delivered IMAT plan in a transverse (a), sagittal (c) and
coronal (e) plane. The 3D plans (b,d,f) are shown in the same three planes. Isodose values are in Gy. PTV is
delineated by a red dotted line, while small bowel is shown by a green dotted line.
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Figure 3: DVHs compiled from the data of the whole
group. Solid lines and black-filled circles represent
the IMAT plans while the 3D plans are shown by the
dotted lines and open circles. For reasons of clarity,
all circles were omitted for CTV and PTV. For each
plan and each structure, the mean +/- the standard er-
ror of the mean is represented. Data are shown for
CTV, bladder and surr (a), and PTV and small bowel
(b). In (c), the individual DVHs for the seven patients
are shown, both for the 3D plans (grey lines) and for
the IMAT plans (black lines). The DVHs for patient
1 (solid lines) and for patient 4 (dotted lines) are dis-
played in bold.
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Figure 4: Dose Volume Difference Histograms
(DVDH) for PTV (solid line), small bowel (dot-
ted line) and surr (dashed line). The grey dotted
line represents the dose absolute volume difference
histogram (DAVDH) for the small bowel (in cc).
The D(A)VDH is constructed by plotting the mean
(over the 7 patients) of Vx
  
 Vx


, in which
Vx is the % volume (or the absolute volume for
DAVDH) receiving dose x. Points were calculated
for 0 Gy < x < 50 Gy with an 0.25 Gy increment of
x. Positive values indicate that the volume irradiated
to dose x was larger in the 3D plans than in the IMAT
plans.
plan are shown in Figure 5. The concave sparing of
the SB by the IMAT plan is clearly visible in the three
planes. The isodose lines are highly conformal to the
PTV form for the IMAT plan. The dose outside the
PTV is distributed over a large volume in the IMAT
plan, which can also be derived from the DVDH (Fig-
ure 4), which shows that IMAT results in deposition
of low dose (between 0 and 11 Gy) in a larger volume
of the surr. The IMAT plan shows serrated isodose
lines (Figure 5a), especially in the low dose region,
caused by the discrete gantry angle calculations.
Dosimetric verification
The results of the PGD are summarized in Table 3
and in Figures 6 and 7. Table 3 shows the volumes
of the clipped structures, and the relative differences
between the measured and the calculated values for
some clinically important parameters. The relative
differences in Dmed were insignificant, and varied
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Figure 6: Dose distributions of the IMAT plan in a transverse plane through the isocenter as it was calculated
(a,b) and measured by polymer gel dosimetry (c,d). Isodose values are in Gy. In (a), the calculations are shown
for the IMAT plan, with calculated control points every 8Æ . In (b), the same plan is shown, but additional
control points were generated and calculated every 2Æ by interpolation of the pre-existing control points. (c)
The measured IMAT plan, delivered to the phantom in a discrete way, i.e. as a static gantry IMRT with 8Æ
interspaced beams. (d) The measured IMAT plan, delivered in dynamic gantry mode.
between -1.1% for the 3D plan and 0.3 % for the
IMATd experiment. The relative difference in max-
imal PTV dose (

) was nowhere larger than 4%,
with the largest difference found for IMATs (+4.0%).
For all techniques, the 

was underestimated by
the dose calculation algorithm, while the minimal
dose (
 
) was overestimated by 2.5% in IMAT, ir-
respective of the delivery (static vs dynamic gantry).
The partial volume of the PTV, in which the -index
was higher than 1 (V
 
), was nowhere higher than
2%. No clear difference was found between the
IMATs and IMATd results. For SB, the relative dif-
ference in Dmean was largest for the 3D experiment
(+5.6%), and smallest for both IMAT experiments
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Table 3: Summary of the results of the polymer gel dosimetry.
Voltrunc (cc) 3D IMATs IMATd
PTV 952 (97%)
D

(%) -1.1 -0.3 +0.3
D

(%) +2.1 +4.0 +3.2
D
 
(%) +0.3 -2.8 -2.4
Vol
 
(%) 0.0 1.6 1.1
small bowel 427 (82%)
D

(%) +5.6 -0.5 -0.5
V

(%) +1.3 -1.8 -2.1
V
 Gy (%) +8.4 +3.9 +0.1
Vol
 
(%) 1.6 6.1 9.7
bladder 124 (100%)
D

(%) +3.1 +12.0 +9.9
Vol
 
(%) 0.0 6.0 11.8
surr 6298 (36%)
Vol
 
(%) 11.7 9.4 5.3
scanned volume
Vol
 
(%) 9.0 10.2 6.4
Voltrunc: the volume of the structure, clipped to the volume of the MRI-measured gel phantom. The percentage
between brackets is the partial volume of the structure in the gel phantom. IMATs: the IMAT treatment,
delivered to the gel phantom in a static gantry mode. IMATd: the IMAT treatment, delivered to the gel phantom
in dynamic gantry mode. D

: relative difference between measured and calculated mean dose, calculated
as
D


D


D


, with D


the median dose in the specified organ, as measured by gel dosimetry,
and D


the median dose as calculated. The same reasoning was followed for D

, D
 
, Dmean,
V

, and V
 Gy. Vol : the partial volume of the clipped structure in which the -index was higher
than unity.
(<1%). The V
 
for SB was 9.7% for IMATd, al-
though there is nearly no difference between calcu-
lated and measured dose when looking at the DVHs
(Figure 7a). The largest differences between mea-
sured and calculated dose was seen for bladder, for
which the mean measured dose was up to 12% higher
than the calculated dose (this was for IMATs). This
is reflected in the high V
 
for IMATs (6%) and
IMATd (11.8%). The V  for the total scanned vol-
ume was lowest for the IMATd (6.4%) and highest
for the IMATs (10.2%) delivery. On Figure 7, the
same data can be found . It shows the good corre-
lation between the measured and calculated dose for
PTV. It is also clear that there is no substantial dif-
ference between the IMATs and the IMATd delivery.
The DVHs for bladder show a higher measured than
calculated dose in all cases, and this is most pro-
nounced in the IMAT deliveries. For SB and surr,
DVH comparison shows no clinically relevant differ-
ences. Calculated and gel-measured dose distribu-
tions are shown in Figure 6. The ripples in the low
dose region, which are a consequence of the gantry
angle discretization that is done for planning and cal-
culations, are also obvious in the IMATs measured
dose distributions (Fig 6c). They disappear when the
dose computation is done for MSs, interspaced by 2Æ
instead of 8Æ (Figure 6b), which more closely resem-
bles the results of the IMATd delivery (Figure 6d).
This IMATd is the delivery mode used in the clinical
IMAT execution.
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Figure 7: Dose Volume Histograms (a,c,e) and -Volume Histograms (b,d,f ) for the three polymer gel ex-
periments. In (a,c,e), the dashed lines represent the calculated DVHs, while the solid lines represent the gel-
measured DVHs. The DVHs and -VHs are shown for PTV, small bowel, bladder and surr. The -VHs for
the total measured volume are also shown (bold curve). Results are shown for the dynamically delivered IMAT
treatment (a,b), the statically delivered IMAT plan (c,d) and for the 3D plan (e,f ).
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Discussion
Although not significant, the minimal dose was lower
for the IMAT plans. The same can be seen for the


of the PTV, which was lower for the IMAT plans.
Still, on the DVH (Figure 3b), it is clear that this un-
derdosage is rather small. The PTV underdosage is
partially caused by the SB sparing. The possibility
to create concave dose distributions with IMAT leads
to a larger PTV surface adjacent to the dose gradient.
This, in combination with the leaf position optimiza-
tion, can result in the observed underdosage, located
at the borders of the PTV. Although the PTV under-
dosage in this group was deemed not to be clinically
relevant, assigning a too high importance for SB in
the optimization could result in relatively large dose
“erosion” at the margins of the PTV. For this reason,
we defined the following PTV acceptance criteria for
future use in IMAT planning for rectal cancer, based
on the results of the present analysis. For the follow-
ing criteria, we took the observed mean  1 SD, thus
resulting in (1) a 

  93.7%, (2) a 
 
  88% of the
target prescription dose (for a prescription to 45 Gy,
this is 39.6 Gy), and (3) a 
 
 0.5%. In case of
a violation of one of the first two criteria, the IMAT
plan should be re-optimized with lower SB impor-
tance. The third criterium should not be an absolute
one, as the higher maximal dose (and more gener-
ally the higher inhomogeneity), is presumably caused
by the discretization to deliverable arcs: ADR can-
not be modulated in a fine sense due to the required
constant ADR. Peeks visible in the ADR graphs can-
not be expressed in the final arcs as the Elekta linac
is not able to fluently deliver short arcs. Balancing
the linac using counterweights and optimization of
the settings of the gantry servo-system reduced the
problems, but arcs smaller than Æ still cause too
many interrupts to be practical. The addition of a few
static gantry intensity modulated beams (replacing
the practically undeliverable short arcs) to the IMAT
arcs may reduce inhomogeneity in the PTV. This pos-
sibility has not yet been explored. During planning, it
is clear that the arc extraction procedure significantly
reduces the quality of the plan (PTV inhomogeneity
and dose to the OARs increase, data not shown). This
is (partly) solved by leaf position optimization. Earl
et al [22] also discuss the limitations imposed by the
constant ADR, and showed that adding an additional
arc could reduce this plan deterioration, but that a
variable dose rate or gantry speed would solve this
problem. We prefer the implementation of a variable
gantry speed over the variable dose rate. In this way,
the optimization even has the possibility to insert a
static gantry IM beam as a part of an arc by lowering
the gantry speed to 0Æ/min. This solution, which de-
livers the optimized non-constant ADR, also reduces
the number of arcs, the total gantry rotation and most
probably also the planning and treatment time. It
also removes the complex planning step of arc extrac-
tion. We plan to investigate the full impact of variable
ADR on planning quality and delivery time.
IMAT offers the possibility to spare SB and blad-
der in comparison with a 3D technique. A relative
reduction of 28% in 

can be seen for SB. For
the 

, a relative reduction of 65% was reached by
applying IMAT. The 
 	
, which was found to be
strongly associated with acute SB toxicity by Baglan
et al [6], was reduced with 28%. Whether this sparing
of the SB on the planning level will translate into a
clinically diminished SB toxicity is beyond the scope
of this study, which was focused on clinical imple-
mentation of IMAT and its planning comparison with
a 3D technique. In the present series, the volume of
SB receiving 90% of the target dose in the 3D plans
(Volsb
  
) rather small (mean 84 cc, range 1 - 234 cc)
compared to previous reports [6, 9]. This might un-
derestimate the full potential of IMAT, as we could
expect a correlation between the Volsb
  
, and the rel-
ative reduction in 

, obtained by IMAT over 3D.
A DVH analysis for the subgroup of patients with
a Volsb
  
greater than 84 cc shows a 

of 32.3%
and 9.6% for 3D and IMAT, respectively. For the
other four patients, the 

was 9.2% and 4.4%. Of
course, the number of patients is too small to draw
strong conclusions, but we hypothesize that the IMAT
technique gets more efficient as the anatomical situa-
tion is more complex. Some subgroups of patients
might have a large improvement of their treatment
plan quality by IMAT, while the effect might be neg-
ligible or clinically irrelevant in others. It was shown
that patients who receive post-operative radiotherapy
have a larger portion of (fixed) SB in the pelvis [23].
These patients are also at higher risk for SB toxic-
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ity than patients who received their radiotherapy in a
pre-operative setting [24]. Besides this group of post-
operatively treated patients, other patients that might
benefit from IMAT could be selected by means of in-
vestigations like volumetry of the contrast-filled SB
during simulation.
The delivery time of the 3D treatments was sig-
nificantly shorter than for the IMAT treatments. As
mentioned, the 3D treatments were delivered us-
ing the RTD. The RTD system operates with a
dose rate of 550 MUs/min (compared to 130 or
260 MUs/min for most of the arcs), and has a faster
checking system than the prototype dynamic soft-
ware used for IMAT. Thus, although clinical IMAT
delivery time is within a standard time slot at the mo-
ment, it could be reduced even further by adaptations
to the linac control software.
Quality assurance of a complex technique like
IMAT remains a challenge. As both the gantry and
the leaves are constantly moving, tracking their po-
sition is not easy. Ramsey et al [25] developed an
elegant method to evaluate the leaf position errors
during arc delivery, based on the logs of a Varian
Clinac MLC, and derived a formula to estimate the
consequent dosimetrical error. Our strategy was to
check the end-of-chain result. Different methods, like
ion chamber point dosimetry and 2D film dosime-
try have been used by others [22, 26]. Although
valuable, these techniques do not offer the possibility
to evaluate the IMAT treatment in three dimensions,
while dose distributions of IMAT treatment plans typ-
ically vary in three dimensions. PGD offers absolute
dosimetry in three dimensions with a high resolution.
Vergote et al [20] optimized PGD for its use in large
phantoms. This resulted in a structural root-mean-
square deviation between gel-measured and Helax-
TMS computed dose distributions of 2% (except in
high dose gradient regions, where it was 5%) and a
stochastic deviation of 2%, resulting in an accuracy
of 2.8% (and 5.4% in high dose gradient regions).
We found a good correlation between gel-measured
and calculated dose distributions for the PTV (V
 
= 1.1%). The SB sparing, obtained by the IMAT
technique, was confirmed by the PGD measurements.
These results ensured us that IMAT planning, calcu-
lation and delivery were accurate and could be im-
plemented in a clinical setting. The largest deviations
were seen for bladder, with a calculated vs measured
Dmean of 23.7 Gy and 26.0 Gy in the IMATd ex-
periment (+9.9%). Nearly the full dose contribution
to the bladder is due to scatter and transmission, as
the bladder is shielded in all arc apertures. Calcu-
lation errors in the computation of both scatter dose
and transmission can thus have a high impact on the
calculated dose of the bladder. PGD also showed that
the interpolation of the 8Æ angularly interspaced con-
trol points to an arc does not produce different dosi-
metrical results than if it were given as static gantry
IM beams. As previously demonstrated [20, 26], de-
creasing the interspacing distance from 8Æ to 2Æ af-
fects the dose distribution for the low dose regions
(the ripples disappear), while for high dose regions,
there is little or no difference.
To our knowledge, there has been no report on
clinically executed IMAT or even IMRT treatment for
rectal cancer until now, despite the fact that IMRT
has been used in a clinical setting for nearly a decade
now. There is one report of a planning compari-
son between IMRT and 3D [27]. The authors found
a relative reduction of 55% to 72% in 

for SB,
depending on the PTV inhomogeneity that was tol-
erated. This is in the same range as our findings,
with a 

for SB 72% for IMAT. In pelvic radio-
therapy, the first clinical results about the implemen-
tation of IMRT for gynecological malignancies have
been published. Mundt et al have shown that IMRT
reduces both acute [28] and chronic [29] SB toxicity
in comparison to conventional treatment. In cervical
cancer, as in rectal cancer, the internal iliac and ob-
turator nodes are important routes of nodal spread,
leading to a concave shaped PTV partially encom-
passing bladder and SB. Therefore, we hypothesize
that a similar toxicity reduction can be achieved in
rectal cancer patients as in patients with cervical can-
cer.
Whether IMAT will prove to be the best option
for rectal cancer irradiation (and for other sites) in
the future, will largely depend on the improvement
of IMAT. A large window for improvement exists for
IMAT, including plan optimization and automation of
the planning process, and improvements of the linac
control software, of which variable gantry speed is
IMAT for rectal cancer
the single most important.
Conclusion
Seven patients with rectal cancer were irradiated with
IMAT. On planning, IMAT allowed to spare SB as
compared to a conventional 3D technique, without
compromising the dose in the PTV. Although treat-
ment time for IMAT was longer in comparison with a
3D technique, it was deliverable within a time slot of
5-10 minutes. Three dimensional PGD showed that
IMAT delivery is as accurate as 3D delivery. We iden-
tified significant potential for improvements both at
the levels of planning and delivery. The single most
important technical improvement for IMAT is the im-
plementation of a variable gantry speed.
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VI Discussion. 
VI. 1. IMRT: is it worth all the trouble? 
IMRT has been increasingly used in the USA, and somewhat later also in Europe. Whereas 
IMRT was developed and initially implemented in academic hospitals, it has left its cradle, 
and is now also implemented in an increasing number of private hospitals. In a recent US 
survey, about one third of responding radiation oncologists were using IMRT, and more than 
90% of the non-users planned to do so in the near future [113]. Although IMRT has been used 
clinically for more than 10 years, not one randomised trial has been conducted comparing 
IMRT with less advanced radiation techniques, like 3D-CRT. The evidence of the superiority 
of IMRT is at best level 3ii (uncontrolled consecutive case series [114]). In this view, it is 
interesting to note that the NCI (National Cancer Institute) convened a group of experts to 
address the issue of using IMRT in trial protocols (in which IMRT is not the subject of the 
trial question!). They allowed the use of IMRT in trials, specifying the requirements to do so 
[115]. A 2005 update of these NCI IMRT guidelines was recently posted [116]. This 
permission might reduce the need (and thus the chance) for a prospective randomised trial 
addressing the benefits of IMRT. However, some specific national reimbursement systems, 
like in Britain, have encouraged some investigators to start up such a trial [117], but accrual 
remains a problem for different reasons. The longer IMRT will be used, the fewer physicians 
will be inclined to enter patients into a randomised trial in which patients might be allotted to 
an (outmoded) conventional technique.  
Nevertheless, it is not obvious that IMRT would result in better clinical results than 
conventional techniques, and some sound criticism is in its place [118;119]. IMRT planning 
results might look very attractive when compared to those of 3D-CRT or conventional 
radiotherapy, they are but an approximate representation of one part of the total treatment 
chain. Some of the major concerns about IMRT will be discussed here, and IMRT users 
should be aware of the possible problems associated with IMRT and how to avoid or 
minimize them: 
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(1) Importance of delineation: As the IMRT planning is entirely based on the delineated 
structures, the importance of the delineation skills of the planner is evident. This is not a 
problem that is specific to IMRT, but in fact to all radiation techniques in which the beam 
outlines are based on the delineated structures, like in 3D-CRT. However, as the dose 
distribution is more conformal, IMRT will be less forgiving for erroneously delineated 
structures. Parts of the tumour not defined as such will be underdosed, and parts of the imaged 
volume that are not defined, will be abused by the optimization algorithm to deposit dose! 
(2) Patient immobilization, changing anatomy and intra-fraction motion: IMRT is less 
robust to inter-fraction set-up variability, changing anatomy during treatment and intra-
fraction motion. For inter-fraction set-up variability and changing anatomy, this is a direct 
consequence of the more conformal dose distribution that can be reached. The intra-fraction 
motion, however, could lead to unwanted underdosage of the target volume, which is directly 
related to the delivery method of IMRT itself. In all but one IMRT delivery method (the use 
of compensators), only parts of the target volume will be irradiated at any given time. 
Therefore, a moving target volume could move in and out these subfields, resulting in a 
different delivered dose than planned. Although this is found to be true for the dose delivered 
in one fraction, this effect is diluted over the whole treatment course, typically consisting of 
20-35 fractions [120-122]. 
(3) Fraction time and biological efficiency: The delivery time of IMRT treatments is not 
only of practical and economical importance, but biological effects are to be considered as 
well [123]. Supposing that the delivery of an IMRT fraction takes 15 minutes, parts of the 
tumour could be in the first and the last segment only, thus leaving 15 minutes for DNA 
repair. This possibility has been tested experimentally, and it was found that prolonging the 
delivery of a 2 Gy fraction resulted in a relatively small but significant decrease of biological 
effect [124]. This underlines the importance of trying to shorten the delivery time as much as 
possible. At GUH, the goal is to keep the treatment time (= beam-on time) under 15 minutes. 
For HNC, the 6-beam coplanar set-up results in treatment times of < 10 minutes, while for the 
non-coplanar 7-beam set-up used for paranasal sinus cancer, this will rather extend to around 
10 to 15 minutes. 
(4) Low-dose hypersensitivity: this phenomenon denotes the observation that cells are 
excessively sensitive to low-dose (0.1-0.5 Gy, but observed up to 1 Gy) irradiation, an effect 
that is not predicted by back-extrapolating the cell survival response from higher doses [125]. 
The precise molecular basis for this is not yet known. In IMRT treatments, the “unwanted” 
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dose is spread out over a large volume of normal tissue. This causes large volumes to be 
irradiated to very low doses per fraction. Although possibly important in IMRT, there has 
been no report of clinically observed low-dose hypersensitivity so far.  
(5) Secondary radiation-induced tumours: Radiation is a known carcinogen, and 
secondary induced cancers represent a serious side effect of a radiation treatment. In the high-
dose regions, secondary sarcomas are observed, while radiation-induced carcinomas are seen 
in the low-dose regions. As previously mentioned, IMRT results in a large volume receiving 
low doses. Also, the number of MUs needed in IMRT is typically higher than in conventional 
radiotherapy (and heavily depending on the planning and delivery method). This increase in 
MUs can result in an increased dose outside the boundaries of the collimated fields/segments, 
due to leakage and scattered photons. Epidemiologically, it is difficult to assess these 
radiation-induced secondary cancers, as a multitude of other factors play an important role in 
the development of secondary induced cancers, like genetic susceptibility and presence of 
other risk factors like tobacco smoking and other environmental influences. Moreover, the 
delay between irradiation and the clinical presentation of the secondary tumour can be up to 
tens of years. Hall et al [126] made a theoretical estimate of the risk of secondary induced 
cancers due to IMRT over conventional radiotherapy, and calculated that an additional 0.75% 
of surviving patients would develop a radiation-induced secondary malignancy due to the use 
of IMRT. This figure represents a doubling of the absolute risk of radiation-induced cancers. 
It is, however, important to mention that the assumptions that are made on IMRT are not 
always fulfilled for all delivery methods of IMRT or for all sites. Two thirds of the additional 
cases of radiation-induced cancers were attributed to the larger volume receiving radiation 
dose. In IMAT for rectal cancer, however, it has been shown that the integral dose was lower 
in IMAT treatments than in the conventional treatment design [98]. Although the volume of 
surrounding tissue receiving very low doses (< 40 cGy/fraction) is slightly larger for IMAT 
than for conventional radiotherapy, the volume of surrounding tissue receiving intermediate 
doses was higher for the three-field technique. These intermediate dose level could be the 
most carcinogenic one [119] The other third of the excess of induced cancer cases was 
ascribed to the increase in MUs. However, this condition is not always present in intensity-
modulated techniques [98]. Other investigators estimated an 8-fold increase of secondary 
cancers due to IMRT [127]. However, this figure was found with the MIMiC-based sliced 
tomotherapy, typically resulting in treatment plans with a very high number of MUs per 
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fraction. We can conclude that IMRT can, on theoretical grounds, result in an increase in 
radiation-induced cancers, but this increase depends on the specific type of IMRT delivery. 
 
Until now, the clinical benefits of IMRT are only suggested in case series, sometimes 
compared with historical results from the same institution or from literature. This level 3ii 
evidence suggests that IMRT enables the sparing of OARs. The most studied OAR in HNC is 
the parotid gland. Numerous groups have shown the possibility of dosimetrical sparing of the 
parotid gland without compromising local control [53;84], and the resulting preservation of 
the salivary outflow [52;128]. Our group found a reduction of both the short-term 
complication of dry eye syndrome [129] as well as a reduction in long-term complications 
[45]. Altogether, there is increasing evidence in favour of IMRT for OAR sparing without 
compromising local control. However, so far, no improvement in local recurrence rates has 
been observed by using IMRT, despite the better target coverage obtained by IMRT.  
VI. 2. Comparison between IMAT and Tomotherapy 
IMAT was first proposed by Yu as an alternative to tomotherapy [95]. Although IMAT has 
since then been used clinically, no direct comparison has been made between both delivery 
techniques. In the comparison that we will give hereunder, IMAT will be compared to the 
“ring gantry”-based helical tomotherapy, as developed at the University of Wisconsin by 
Mackie et al [94], rather than to the serial tomotherapy, as described earlier (p. 44). It is 
believed that this helical approach represents the future direction of tomotherapy, rather than 
the serial tomotherapy with the plug-on MIMiC fan beam MLC [130] (although one could 
argue that the latter offers the “cheapest” solution for tomotherapy and does not hamper non-
coplanar treatments). 
The helical tomotherapy treatment unit can be looked at as the fusion between a CT scanner 
and a linac [130;131]. A 6 megavolt (MV) linear accelerator waveguide and a MV CT 
detector are installed on a rotating gantry assembly. Power supply and data transmission is 
achieved by slip-ring technology, allowing continuous rotation. A binary MLC, resembling 
the MIMiC MLC, is incorporated in the linac head. The treatment couch can be longitudinally 
moved into the gantry ring. This translation can be quantified by the “pitch”, which is defined 
as the ratio of the longitudinal couch translation per gantry rotation to the slice width. In 
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tomotherapy, typical values for the pitch are 0.35-0.5, such that each point in the target 
volume is irradiated during more than one rotation of the gantry. This TomoTherapy Hi-Art 
System® (further referred to as TomoTherapy) is now commercially available and clinically 
used in the USA and Europe (http://www.tomotherapy.com). It is sold as a completely 
integrated treatment package, and includes a dedicated TPS.  
A comparison between IMAT and TomoTherpy is summarized in Table 4.  
TomoTherapy requires the acquisition of a dedicated treatment unit, while IMAT can be 
implemented on an MLC-equipped linac, as most of the radiotherapy centres in the Western 
world have one. Arc therapy is possible on both Elekta [95;96] and Varian linacs [102]. For 
the Elekta linac, dynamic prescriptions, like for IMAT, are not yet possible in clinical mode. 
Therefore, IMAT delivery is still done in local service mode, but with the same tolerances as 
in clinical mode. Varian linacs are capable of IMAT delivery in clinical mode (Eugene Wong, 
personal communication). 
 Favourable characteristics Unfavourable characteristics 
TomoTherapy • Fully integrated megavoltage 
CT for image-guided 
radiotherapy. 
• Dedicated TPS, integrated in the 
treatment unit. 
• Possibility of transit dosimetry 
and reconstruction of the 
delivered dose  
 
• Planning software is a black 
box. What happens inside? 
• Treatment times in the range of 
20-30 minutes, and dependent 
on longitudinal PTV length. 
• Intra-fraction motion might 
have an impact on tumour 
control. 
• Low MU efficiency 
 
IMAT • Can be executed on widely 
installed MLC-equipped linacs 
• Possibility of isocentric table top 
rotation and sagittal arc set-up 
• Treatment time +/- independent 
of longitudinal length of the 
PTV 
• More robust against intra-
fraction movement than 
tomotherapy 
• The outlines of the arcs are 
intuitive and reflect anatomy. 
• No commercially available 
planning software. 
• Long planning time needed 
(interactive and computational). 
• Sub-optimal gantry acceleration 
control (on Elekta).  
• Dynamic delivery still in local 
service mode (on Elekta) 
Table 5: Summary of favourable and unfavourable characteristics of IMAT and tomotherapy. Details 
about each point are given in the text.  
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From its architecture, it is clear that there is no possibility of isocentric table top rotation in 
TomoTherapy. In IMAT, it is possible to use non-coplanar arcs [97], which might be of 
interest in the treatment of sino-nasal cancer and lung cancer. Although the influence of this 
possibility to the target dose will be rather small, the use of non-coplanar arcs enables to avoid 
primary radiation to surrounding structures and OARs.  
The fact that the TomoTherapy TPS is a black box might be regarded as a drawback of 
TomoTherapy. Due to the fact that the IMAT TPS was developed at GUH, precise 
information on the applied methodology (e.g. on optimization algorithms) is available, and 
possible improvements can be easily implemented. On the opposite side, information on the 
details of the TomoTherapy TPS or any possible improvements, have to pass via the 
company. This is – of course – not a major concern for centers focusing on clinical 
applications, but might be one if the emphasis is on the development of delivery techniques, 
like at our institution. The fact that the IMAT TPS is home-made has, besides its mentioned 
benefits, also the disadvantage of being difficult to export to other centers.  
Treatment time (and inversely patient throughput) is an important biological, practical and 
economical criterion in the choice of radiation techniques. Data on time measurements on a 
TomoTherapy unit (kindly provided by Paul Bijdekerke, AZ-VUB), shows that the total 
treatment time (positioning time + radiation time) for head an neck tumours (averaged over 10 
patients) is 25 ± 3 minutes (range 21-30 minutes). The radiation time (up to the exit of the 
patient) was 11 ± 3 minutes. The positioning time (including patient positioning, acquisition 
of the MV CT, registration of MV CT and planning CT and subsequent analysis and 
repositioning) is estimated to be 14 minutes. No direct comparison can be made with IMAT 
(not implemented for HNC). 
Intra-fraction motion is an important issue that has to be considered in all delivery techniques 
in which (a part of) the “beams” cover only a part of the PTV [132]. Unlike conformal field 
treatments, where intra-fraction organ motion only affects the boundaries creating broad dose 
penumbra, the interplay of the movement of the beam aperture and the movement of the 
patient anatomy can create regions of over- and underdosage throughout the field. Clearly, the 
latter situation is encountered in all IMRT techniques. Due to the fact that TomoTherapy 
delivery implies a continuous translation in cranio-caudal direction of the PTV through the 
slit-beam, over- and underdosage in the PTV can be expected for moving targets with a 
relatively large amplitude in cranio-caudal direction (e.g. lung tumours) [133]. These hot and 
cold spots are minimized by using a large jaw width, and when the couch translation velocity 
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is small relative to the motion amplitude and frequency. On the other hand, conformal arc 
therapy is relatively insensitive to intra-fraction motion (only the borders can be affected). In 
IMAT, the whole extent of the PTV (in cranio-caudal direction) is within the beam aperture at 
any moment. Therefore, intra-fraction target motion in cranio-caudal direction will have less 
influence on the dose distribution. It has to be mentioned that the problem of hot and cold 
spots in TomoTherapy will be blurred after multiple fractions, but the effect might be  
important for treatments with a low number of fractions. 
TomoTherapy integrates image-guided radiation therapy (IGRT) in its design [134]. The aim 
of IGRT is to reduce uncertainties of the relevant anatomical structures at the time of 
radiation. By the MV CT detectors that are built on the rotating ring, MV tomograms can be 
made with TomoTherapy. Fusion software then performs the registration of the planning CT 
and the MV-CT. Corrections can be made by translations of the table couch. Rotational 
positioning errors around the longitudinal axis can be corrected by modifying the gantry start 
angle. Although this CT-based position verification is ingrained in TomoTherapy, it is not an 
exclusive feature. Other linac companies are developing tomographic position verification 
systems as well, with cone-beam kilo-voltage CT (Elekta, Varian), or a separate CT, lined up 
with the linac (Siemens). These cone-beam CT scanners, which are mounted orthogonally to 
the linac gantry, offer the same possibilities as the MV-CT of TomoTherapy, with even higher 
quality CT (better soft tissue contrast due to the kilo-voltage) [135]. Another feature of 
TomoTherapy is the possibility for transit dosimetry and – given a MV CT is provided - 
reconstruction of the delivered dose [136]. Indeed, the measured photon intensities can be 
back-projected through the MV CT (or another relevant data set), and a 3D dose distribution 
can be computed. Again, transit dosimetry is not an exclusive characteristic of TomoTherapy, 
and is also possible using electronic portal imaging devices on linacs [137]. Nevertheless, 
TomoTherapy is – at the moment – the commercially available system that offers the most 
integrated form of ready-to-use solutions for IGRT, and offers the most advanced 
opportunities to apply adaptive radiotherapy.  
The need for adaptive radiotherapy becomes clear from the clinical example in Figure 19 and 
is also shown in publication V. 1, Figure 5. In most treatment protocols, one snapshot (i.e. the 
planning CT) is taken as the basis for the delineation and planning for the whole treatment 
course. Safety margins for microscopic extension and set up errors are applied, but in most 
cases, no attention is given to the changing anatomy, which can be a result of the treatment 
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itself, as shown in the presented case. Other investigators have observed the same finding in 
lung cancer [138]. Tumour shrinkage could lead to unwanted high-dose irradiation of OARs,  
   
(b) (c) (a) 
Figure 19: Illustration of changing anatomy during treatment. A patient with a recurrent squamous cell 
carcinoma of the cervix was treated with concomitant radiotherapy and chemotherapy. Radiotherapy 
was prescribed as 25 fractions of 1.8 Gy to a PTV around the GTV and the elective pelvic lymph nodes, 
followed by a boost of 5 fractions of 1.8 Gy to a PTV around the GTV. (a) Planning CT scan before the 
start of the concomitant treatment (CT0Gy). The GTV is indicated in red. (b) Planning CT of the same 
patient at 45 Gy (CT45Gy). Again, the (shrunken) GTV is indicated in red. (c) Back-projection of the 
original GTV (in red) on the CT45Gy after registration of both CT scans. The space occupied by the 
original GTV on the GTV0Gy is now taken by a (contrast-filled) small bowel loop (black arrow). This 
clearly illustrates that, if no re-imaging had been done, the high-dose region would have encompassed 
small bowel. 
 
which move into the high-dose region, as the tumour disappears (see presented case). 
Therefore, an adaptive therapy process, in which the planning is adapted to the new 
anatomical situation (or to the previously reconstructed dose distributions) will lead to a 
higher uncomplicated cure rate, as both OARs will receive less dose, and the smaller target 
volumes will allow higher doses to be delivered. Adaptive radiotherapy will also allow to 
incorporate patient-specific motion and set-up errors into the re-planning, possibly allowing 
for smaller margins to be used. A review of adaptive radiotherapy is given elsewhere [139]. 
A subject that is closely related to adaptive radiotherapy is the ease and speed of the planning 
process. Adaptive radiotherapy will need a fast (and ultimately “online”) planning procedure. 
Planning time can be divided in computational time and interactive time. In the total planning 
time, computational time is less important than the interactive time, as these processes can be 
done over-night, while the interactive time necessitates human input (and time). The IMAT 
planning process in the GUH approach is, in its present state, cumbersome and requires long 
computational and interactive time. This is a major drawback for IMAT in comparison with 
TomoTherapy. When placed in a historical perspective, however, the same situation was seen 
in the early days of the static-gantry IMRT at GUH. The first IMRT plans at GUH started 
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with the manual creation of leaf settings per segment, and even with manual weight 
optimization through trial and error [1]. It was only after a while that planning tools were 
developed for the automation of both the creation of segments [21], as for the optimization of 
weights [13;14] and segment outlines [27]. These additional tools, in association with the 
development of class solutions and scripts, have led to the present situation, in which the 
largest part of the static-gantry IMRT planning process is executed by trained radiation 
technologists and assisted and supervised by radiation oncologists. The lack of effective 
planning tools for IMAT is probably the major reason why IMAT has not been implemented 
on a larger scale [17].  
We can state that IMAT is not only an alternative to tomotherapy, but rather a delivery 
technique that allows creating dose distributions of the same quality, and with some distinct 
advantages over tomotherapy. In that view, it is hard to understand the lack of interest from 
the commercial linac vendors for IMAT. At least two linac companies (Elekta and Varian) 
produce linacs that are mechanically capable of delivering IMAT treatments. Still, nearly no 
development in hardware or planning software is done in that area, despite of feeling 
TomoTherapy breathing down their neck (as of June 2005, 35 treatment centers installed 
TomoTherapy, most of them in the USA). The most likely reason for this is, again, the 
difficulty of the IMAT planning process, to which the linac and TPS vendors do not have a 
solution. Resuming the chronology of IMAT planning, the first approach was the inverse 
planning strategy of Yu [95]. However, in the reports on the clinical implementation of the 
same research group, an anatomy-based approach was used [97;140], indicating the 
difficulties they had to implement the inverse planning strategy first proposed. The group 
states, however, that the full potential of IMAT will only be reached using inverse planning 
[97], whereas we believe that the anatomy-based approach is the most logical way to follow, 
as there is a firm physical background to do so [1;9] and it elegantly minimizes the constraint 
of MLS [96]. It is interesting to note that both approaches are converging [104]. 
In the IMAT planning and delivery process, as applied at GUH, there is still a large window 
for improvement. In our view, the most important improvement would be the possibility of 
delivering arcs with a variable gantry speed, thus allowing arcs with an non-constant ADR 
[96;98;104]. A variable gantry speed would obviate the need for the extraction of arcs with a 
constant ADR, as explained on p. 56 and shown in Figure 18a. This step of arc extraction is 
the most complex and time-consuming one, and leads to a deterioration of the planning 
quality, and to a higher number of arcs (and a longer treatment time). We prefer a variable 
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gantry speed above a variable dose rate because with the former option, static beams are 
possible within an arc, when the gantry speed is brought to zero. The possibility of a variable 
gantry speed would of course bring along the need to explore the possible gantry acceleration, 
and to incorporate this constraint in the TPS. Another possible improvement in the IMAT 
planning would be the optimization of the start and stop angles of the arcs. At this moment, 
the start and stop angles are determined manually during the arc extraction step. The 
optimization of the start and stop angle could be done in a parallel way as is done for the 
LPO: calculating the dose contribution for a small arc, computing the influence of the 
addition/omission of the small arc to/from the already existing arc on the objective function, 
and accepting or rejecting the new situation. This method, however, has not yet been 
implemented at GUH. 
VI. 3. Future perspectives 
Although much research is still ongoing and needed, it is fair to state that IMRT has now 
become a clinically implemented and widely accepted radiation technique. As shown in the 
current thesis (publications V. 2 and V. 3, reviewed in publication V. 1), and by others [141], 
IMRT in HNC results in lower chronic toxicity. Unfortunately, there are no data (that is: not 
from controlled trials!) suggesting a better local control by the use of IMRT over conventional 
RT techniques. Still, IMRT creates the possibility to escalate the dose to small volumes [85]. 
In publication V. 4, this possibility was explored, together with the use of FDG-PET as a 
guide for delineation and dose escalation. This was done within the frame of a clinical Phase I 
trial, in which the dose is escalated stepwise. Lauve et al [142] have used a similar approach, 
and found a maximal tolerable dose 70.8 Gy (in 30 fractions, and as the sole treatment 
modality). The analysis of clinical results from these trials will help us to select the maximal 
tolerable dose. This dose level could then be used in a controlled trial, to investigate whether 
this would result in a better local control.  
As shown in Figure 1, a growing body of literature on IMRT becomes available, both on 
IMRT physics and on clinical (toxicity) outcome. Thus, knowledge on dose-volume effects on 
toxicity is increasing, but fragmented. The actual NTCP models are still largely based on 
clinical data from the pre-3D-CRT era [24]. Although useful, these data are only rough 
estimates and cannot fully reflect the biological effects of inhomogeneous irradiation [143]. 
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There is an obvious need for new models, and efforts should be made to pool all clinically 
available data, in order to construct NTCP models adapted to IMRT [144]. 
IMAT planning and delivery will need to be further developed and automated. This process 
will require mutual input from researchers and linac/TPS vendors. Ultimately, this should 
result in a TPS and delivery technique that are not only available at specialized university 
hospitals, but can be dispersed on a larger scale. As shown in Table 4, a quite large number of 
radiation techniques are at the disposal of the radiation oncologist. Choosing the best 
available radiation technique for a given clinical case is not always trivial, and should be 
examined for each group of clinical problems. However, the diversity of delivery techniques 
should no longer impede multicenter trials on IMRT/IMAT. Solutions to overcome this 
heterogeneity consist of meticulously formulated planning goals and constraints (section III. 
4.2.3) that have to be met by all participating centers, and an end-of-chain dosimetrical 
control [145], for which PGD is a promising candidate. 
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Kruisdankwoordraadsel 
Een promovendus moet aanvaarden dat het dankwoord het meest gelezen deel zal zijn van de 
thesis. Van U, beste lezer, weet ik dat U eerst de thesis las, en dit stukje voor het laatst hebt 
gehouden, maar geloof me, er zijn er anderen…. 
 
Een thesis maak je niet alleen, dat is algemeen geweten. Een netwerk van mensen staat naast 
en achter je, gedurende al die tijd. Ieder van hen draagt op zijn manier bij aan het geheel, 
soms heel direct, soms meer achter de schermen. De onderstaande mensen wil ik in het 
bijzonder bedanken: 
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Horizontaal 
 
(1) Bedankt om voor mij het pad te effenen, en 
mij die eerste jaren geduldig te leren wat er 
te leren viel. Je manier van werken, je 
zelfkritiek,… het was allemaal inspirerend 
voor mij. Hoe je met die “broken pipe” 
omging, getuigde van diep inzicht (U asked 4 it). 
(2) Officieus lid van de leescommissie, maar 
bovenal begeleider in bange uren en laatste 
loodjes. Als U een Engelse tekst wil laten 
nalezen, bent U beter af bij hem dan bij een 
“native speaker” (trouwens; je aanvraag 
voor de 170-uren werkweek is afgewezen). 
(3) “Eminence grise” van de dienst. Zijn a-
dogmatische vragen mogen dan al eens 
verward worden met naïviteit, voor mij 
waren ze een belangrijke reden om voor 
radiotherapie te kiezen. 
(4) The Irish soul backing. Ta gra agam ort. 
(5) Vereenzelvigd worden met een tak van de 
wetenschap: het is niet iedereen gegund. 
Interface tussen mens en machine, 
menigmaal hebben Bart en Marc me uit de 
nood geholpen (ik had dat commando zelf 
óók al geprobeerd, echt waar…) 
(6) De samenwerking met jou was één van de 
leukste momenten tijdens mijn doctoraat. Je 
introduceerde me in de wondere wereld van 
de geldosimetrie (werkt dat nu eigenlijk?), 
en bracht een stukje Jamaïca op P7, op zich 
een kunst. 
(7) Schippert tussen Poperinge en de krtkg6. De 
inzet waarmee hij keer op keer streeft naar 
het onbereikbare, optimale plan is 
indrukwekkend. Bedankt voor het samen 
werken: je gunde me een blik achter het 
(mist)gordijn van algoritmes en C++ (soms 
begreep ik het). 
(8) Bedankt om mij en dit werk te “promoten”. 
Zonder Uw nooit aflatende ideeënstroom 
(die mij soms tsunami-gewijs overspoelde), 
zou dit werk niet mogelijk geweest zijn. 
(9) Heerlijk boontje (nee, niet mijn vrouwtje) 
met onvolprezen kwaliteiten. Presteert het 
best onder hoge druk. 
 
Verticaal 
 
(1) Mijn lieverd, mijn boontje: bedankt voor al 
je liefde, het opgebrachte geduld (telkens 
weer) en het gezonde tegengewicht dat je 
bood (there is life out there!). Wat we samen 
schreven is (eindelijk) aanvaard door 
“Nature”. Ik verlang naar het ogenblik dat 
het ter perse gaat! 
(2) Bedankt voor al het stille werk dat je 
verricht hebt. Dossiers opvragen, databases 
aanvullen, ik kon het met een gerust hart aan 
jou overlaten. 
(3) Mama en papa, zonder jullie zou ik hier niet 
staan: waarschijnlijk helemaal niet, en dan 
toch alleszins niet als de persoon die ik nu 
ben. Bedankt! 
(4) Instelling met mooi briefpapier. Stelde mij 
in staat om dit werk uit te voeren en tóch 
betaald te worden.  
(5) Net voor de eindmeet durft het schrijven van 
een thesis nogal eens “tegensteken”, en 
wordt het allemaal “fuzzy”. De kandidaat 
durft dan al eens dingen op papier te zetten 
die hij uiteráárd niet zo bedoeld had. Ik dank 
dan ook de professoren Yves De Deene, 
Marc Peeters, Guy Storme en Eugene Wong 
voor hun kritische nalezing en waardevolle 
suggesties. Zij hebben dit werk verbeterd. 
(6) Zelf het beste plan is niet veel waard zonder 
mensen die het – elke dag weer - met 
toewijding en zorg ten uitvoer brengen. 
Gelukkig hebben wij zulke mensen op de 
dienst radiotherapie. 
(7) Mijn rechtstreekse collega’s over de loop 
der jaren: Ilse Vanhoutte, Joost Nuyttens, 
Samuel Bral, Frederic Duprez, Valerie 
Fonteyne, Sabine Meersschout, Nathalie 
Meireson, Katrien Vandecasteele en 
Benedict Engels (de lengte van de lijst 
begint me zorgen te baren). Bedankt voor de 
samenwerking, de babbels en de 
vervangingen alom. 
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